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ABSTRACT 
 
This dissertation discusses anti-HIV-1 microbicide research. In particular, it concentrates on 
microbicide formulation and delivery. Microbicides are anti-HIV-1 agents that when applied in 
the human vagina or rectum may prevent sexual HIV-1 transmission. Although most of the anti-
HIV-1 agents being developed as microbicides are active in vitro, they have proved to be 
ineffective in vivo. A review of microbicide development over the last decade expounds the view 
that unsatisfactory microbicide failures may be a result of inefficient delivery systems employed. 
Thus, necessitating a thorough scientific qualitative and quantitative investigation of important 
aspects involved in HIV-1 transmission as a prerequisite for microbicide development. In this 
dissertation it is postulated that intravaginal targeting of HIV-1 increases the chances of 
microbicide success, wherein vaginal micro-environmental factors including pH would be 
maintained at HIV-1 prohibitive acidic levels to ward off other sexually transmitted diseases 
which compromise vaginal epithelial barrier properties. Furthermore, targeting early stages of 
the HIV-1 infection accompanied by computation and delivery of appropriate microbicide 
quantities could result in an effective microbicide formulation.  
 
In an effort to address microbicide formulation challenges, an intravaginal delivery system able 
to deliver anti-HIV-1 agents (zidovudine and BP36) over 28 days was formulated. This delivery 
system is a caplet-shaped composite system comprising zidovudine (AZT) and BP36-loaded 
pectin-mucin-polyethylene glycol submicrospheres embedded within a poly(D,L-lactide), 
magnesium stearate, polyvinyl acetate/polyvinylpyrolidone (Kollidon® SR) and poly(acrylic acid) 
based polymeric caplet matrix.  The delivery system was tested in vitro and in vivo in the pig 
model. X-ray imaging illustrated the delivery system swelling and its matrix contrast fading over 
time as vaginal fluid permeated the matrix’s core. Plasma, vaginal fluid and tissue drug was 
detected and quantified using ultra performance liquid chromatography-tandem photodiode 
array detector. AZT plasma and vaginal fluid concentrations measured on days; 3, 7, 14, 21 and 
28 decreased gradually with time. Vaginal tissue AZT concentrations (after 28 days) were 
higher than plasma AZT concentrations and were in the same range as vaginal fluid AZT 
concentrations. The herbal extract, BP36, was detected in plasma, vaginal fluid and tissue but 
was only qualitatively analysed due to its lack of standardization. Histopathological analysis of 
excised vaginal tissue revealed different scores of abnormalities comprising mild to moderate 
epithelial proliferation and exocytosis, subepithelial leukocyte influx, perivascular cell cuffing and 
isolated epithelial erosion, stromal fibrosis and isolated tissue necrosis.  
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CHAPTER 1 
BACKGROUND AND MOTIVATION FOR THE FORMULATION OF AN INTRAVAGINAL 
DELIVERY SYSTEM TO PREVENT TRANSMISSION OF STIs INCLUDING HIV-1   
 
1.1. Introduction  
On average 2.5 million people worldwide were infected with HIV-1 in 2011 and approximately 
1.8 million of them were from Sub-Saharan Africa (WHO Data and Statistics, 2011). Existing 
infection prevention measures, including education and condom use, are already being utilized 
to curb HIV-1 transmission. Condoms are approximately 90-95% effective in preventing HIV-1 
transmission but their use is mired by improper and male-controlled usage (Pinkerton and 
Abramson, 1997). Therefore, HIV-1 transmission is still a major challenge, especially in South 
Africa and Sub-Saharan Africa. A promising new preventative modality is the use of 
microbicides, which are chemical entities that are proposed to reduce HIV-1 transmission when 
applied vaginally or rectally (Coplan et al., 2004). These pharmaceutical applications can be 
used discretely, therefore aiding in effective prevention of HIV-1 transmission by the volition of 
the female partner thereby shifting the responsibility of HIV-1 transmission prevention from the 
dominion of men to that of women (World Health Organization, 2009; Coplan et al., 2004). The 
incessant spread of HIV-1, the failure of condoms to provide foolproof protection and the still-to-
be discovered or invented cure and/or vaccine make microbicides the new face of hope 
(UNAIDS, 2010; Gabby and Gibbs, 1996; Crosby et al., 2005; Walsh et al., 1999).  
 
Starting with the Nonoxynol-9 (N-9) surfactant followed by a plethora of other microbicides, 
there has been a surge in scientific research in HIV-1 prevention using microbicides, with 
several potent anti-HIV-1 compounds being discovered (Cutler and Justman, 2008). However, 
very few tangible successes have been recorded from a human effectiveness viewpoint (Cutler 
and Justman, 2008). There is no microbicide that is effective against HIV-1 on the market to 
date, yet there are numerous patents of microbicide candidates resulting in the current paradox 
and inspiration for partaking on this study, whereby, there are successful in vitro microbicide 
studies but disappointing in vivo human studies. Leading us to point at, ‘ineffective delivery 
systems’, as exemplified by the failure of Pro2000 (Endo Pharmaceuticals Solutions, Chadds 
Ford, PA, USA; McCormack et al., 2010), as the cause of microbicide failures. Therefore, inept 
systems which have been employed to deliver microbicides, may have contributed to the lack of 
correlation between in vitro and in vivo efficacies. Available microbicide applications are mostly 
gels, thus effectiveness is dependent on gel distribution and residency intravaginally.  
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The route of HIV-1 infection through the vaginal wall involves a substantial amount of virons 
penetrating the mucosal epithelia and attacking the susceptible immune cells in the subepithelia 
(Fox and Fidler, 2010). The infected subepithelial cells disseminate to the regional lymph nodes 
leading to systemic infection (Fox and Fidler, 2010). HIV-1 epithelial cell layer bypass may occur 
indirectly via Langerhans cell-assisted entry or directly through the disrupted vaginal epithelia 
layer (Wu and KewalRamani, 2006). To prevent HIV-1 infection, potent microbicides have to 
create a quantitative and qualitative chemical or physical barrier. This entails the microbicide 
being present at the site of action longer than the residence time of HIV-1. Additionally, the 
microbicide has to be bioavailable in the subepithelia to prevent HIV-1 dissemination to the local 
lymph nodes (Cutler and Justman, 2008; Mayer and Pizer, 2009). 
Therefore this study aimed at designing a composite polymeric intravaginal delivery system for 
dual delivery of a novel microbicide agent (BP36) and an antiretroviral (ARV) zidovudine (AZT). 
The composite polymeric delivery system, in caplet form would be inserted into the posterior 
fornix of the vaginal cavity as a way of reducing interference with normal vaginal activities such 
as intercourse, menstruation and micturition. Its intended position in the vaginal cavity leads to 
gravity-assisted microbicide agent distribution. The delivery system would be a submicrosphere-
embedded erodible polymeric matrix that would release active pharmaceutical ingredients (API) 
to be distributed throughout the vaginal cavity. Biocompatible and biodegradable polymers such 
as poly(D,L-lactide), polyvinyl acetate/polyvinylpyrolidone, poly(acrylic acid), pectin, porcine 
gastric mucin and poly ethylene glycol were the main polymers for the assemblage of the 
composite polymeric delivery system. Mucoadhesive properties of the delivery system were 
provided by the incorporation of poly(acrylic acid). The delivery system was designed to eroded 
and release the active pharmaceutical ingredients (BP36 and AZT) dually encapsulated in the 
pectin-mucin-poly ethylene glycol submicrospheres. 
The submicrospheres were to be synthesized from biocompatible and biodegradable polymers 
such as pectin, mucin and polyethylene glycol. The interpenetration of pectin fibres and mucin 
(Sriamornsak and Wattanakorn, 2008) would be exploited to encapsulate the active 
pharmaceutical ingredients and to modulate drug release from the delivery system. Upon 
hydration the submicrospheres would, in a modulaterd manner, release the active 
pharmaceutical ingredients (APIs) into the vaginal cavity. The APIs would then be distributed 
throughout the vaginal cavity through gravity and inherent vaginal movements to create a 
chemical barrier against HIV-1 transmission. The matrix of the composite polymeric delivery 
system, to be formulated from poly(D,L-lactide, polyvinyl acetate/polyvinylpyrolidone, and 
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poly(acrlic acid) would swell upon absorption of vaginal fluid and erosion takes place creating 
pores through which the anti-HIV-1 agents would percolate. The erosion of the polymeric matrix 
was envisaged to involve the hydrolysis of poly-D.L-lactide and the solubilization of the polyvinyl 
pyrolidone part of polyvinyl acetate/polyvinylpyrolidone. Poly(D,L-lactide) hydrolysis in the 
aqueous vaginal environment would produce acids and diacids that would help to maintain the 
acidic vaginal pH which is hostile to pathogens (Li and McCarthy, 1999). Absence of additional 
fluid from the delivery system itself renders discreetness to the composite polymeric delivery 
system unlike gel-based formulations. 
 
The choice of the anti-HIV-1 agents used was made to ensure greater success in preventing 
HIV-1 transmission. BP36, a natural product extract has been discovered to have anti-HIV-1 
properties whose mode of action include HIV-1 entry inhibition whilst zidovudine (AZT) would be 
employed to counter the virus that would have bypassed the viral entry-inhibition stage and it 
would prevent viral replication. Therefore, the composite polymeric delivery system would have 
two different modes of action, entry inhibition and replication prevention, thus activity will be 
both intracellular and extracellular. The delivery of the anti-HIV-1 agent/s using a composite 
polymeric delivery system was further tested in vivo in the pig model. 
 
1.2. Rationale and motivation for this study 
The design of a microbicide delivery system should at least ensure that the microbicide: 
• Acts as a foolproof chemical and or physical barrier at the vaginal mucosal layer. 
• Outlasts the virus: be always present at the site of action. 
• Prevents dissemination of infected cells from the sub-epithelia to the regional lymph nodes 
(Mayer and Pizer, 2009). 
Failed microbicides such the nonoxynol-9 surfactant showed in vitro success of disrupting the 
HIV-1 membrane. However, in vivo studies have shown that nonoxynol-9 also disrupts the 
vaginal epithelial membrane integrity thus increasing HIV-1 transmission according to the COL-
1492 study (Van Damme et al., 2002). Gel microbicides formulations have failed to outlast the 
virus. They are as good as their distribution and residence at the site of action. These gel 
formulations also fall short in preventing the dissemination of infected cells from the mucosa to 
the lymph nodes simply because they are not bioavailable in the sub-epithelium. 
 
With enough scientific input, analysis and innovation microbicides delivery can be improved. 
The understanding of the human vaginal anatomy and physiology is important when designing a 
 4 
 
microbicide delivery system. Anatomical markers that can help and have incited us to consider 
this study include the presence of a posterior vaginal fornix and mucus-lined mucosal 
membrane that can act as a port of anchor for a long-term delivery system. Thus formulating a 
delivery system able to prolong anti-HIV-1 agent release for at least a month to curtail drug 
dosing frequency challenges and ensure that the anti-HIV-1 agent/s outlasts the virus is key. 
Taking a cue from the successes of triple therapy in antiretroviral treatment and the use of 
antiretrovirals (nevirapine therapy) in the prevention of mother to child transmission, this study 
employs a model antiretroviral, AZT together with a novel microbicide agent, BP36, to prevent 
HIV-1 transmission.  
 
According to the  Council for Scientific and Industrial Research (CSIR) BioSciences (the 
organization that holds the patent for BP36) BP36 is a sulfated polysaccharide containing 
galacturonic and methyl galacturonic moieties  whose anti-HIV-1 properties involve the blockage 
of HIV-1’s attachment to the gp120 site on T-cells. BP36 was shown to have anti-HIV-1 activity 
with the same potency as AZT and nevirapine as demonstrated in the multinuclear-activation 
galactosidase indicator (MAGI) assay they conducted. BP36 is an extract from a native plant of 
South Africa. Hence, its success would materialize in financial benefits for the local people as 
they would be involved in the agricultural production and marketing of the plant.  
 
The microbicide pipeline has several ‘inadequate’ microbicide delivery systems. Most of these 
are gels and semi-solids which are indiscreet when used (Rohan and Sassil, 2009). These 
unaesthetic modalities have motivated us to look at another angle, a composite polymeric 
intravaginal delivery system in the form of a caplet that is not a gel or semi-solid, which does not 
add to the fluid in the vagina but instead uses the vaginal fluid as a vehicle to distribute the anti-
HIV-1 agent/s throughout the vaginal cavity.  
 
The exact mechanism by which the HIV-1 infection occurs is complex. The vaginal mucosa is 
lined by stratified squamous epithelia that traditionally do not possess receptors for HIV-1 (with 
the exception of Langerhans cells which can be found on the epithelia and have extensions into 
the sub-epithelia) but the sub-epithelial tissue contains multiple targets of the HIV-1 virus (Mayer 
and Pizer, 2009). There are two common theories postulated of how the virus ends up in the 
sub-epithelium. The first is the Langerhans cell-assisted entry and the other one is that of the 
breach of the vaginal mucosa thus opening the floodgates for the virus to enter the sub-
epithelium (Wu and KewalRamani, 2006). Epithelial breach can be caused ether by local trauma 
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or by inflammation as a result of sexually transmitted infections (STIs) (Mayer and Pizer, 2009). 
The astute strategy therefore would be to prevent HIV-1 from entering the sub-epithelia. 
Therefore, this study focuses on ensuring adequate amount of the anti-HIV-1 agent is available 
in the vaginal fluid over an extended duration. Exploring these possibilities may lead us to 
create new intellectual property with possible applications of the composite polymeric delivery 
system that include; 
• The use of the delivery system to prevent transmission of HIV-1 and other STIs.  
•  The intravaginal delivery of other systemic drugs that are otherwise degraded by the normal 
gastrointestinal environment, such as insulin. 
• The delivery of drugs through the vaginal mucosa to avoid the liver’s first pass metabolism. 
• The delivery of personal hygiene, antibacterial and antifungal agents. 
• The adaptation of the delivery system for use in other sites of the body that envisage 
biodegradation and extended drug delivery as preferred characteristics.  
 
The novelty of this study involves the delivery of a combination of an antiretroviral, zidovudine, 
and a microbicide candidate, BP36, in a single extended release formulation using an optimized 
blend of polymers to yield the desired drug release properties to prevent vaginal HIV-1 
transmission. Potential scientific or societal benefits that motivated us to carry out this study 
include; 
• The possibility of adding to the HIV-1 transmission prevention arsenals already available, a 
composite polymeric delivery system that improves patient compliance thus aiding in the 
reduction of the spread and prevalence of HIV/AIDS. 
• The ability to shift the HIV-1 prevention dominion from the man to the woman since the 
delivery system may be used discreetly by women.  
•  The generation of scientific data to be published in high-impact peer reviewed journals and 
presented at various conferences for the advancement of science and medicine.  
•  The possibility of creating a home grown functional pharmaceutical application comprising 
BP36, the novel compound extracted from an indigenous South African plant, that may be 
affordable to the local population and thus have a huge positive impact on people’s quality 
of life, especially those living in the third world countries where HIV/AIDS prevalence rate is 
high. 
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1.3. An intravaginal composite polymeric system: concept and outline 
The composite polymeric delivery system was to be made up of AZT and BP36 encapsulating 
submicrospheres uniformly embedded within a polymer matrix which would be directly 
compressed into a caplet shaped dosage form as depicted in figure 1.1. The submicrospheres 
were to be made from pectin, porcine gastric mucin and polyethylene glycol whilst the caplet 
matrix would be a proportional blend of poly-D.L-lactide, polyvinyl acetate/polyvinylpyrolidone, 
poly(acrylic acid) and magnesium stearate. The functionality of the composite caplet matrix 
would involve the vaginal fluid–modulated hydrolysis of poly-D.L-lactide, penetration of vaginal 
fluid into the interior of the caplet matrix as it solubilises the polyvinylpyrolidone part of the 
polyvinyl acetate/polyvinylpyrolidone, resulting in matrix swelling. Once vaginal fluid reaches the 
caplet interior it would be absorbed by the submicrospheres causing the release of AZT and 
BP36 which will then percolate out of the caplet matrix through the pores formed by the 
solubilized polyvinylpyrolidone as well as through diffusion as the caplet matrix continues to 
swell on absorption of more vaginal fluid. The composite polymeric device would fight HIV-1 and 
STI transmission on two main fronts. The first front would be the HIV-1 in the vaginal fluid. This 
front would be countered by the anti-HIV-1 agents released into the vaginal fluid. The second 
front would the subepithelia and HIV-1 in this region would be countered by the anti-HIV-1 
agents that would have diffused though the epithelia.  
 
 
Figure 1.1: A composite polymeric delivery system inserted into the human posterior vaginal fornix  
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1.4. Aim and objectives of this study 
The aim of this study was to formulate an intravaginal composite polymeric drug delivery system 
laden with submicrospheres encapsulating anti-HIV-1 agents for the purpose of reducing 
vaginal STI and HIV-1 transmission over and extended duration. In order to achieve this aim the 
following objectives had to be met; 
1. Preformulation, formulation and optimization of drug encapsulating pectin-mucin-
polyethylene glycol submicrospheres. 
2. Elucidation of the; submicrosphere morphological characteristics, zeta potential, stability of 
the submicrosphere emulsion, Fourier transform infrared spectroscopy, thermal and 
thermogravimetric properties of the native materials and the submicrospheres. 
3. Determination of drug encapsulation and drug release from the submicrospheres as well as 
model fitting of the submicrosphere dissolution profile. 
4.  Fabrication and optimization of the composite polymeric delivery system in the form of a  
caplet by direct compression of a material blend comprising poly(D.L-lactide) polyvinyl 
acetate/polyvinylpyrolidone, magnesium stearate, AZT and BP36 laden submicrospheres  
5. Elucidation of the drug release kinetics of the composite polymeric delivery system in vitro in 
simulated vaginal fluid. 
6. Textural profiling and determination of the friability of the composite delivery system.  
7. Performance of in vivo animal studies in the Large White pig model to determine caplet drug 
release in the vaginal cavity, bioavailability of BP36 and AZT in the pig plasma and vaginal 
epithelial fluid and tissue. 
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1.5. Overview of this Dissertation 
Chapter one begins with an introduction in which the epidemiological status of HIV/AIDS and 
the huge health burden it posses to the population especially people living in Sub-Saharan 
Africa is highlighted. Furthermore, ways of preventing HIV-1 transmission are discussed with 
their advantages and disadvantages noted. One of the disadvantages noted is that the control 
of HIV-1 prevention is to a greater extent controlled by the male partner. The need to find 
alternative ways and tools to prevent the spread of sexually transmitted infections, especially 
HIV-1 became the rationale and motivation of the study with endpoints that include the shifting 
of the dominion for preventing HIV-1 transmission from the male to the female. The 
conceptualization and outline of a HIV-1 prevention modality is presented in this chapter. This 
modality is in the form of a drug-loaded composite polymeric delivery system to be inserted into 
the posterior fornix of the vagina. The delivery system, which is to be inserted discreetly by the 
woman, would release the anti-HIV-1 active/s into the vaginal cavity over an extended duration 
to prevent HIV-1 transmission. Lastly the study’s aims and objectives are outlined. 
 
Chapter two is a critical review of the progress made thus far in microbicide research. It 
outlines the successes and failures reported, with a table containing a comprehensive summary 
of some of the clinical trials performed on microbicides candidates. This chapter also reviews 
the different factors involved in vaginal HIV-1 infection and then discusses key issues that need 
to be addressed during microbicide development. Among the subjects discussed are: the 
determinants and dynamics of HIV-1 infection; the vaginal cavity and the challenges and 
opportunities it presents as a site for microbicide delivery and qualitative microbicide targeting 
that involves, direct viral and cellular targeting, vaginal microenvironment targeting, subepithelial 
targeting and multitargeting. Quantitative targeting was also identified as a key element that 
determines the success or failure of a microbicide with two new terms coined; microbicide 
critical activity window (MCAW) which refers to the initial phase of HIV-1 transmission when 
microbicide intervention would most likely succeed and the microbicide critical concentration 
(MCC) which refers to the minimum amount of microbicide agent required to prevent HIV-1 
transmission during the initial stages of infection.  
 
Chapter three details the characterization and preformulation studies performed on the anti-
HIV-1-agents (zidovudine and BP36) and the biocompatible and biodegradable polymers; 
pectin, porcine gastric mucin (mucin) and poly ethylene glycol. The aim of the preformulation 
studies was to infer if it was possible to harness the individually desirable characteristics of the 
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polymers by combining them to form submicrospheres. Therefore, the focus of the 
preformulation study was the formation of a macromolecular interpenetrating network of pectin, 
mucin and poly ethylene glycol. Techniques used to determine pectin, mucin and poly ethylene 
glycol interactions included; attenuated total reflection Fourier transform infrared spectroscopy 
(AT-FTIR), thermal and thermodynamic analysis using differential scanning calorimetry (DSC) 
and thermogravimetric analysis (TGA), ultraviolet spectroscopy and rheology measurements of 
aqueous dispersions of the polymers. Furthermore, static atomistic simulation of the pectin-
mucin-poly ethylene glycol submicrospheres was performed as a precursor to the experimental 
formulation of the submicrospheres which was then carried out in chapter four. 
 
Chapter four provides details on the formulation of drug loaded pectin-mucin-poly ethylene 
glycol submicrospheres using the emulsion crosslinking technique. A 3 factor 3 level (33) Box-
Behnken statistical design was utilized in the optimization of the preparation of drug-loaded 
submicrospheres. In the Box-Behnken design; ultrasonication time, surfactant concentration and 
drug:polymer ratio were taken as the independent parameters whilst; particle size, zeta potential 
and mean dissolution time were regarded as dependent parameters or responses. 
Determination of the stability of the water in oil (W/O) emulsion, a crucial intermediate in the 
formation of submicrospheres, was performed and detailed in this chapter. In addition, the 
characteristics of the submicrospheres including particle size and zeta potential are presented. 
Submicrosphere drug encapsulation and release were measured and key parameters such as 
submicrosphere encapsulation efficiency and the mean dissolution time were determined. Other 
techniques used to confirm the composition and characteristic of the drug loaded pectin-mucin-
polyethylene glycol submicrospheres include; AT-FTIR, DSC, TGA and X-ray diffraction. 
 
Chapter five reports on the fabrication of a composite polymeric delivery system in the form of 
a caplet composed of drug loaded pectin-mucin-poly ethylene glycol submicrospheres 
embedded within a polymeric matrix blend of poly(D,L-lactide) and polyvinyl 
acetate/polyvinylpyrolidone. A 33 Box-Behnken design was employed to optimize the caplet 
with; mass of poly(D,L-lactide), mass of magnesium stearate and mass of polyvinyl 
acetate/polyvinylpyrolidone taken as independent parameters whilst the fraction of drug 
released in 7 days, the caplet hardness and fractional simulated vaginal fluid (SVF) intake were 
the dependent parameters or responses. Drug release studies performed on the caplet over 30 
days are presented in this chapter. Characterization of the dissolution profiles was attained by 
determining specific parameters such as mean dissolution time, dissolution efficiency and fitting 
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the dissolution profile into different known kinetic models. Caplet characterizations provided in 
chapter 5 include textural profile analysis that involves the determination of caplet matrix 
hardness and matrix resilience using a texture analyzer. The friability of the caplet was also 
tested 
 
Chapter six describes the in vivo studies performed which involved intravaginal application of 
the composite delivery system in Large White pigs with the intention of having the delivery 
system retained intravaginally for 30 days whilst blood samples and vaginal swabs are taken at 
predetermine time points. On completion of in vivo experimentation, the pigs were euthanized 
and their vaginal tissue was excised for further histopathology examination. In the chapter, 
detection and quantification of drug from withdrawn plasma samples, vaginal swabs and in 
tissue were performed using ultra performance liquid chromatography-tandem photodiode array 
(PDA).  
 
Chapter seven is the conclusions and recommendations section of this dissertation. It provides 
the summation of various aspects discussed in the dissertation on microbicide development in 
general and the composite polymeric delivery system in particular. Recommendations for further 
research on microbicides and microbicide delivery with a focus on the observed shortcomings of 
the composite delivery system are provide in this chapter. 
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CHAPTER 2 
A REVIEW OF THE KEY ASPECTS ESSENTIAL FOR ANTI-HIV-1 MICROBICIDE DELIVERY 
SUCCESS  
 
2.1. Introduction 
There has been an increase in interest among pharmaceutical scientists for the possible use of 
anti-HIV-1 agents as microbicides to prevent heterosexual vaginal HIV-1 transmission. 
However, clinical studies conducted have largely been disappointing. This chapter reviews the 
development of microbicides with an aim to expand the view that unsatisfactory microbicide 
failures may be a result of inefficient delivery systems employed. A thorough scientific 
qualitative and quantitative analysis of important aspects involved in HIV-1 transmission as a 
prerequisite for microbicide delivery is discussed in this chapter. Highlighting that intraluminal 
vaginal targeting of HIV-1 increases the chances of microbicide success, wherein the micro-
environmental factors including pH is maintained at HIV-1 prohibitive acidic levels 
simultaneously to ward off other sexually transmitted diseases which compromise vaginal 
epithelial barrier properties. Furthermore, choice of receptors to target, both on HIV-1 and on 
target cells is vital in deterring transmission. Appropriate modeling of virus-target cell 
interactions as well as targeting early stages in the HIV-1 infection, accompanied by 
computation and delivery of appropriate microbicide quantities have the potential of delivering a 
women-controlled HIV-1 prevention modality. 
 
Several novel compounds are being discovered and existing ones are being tried for the 
treatment of HIV/AIDS yet the eradication of the disease remains elusive, leading to a refocus 
towards prevention (Ndesendo et al., 2008; Hladik et al., 2010). Contemporary strategies 
include microbicides, vaginally or rectally applied topical chemical agents, having the ability to 
block HIV-1 infection (Hladik et al., 2010). Nonoxynol-9 was the first chemical entity to be 
extensively tried as a preventative microbicide against HIV-1. It is quite effective as a viral 
membrane lysis agent, however its efficacy in vivo as an HIV-1 prevention application was not 
demonstrated due to its detrimental effects on the vaginal membrane which even led to an 
increase in HIV-1 infection according to the COL-1492 study (Van Damme et al., 2002). Several 
microbicide trials have failed, restricting microbicide agents to test tube therapies (Baleta 2007; 
Hendrix et al., 2009). They may be highly effective in vitro but they are not sufficiently effective 
in vivo (Cutler and Justman, 2008).  Various reasons have been postulated to explain this failure 
of microbicides. This chapter focuses on microbicide formulation and delivery as one of the 
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causes of microbicide failures and as an aspect that can be improved to enhance microbicide 
efficacy. 
 
Potent anti-HIV-1 agents have been formulated into gels, creams, tablets and rings. Gels and 
creams are applied prior to and/or after coitus. They constitute the anti-HIV-1 agent in a gel or 
cream vehicle which will cover the vaginal epithelia when applied creating a chemical and 
physical barrier to HIV-1. The advantage of using such formulations is that the gel or cream can 
be tailored to enhance gel or cream adherence to the vaginal epithelia by employing 
mucoadhesive materials such as mucoadhesive polymers. Gels and creams may also act as 
lubricants needed during coitus to avoid vaginal epithelial microtrauma which compromises 
vaginal epithelial integrity. However gels and creams are indiscreet (i.e. messy and sticky), they 
are short acting thus require frequent application and their efficacy depends on the extensive 
and exclusive coverage of the vaginal epithelia to create a comprehensive microbicide barrier. 
On the other hand tablets and rings are discreet and are inserted into the vagina well before 
coitus. They release the potent anti-HIV-1 agent upon degradation, erosion, disintegration or 
diffusion of the anti-HIV-1 agent from the dosage form matrix.  Their disadvantages are that they 
have to release the right quantity of anti-HIV-1 agent at the desired time (i.e. on exposure to 
HIV-1) and the anti-HIV-1 agent has to sufficiently distribute in the vaginal cavity to prevent HIV-
1 transmission.  
 
A comprehensive list of some of the microbicide trials that have been carried out thus far is 
illustrated in table 2.1. A closer analysis of this table reveals that most microbicide trials pass 
phase I tests, a few pass phase II testing and although microbicide research has recently 
revealed the success of a phase IIb CAPRISA 004 tenofovir gel trial (Abdool Karim et al., 2010; 
Mohammadi, 2010), there has not been any successful phase III trial. Therefore, there is 
nothing on the market in the form of a microbicide to effectively deter the HIV-1 transmission. 
Table 2.2 enlists microbicide agents that have been formulated into different delivery systems 
(i.e. gels, creams, tablets and vaginal rings) and the mechanism by which they inhibit HIV-1 
transmission. These formulations include the ones that have failed at different stages of clinical 
trials and others still under investigation. 
 13 
 
Table 2.1: Microbicide clinical trials 
Phase I 
 
Phase I/II 
 
Phase II 
 
Phase II B 
Phase II/IIB 
Phase III 
Phase II/III 
 
*IPM 010/ 
MTN 012 
° Male 
tolerance 
-Dapivirine 
gel 
+Ongoing5,93,1
33
 
 
*MTN 002 
° P/K and 
Placental transfer 
+Data analysis 
Shown to be safe 
for pregnant 
women with less 
transfer of drug to 
foetus compared 
to oral dosage133 
 
*Invisible 
Condom® 
° Safety and 
acceptability 
+Result-2007: 
Safe, well 
tolerated and 
acceptable6 
 
*HPTN 047 
° Safety and 
acceptability 
study 
-Pro 2000/5 
gel 
+Result- 2006 
Safe and 
acceptable85 
 
*IPM 014A 
° Safety and 
acceptability 
-Dapivirine 
gel 
+Safe and 
well 
tolerated93,63 
 
 
*MTN  010 
° Expanded 
safety 
-UC-781 gel 
+Withdrawn133 
 
*VOICE (MTN 
003) 
° Safety and 
efficacy 
-Tenofovir gel 
+Ongoing5,64 
 
 
*IPM 009 A/B 
° Efficacy 
-Dapivirine  ring 
+To be 
determined93,64 
 
 
*MIV-
150/Zinc Salt 
Gel study 
+Planned4 
 
*TFV 010 
-Tenofovir gel 
+Data analysis4 
 
*IPM 001 
° Safety 
-Dapivirine  ring 
+Result-2009 : 
Safe and well 
tolerated93 
*HPTN 049 
° Safety and 
acceptability 
study 
-6% Cellulose 
sulphate  gel 
+Result-2006: 
Safe , well 
tolerated and 
acceptable85 
 
 
 
*IPM 014B 
° Expanded 
safety 
-Dapivirine 
gel 
+Data 
analysis93,64 
 
 
 
*MTN 001 
° Adherence 
and P/K 
-Tenofovir gel 
+Closed , to 
follow up 133,13 
 
*CAPRISA 004 
° Safety and 
efficacy 
-1% Tenofovir 
gel 
+Result – 2010:  
39% 
effective64,3 
 
*MDP 302 
-Tenofovir gel 
+Planned4 
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*Vaginal 
Applicator 
Study 
-Tenofovir gel 
+Planned3 
*RMP 002/ MTN 
006 
° Safety study 
-Tenofovir gel 
+Relatively safe 
134
 
*IPM 008 
° Safety 
-Dapivirine  ring 
+Result- 2009: 
Safe and well 
tolerated14 
*Project Gel 
°Safety and 
acceptability in 
young men 
-Tenofovir 
+Result – 
Ongoing5 
*IPM 015 
° Expanded 
safety 
-Dapivirine 
vaginal ring 
+Ongoing 
Planned5,64 
*HPTN 059 
° Expanded 
safety and 
acceptability 
-1% Tenofovir 
gel 
+Results-2008: 
Safe to use 
daily for six 
months85,133 
 
*MTN 003B 
°Bone and 
mineral 
density study 
-Tenofovir 
Gel 
+Enrolling5 
*FHI Cellulose 
Sulphate Gel 
° Safety and efficacy 
+Result- 2007: 
Trial stopped after 
CONRAD trial56,89 
 
*PK/PD  
° Safety 
Study 
-UC-781 gel 
+Planned4 
*Ethanol in 
emollient gel 
° Safety  
+Ongoing6 
*IPM 012 
° P/K 
-Dapivirine gel 
+Results- 2010 
Safe and well 
tolerated93 
 *NCT001366
43 
° Safety and 
tolerability 
-Invisible 
Condom® 
+Result- 
2007: 
Safe, well 
tolerated and 
acceptable201 
 
*Praneem 
polyherbal 
vaginal tablet 
° Expanded 
safety 
+Result- 2008 
Safe for 6 
months use6 
 
 
*CARRAGUARD 
Gel 
° Safety and efficacy 
+Result – 2008: 
Safe but no 
evidence of 
efficacy3,4 
 
*Zinc Salt 
Gel Study 
Zinc acetate 
gel 
*AF 020 
° Safety study 
-AmphoraTM/ 
ACIDIFORMTM 
*CTV-05 
LACTIN-V 
° Safety and 
acceptability 
 *IPM 003 
° Safety , 
tolerability  
and systemic 
*CTV-05 
LACTIN-V 
° Colonization 
efficiency, 
 
*MDP 301 
° Safety and efficacy 
-0.5% Pro 2000/5 
+Result – 2009 
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+Planned4 
 
 
gel 
+Ongoing5 
-Lactobacillus 
cripatus 
+Resullts- 2009: 
Safe and 
Acceptable79 
absorption 
-Dapivirine 
gel 
+Results- 
Safe and well 
tolerated for 
twice daily 
dosage93 
safety and 
acceptability 
-Lactobacillus 
cripatus 
+Result- 2010: 
High 
colonization 
efficiency, safe 
and accepted80 
No evidence of 
efficacy3 
 
*IPM 024 
° P/K 
-Dapivirine 
ring 
Data analysis 
+Result- 
2010: 
 safe and well 
tolerated93 
 
*IPM 013 
° Safety study 
-Dapivirine  ring 
+Data analysis5,93 
 
*IPM 018 
° P/K feasibility 
-Dapivirine ring 
+Results-2007, 
Pharmacokinetic 
data show 
sufficient 
distribution93 
 
  
*IPM 005B 
° Safety 
-Dapivirine 
gel 
+Results- 
2009 
Safe and well 
tolerated for 
twice daily 
application93 
  
 
*NCT00000929 
-Nonoxynol-9 film 
study 
° Efficacy 
+Result- 1998 
No evidence of 
efficacy201 
 
 
*MTN 007 
°Safety and 
acceptability 
-Tenofovir gel 
+ Ongoing4 
 
*Pilot Study 
-UC-781 gel 
+Ongoing4 
 
*HTPN 032 
° Male tolerance 
and toxicity 
acceptability 
study 
-BufferGel and 
    
*COL-1492 study  
° Efficacy 
-Nonoxynol-9 gel 
+Result-2002: 
No evidence of 
efficacy. 
Toxicity  and 
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Pro 2000/5 gel 
+Result- 
Safe and 
tolerated85 
increased infectivity 
with multiple use204 
P/K – Pharmacokinetic   
Structure: 
* Study name or identifier 
° Type of study 
-Active pharmaceutical ingredient and/dosage form 
+ Result or status 
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A critical review of HIV-1 infection mechanisms and pathways by analyzing the cellular 
components that involved; Langerhans cells, macrophages, T-cells, dendritic cells and their 
respective receptors and co-receptors, gp120, gp41, CD4+, CXCR4, CCR5, langerin and 
DC-SIGN is also done in this chapter. In order to increase microbicide chances of preventing 
HIV-1 transmission, the choice of receptors and co-receptors to target is vital and is 
discussed in detail. The properties and role of the vaginal epithelia in the prevention of HIV-1 
transmission, ways of enhancing those properties and how microbicides can be tailored to 
provide a comprehensive anti-HIV-1 barrier are also given due consideration. This chapter 
deliberates on the contentious issue of the appropriate microbicide quantity essential to 
block HIV-1 in the vaginal cavity. Due to the variability of the vaginal cavity dimensions, the 
concentrations of virus in semen and the frequency of coitus, different microbicide 
formulations have to be tailored to deliver enough anti-HIV-1 agents to deter transmission. 
After scientifically considering all important aspects and issues raised in this analysis and by 
employing techniques such as the use of combination anti-HIV-1 agents released from 
extended microbicide delivery systems, scientists may be able to develop an effective 
microbicide. 
 
Table 2.2: Different microbicide formulations  
Chemical Entity                      Formulation/Delivery 
System 
Anti-HIV-1 Activity                    
 
Carbomer® (polyacrylic acid)207 
 
Gel - BufferGelTM 
 
Acidifying agent.  
 
Carrageenan14,159 
 
Gel - Carraguard® Blocks viral infected semenal 
mononuclear cell migration. 
 
Cellulose acetate phthalate  
(CAP)123 
Gel 
 
Adsorbs and inactivates  virus 
Cellulose sulphate9 Gel – UshercellTM Viral replication inhibitor 
 
Cetyl Betaine54,148 Cream - C31G , SavvyTM Broad spectrum antimicrobial 
 
Cyanovirin-N15,199 Gel Viral entry inhibitor, 
Blocks virus-CD4+ fusion. 
 
Dapivirine (TMC120)148,185 Vaginal ring  Inhibits viral replication, 
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NNRTI148 
 
Monocaprin197 Hydrogel Inactivates virus 
 
Myristamine oxide54 Cream- C31G, SavvyTM Inactivates virus 
 
Napthalene Sulphonate127 
 
Gel – Pro 2000TM Disrupts viral cell membrane 
Nonoxynol-9 (N- 9)8 Gel- Advantage S® Disrupt viral cell membrane 
 
Polystyrene sulfonate 
(PSS)61,148 
Vaginal tablets 
Gel- (T-PSS) 
Fusion inhibitor 
 
 
Praneem (Azadirachta indica, 
Neem tree)97,148 
Vaginal tablets Unknown, possibly 
cytoadhesion inhibition 
 
Sodium lauryl sulphate 
(SLS)164 
 
Gel- Invisible CondomTM    Fusion and entry inhibitor 
 
SPL7013148,96 Gel- VivaGel TM    Fusion and entry inhibitor 
Uses dentrimer technology 
 
Stapidine142 Gel NRTI88 
 
Tenofovir disoproxil fumarate 
(TDF)148 
Gel-PMPA gel, TenofovirTM Viral replication inhibitor 
NRTI88 
 
Theophen-thiourea  (PHI-
443)148 
Gel Viral replication inhibitor 
NNRTI148 
 
UC-781148 Gel 
 
Viral replication inhibitor 
NNRTI148 
1 Non-nucleoside reverse transcription inhibitor                        
2 Nucleoside reverse transcription inhibitor 
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2.2. Mechanism of HIV-1 infection: determinants and dynamics 
The mode of HIV-1 transmission among humans has been under intensive investigation 
from the time when HIV-1 was first discovered. Technological advances in viral detection 
have made it easier for researchers to be able to understand the cellular and molecular 
mechanisms of HIV-1 transmission. Transmission can be established either by cell-free or 
cell-associated viruses (Hladick and Hope, 2009). Investigation has shown that in several 
instances HIV-1 invasion occurs when the virus penetrates the epithelia then goes into the 
subepithelia, passes through the lymphatic system and ultimately enters the systemic 
system (Haase, 2010). How it manages to penetrate the vaginal epithelia has been attributed 
to several pathways, simplest of which involves the free passage of the virus through 
breached epithelia (Morrow et al., 2007; Nazli et al., 2010).  Epithelial disruption can be 
caused by several factors including microtrauma during sexual intercourse, use of irritating 
chemicals or as a result of inflammation caused by co-infection with other sexually 
transmitted diseases (Norvell et al., 1984; Gray and Wawer, 2007; Wilkinson, 2007; Van de 
Perre et al., 2008; Hayes et al., 1995; Hester and Kennedy, 2003). 
Figure 2.1 is a comprehensive time-based illustration of the HIV-1 infection process. HIV-1 
has been shown to transcytose the single columnar epithelia, particularly at the 
squamocolumnar junction where high cell turnover enhances HIV-1 penetration through 
epithelial transcytosis (Bomsel, 1997). Another well documented epithelial HIV-1 
transmission strategy used by HIV-1 is the Langerhans-cell assisted HIV-1 transfer route 
(Pignet and Blauvelt, 2002; Wu, 2008). Langerhans cells (LCs) are considered to be the 
bastions of epithelial immunity (Pignet and Blauvelt, 2002; Wu 2008). Their immature forms 
abide within the subepithelia whilst having cellular projections onto the epithelial surface and 
into luminal compartments of the vaginal cavity. The job of LCs is to detect and interact with 
the invading HIV-1, after which they migrate, maturing in the process, to the T-cell rich lymph 
nodes where they present HIV-1, initiating an immune response. HIV-1 manipulates this 
process to penetrate the vaginal epithelial barrier. Immature LCs residing within the epithelial 
layer express CD4+ receptors and CCR5 co-receptors which are essential for HIV-1 
infection. The productively infected LCs migrate into the subepithelia and ultimately towards 
the lymph nodes where they transfer HIV-1 to T-cells (Zaitseva et al., 1997; Kawamura et al., 
2003). Another chemokine co-receptor expressed by LCs is CXCR4 and is only expressed 
by the mature LCs (Zaitseva et al., 1997; Zhang and Moore, 1999). However, the role of 
CXCR4 as an HIV-1 trans-epithelial passage facilitator is limited as it has been shown that 
the majority of HIV-1 strains isolated from patients immediately after primary infection utilized 
the CCR5 co-receptor (R5 virus) as compared to the CXCR4 co-receptor (X4virus) (Zhang 
and Moore, 1999). 
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Figure 2.1: Schematic of HIV-1 infection pathway and mechanism (adapted from Wu and KewalRamani 2006).
 `                    
There is a sudden increase in further HIV-1 transmission once the virus passes the vaginal 
epithelia and enters the subepithelia, aided by an increase in concentration of HIV-1 
susceptible cells that include; T-cells, macrophages and dendritic cells (DC) (Shen et al., 
2011; Wu and KewalRamani, 2006). HIV-1 either productively infects some of these cells 
through receptor and co-receptor interactions or it captures the virus using the dendritic cell-
specific intracellular adhesion molecule (ICAM) grabbing non-integrin (DC-SIGN, CD209) 
whose affinity for the HIV-1 gp120 is stronger than that for CD4 (Geijtenbeek et al., 2000). 
Figure 2.2 illustrates the various HIV-1-receptor interactions that may occur during the 
infection process (De Witte et al., 2007). Monocyte derived dendritic cells (MDDC) which 
express DC-SIGN can bind and transfer HIV-1 without being infected in a process referred to 
as trans-infection, whereby HIV-1-carrying dendritic cells facilitate the infection of T-cells by 
concentrating the virus in an infectious synapse (Kwon et al., 2002; Donaghy et al., 2006). 
An augmenting process termed cis-infection occurs concurrently; this is whereby HIV-1 
attached via DC-SIGN is directed onto the same DC membrane for CD4-co-receptor 
dependent membrane fusion (Kawamura et al., 2003). 
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Figure 2.2: HIV-1 interactions with receptors and co-receptors on Langerhans cells (LCs) and dendritic cells 
(DCs) (adapted from Kawamura et al., 2005; De Witte et al., 2007). 
 
 
Figure 2.3: Transmission electron micrograph (TEM) of: a) HIV-1 virus captured by a dendritic cell; b) HIV-1 virus 
attached to a dendritic cell (adapted from Blauvelt et al., 1997). 
 
In figure 2.3.a, C-type lectin DC-SIGN is involved in the attachment and capture of  HIV-1 
into a low pH non-lysosomal competency retention compartment in the DC for further trans-
infection to CD4+ and chemokine expressing cells (Blauvelt et al., 1997), whereas in figure 
2.3.b there is direct viral and DC membrane fusion as a consequence of the attachment of 
the viral gp120 to the DC CD4+ and the chemokine co-receptor. HIV-1 viral capture by 
dendritic cells is independent of DC4, CCR5 and CXCR4 whilst productive dendritic cell 
infection is CD4, CCR5 and CXCR4 dependent (Blauvelt et al., 1997). The complexity of the 
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HIV-1infection poses a huge challenge to the defence capacity of the human immune 
system; however it also provides numerous opportunities for external therapeutic 
interventions to prevent transmission. Knowing and understanding these complex HIV-1 
infection pathways are a prerequisite for microbicide development since each pathway and 
cellular target in the infection sequence may present a possible way to prevent HIV-1 
transmission.  
 
2.3. The vagina as a target site for microbicide delivery 
Research has shown that the majority of HIV-1 infections occur by passage of viral particles 
through the epithelia of various body organs (Pope and Haase, 2003; Epple et al., 2010). 
Viral particles, cell-bound or not, are carried in most body fluids and are particularly 
abundant in genital fluids. The type of epithelial cells lining the vaginal cavity is a major 
determinant in HIV-1 transmission (Epple et al., 2010). Table 2.3 shows different locations of 
the vaginal epithelial layer and the types of epithelial cells that constitute it (Hladick and 
McElrath, 2008). The vaginal cavity is partially lined by both, a columnar epithelial monolayer 
on the endocervix and less susceptible stratified squamous epithelia on the vagina and 
ectocervix (Hosein and Wilson, 2011; Celum et al., 2008). 
 
Table 2.3: HIV-1 invasion sites, location and the type of epithelial cells located there (Hladick 
and McElrath, 2008). 
HIV invasion site Anatomical location Epithelium type 
 
 
 
 
Female genital tract 
 
Vagina 
 
Squamous  
Stratified 
 Non-keratinized  
 
Ectocervix Squamous 
Stratified 
Non-keratinized 
 
Endocervix Columnar  
Monolayer 
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In designing microbicide delivery systems, one should always take into account the epithelial 
cell location and type. A good example of where the location and epithelial cell type has 
contributed in mitigating HIV-1 transmission is in male circumcision (Templeton, 2010; Bailey 
et al., 2007; Gray et al., 2007; Siegfried et al., 2005; Denniston and Hill, 2007). Circumcision 
in males has been found to reduce transmission by more than 50% and this can be 
attributed to post-circumcision reduction in the squamous epithelial layer surface area due to 
the removal of the foreskin, which also houses LCs that facilitate HIV-1 infection (Templeton, 
2010; Bailey et al., 2007; Gray et al., 2007; Siegfried et al., 2005; Denniston and Hill, 2007). 
Microbicides delivery systems should maintain the epithelial barrier lining or enhance it, but 
not disrupt it as in the case of Nonoxynol-9 gel in the COL-1492 study (Van Damme et al., 
2002).  
 
In this dissertation, focus is on the vaginal cavity as it has been anatomically shown that 
chances of succeeding in deterring HIV-1 transmission occurring via the vaginal route are 
higher compared to other routes such as the rectal route (Hladick and McElrath, 2008). 
Additionally the vaginal cavity is a semi-closed pouch unlike the rectum which is an open-
ended tube-like system (Stone, 2002). This makes it easier for extensive intravaginal 
microbicide distribution and retention to be achieved. The dimensions of the vaginal cavity 
vary depending on factors such as age, height and the sexual arousal state (Barnhart et al., 
2006). This presents a challenge when trying to determine the sufficient microbicide 
formulation quantity required to prevent HIV-1 transmission. However, the use of 
experimentally determined average vaginal cavity dimensional values may be useful in 
microbicide delivery system design. Barnhart and co-workers determined the mean vaginal 
length from the cervix to the introitus as 62.7mm, with the vaginal width being greatest in the 
proximal vagina, 32.5mm, decreasing at the proximal diaphragm, 27.8, and smallest at the 
introitus, 26.2mm (Barnhart et al., 2006). 
 
2.4. Qualitative microbicide targeting  
The delivery of potent anti-HIV-1 agents intravaginally has to be tailored to match the pre-
existing anatomical and physiological conditions. In order to effectively prevent HIV-1 
transmission, certain aspects in the HIV-1 transmission pathway have to be prioritized and 
particular targets have to be pursued. Such targets include viral and cellular targets, vaginal 
epithelia, the vaginal cavity microenvironment and subepithelial microbicide bioavailability 
(Haase, 2010; Wu, 2008). In addition, there has to be some correlation between employing 
an anti-HIV-1 agent and preserving or enhancing the host defence system. 
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2.4.1.     Direct viral and cellular targeting 
Strategic targeting of HIV-1 is important to achieve an effective microbicide as HIV-1 uses a 
complex combination of proteins and receptors, some of which have already been 
mentioned earlier in this chapter. Table 2.4 gives an array of receptor targets that can be 
exploited by microbicide agents. The variety of HIV-1 targets is a dilemma for microbicide 
developers as to which anti-HIV-1 agent to use. Hu and co-workers provided some light as 
which receptor/s microbicide developers should prioritize (Hu et al., 2004). Ex vivo studies 
on human cervical tissue explants demonstrated that in addition to the blockage of viral 
gp120 cellular targets, CD4 alone or CCR5 and CXCR4 together, other non-HIV-1 receptors 
such as mannose-binding C-type lectin receptor (MCLR) DC-SIGN, mannose receptor (MR) 
and non-MCLRs should also be blocked (Hu et al., 2004; Pohlam et al., 2001; Jameson et 
al., 2002; Gummuluru et al., 2003; Turvile et al., 2004). Blockade of the gp120 removes 
downstream receptors such as the g41 from the equation and ultimately renders HIV-1 non-
infectious. Additionally, Lamers and co-workers predicted the use of the R5X4 co-receptor 
with an accuracy of 75.5% using neural networks proving that dual tropic viruses may 
increase microbicide efficacy (Lamers et al., 2008). 
 
Table 2.4: HIV-1 receptor targets and their corresponding inhibitory agents (Balzirini and Van 
Damme, 2007; Shattock and Solomon, 2004). 
Viral envelope glycoprotein Anti-HIV-1 microbicide agent 
gp120 
 
 
 
• mAb b12 
• Carbohydrate binding agents (cyanovirin, plant 
lectins pradimycin A derivatives; and mAb 2G12) 
• CD4 IgG2 (PRO-542) 
• BMS-806 
• CD4 mini protein 
gp41 
 
• T20 (enfuvirtide) 
• T-1249, 
• mAbs 2F5, 4E10 
Viral Intracellular targets 
 
Viral intergrase 
 
•  Elvitegravir and MT-2048 
Viral reverse transcriptase • NNRTI : PMPA (tenofovir disoproxylfumarate) 
• NRTI: TMC120 (dapivirine), UC781, MIV-150 and 
DABO 
Viral membrane 
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 • Nonoxynol 9 
• C31G, SLS 
• Cyclodextrins 
 
Various innovative techniques for direct HIV-1 blockage have been developed to date, with 
the employment of nano-constructs active against the HIV-1 being the latest (du Toit, Pillay 
and Choonara, 2009). Nano-size gold and silver particles have been demonstrated to inhibit 
viral attachment to target receptors by preferentially binding to gp120 (Elechiguerra et al., 
2005; Yacaman et al., 2006). Dendrimers, tri-component multi-branched three-dimensional 
nanostructures composed of a poly-functional core, can act as a drug carrier wherein the 
interior layers and the multivalent surface can be functionally modified to disrupt the normal 
virus-target cell interactions thus preventing viral attachment and subsequent infection 
(Witvrow et al., 2000). One such dendrimer, VivaGelTM, has been granted “Fast Track” status 
by the United Stated Food and Drug Administration (FDA), as an investigational new drug 
(IND) against HIV-1 and other sexually transmitted diseases. Other dendrimer compounds 
that have shown anti-HIV-1 activity include SPL2923, SPL6195, SPL7013, SPL7304 and 
SPL7320 (McCarthy et al., 2005). Investigational anti-HIV-1 work has been done on the 
microbicide potential of carbon-60 aggregates, fullerenes, and virus targeting nano-micelles 
termed NanoViricidesTM (Marcorin et al., 2000; Schuon 2008).  
 
Despite all these imposing anti-HIV-1 interventions, no microbicide has reached the market 
and this warrants a re-think on the choice of HIV-1 target receptors with an emphasis on 
targeting more than one receptor as discussed further in the multi-targeting section of this 
review. Fractionally but importantly, besides targeting the HIV-1, microbicide developers 
should not ignore other factors that enhance HIV-1 capabilities such as semen, since it is 
now known that the amyloid fibrils found in semen enhance HIV-1’s ability to attach to 
epithelial cells and to leukocytes (Munch et al., 2007). 
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2.4.2. Targeting of the vaginal microenvironment  
Altering some of the basic vaginal microenvironment properties, such as pH may have 
tremendous implications on the HIV-1 transmission sequence (Hilber et al., 2007). The 
approximate normal vaginal pH of 4.5 is maintained by the lactic acid produced due to 
anaerobic metabolism of glucose by resident lactobacilli and this acidic pH can hinder HIV-1 
transmission (Lai et al., 2009). Using high resolution multiple particle tracking techniques, Lai 
and co-workers managed to demonstrate that at approximately pH 4.5 cervicovaginal mucus 
traps HIV-1-mimicking polystyrene nanoparticles causing them to diffuse 1000-fold slower 
than they would in water. In contrast diffusion of the HIV-1-mimicking nanoparticles in 
cervicovaginal mucus at pH 6-7 was found to be only 15-fold slower than in water.  
 
On further assessment they found that in acidic pH, HIV-1 has a negative surface charge 
that is neutralized by lactic acid whilst at neutral pH of 6-7 this negative charge is 
maintained. The surface charge of the HIV-1 determines whether the virus can slip through 
the mucus layer, composed mostly of polyanionic mucin and water, which lines the 
cervicovaginal epithelia and ultimately determines infectivity (Lai et al., 2009). The success 
of anti-HIV-1 microbicide delivery systems thus depends upon the pharmaceutical scientist’s 
ability to take into account the vaginal micro-environmental pH. Any measure that aims to 
maintain the acidic vaginal pH would be a step in the right direction, for not only will this 
prevent HIV-1 transmission, but it may also prevent invasion by other micro-organisms that 
may cause ulcers and inflammation resulting in impaired barrier properties of the vaginal 
epithelia. Products developed by exploiting this concept include the microbicide gels: 
BufferGel® and Acidiform® (Van de Wijgert, 2001; Von Mollendorf et al., 2010). Even Lime 
juice has been studied pre-clinically for its acidifying HIV-1 transmission prevention 
properties (Hemmerling et al., 2007). 
 
2.4.3. Targeting the vaginal epithelia 
The biofunctionality of the vaginal epithelia as a physical barrier that blocks invasion by 
pathogens from the external environment is of vital importance in the prevention of HIV-1 
transmission. Maintenance and enhancement of its physical and immunological HIV-1 
deterrent properties are vital in designing an effective microbicide delivery system 
(Kozlowski and Neutra, 2003; Bergmeier and Lehner, 2006). The integrity of the vaginal 
epithelia can be compromised by a plethora of varying factors such as microtrauma during 
coitus, sexually transmitted diseases and the mere exposure to pathogens such as HIV-1 
(Templeton, 2010; Bailey et al., 2007). An investigation into microtrauma of vaginal epithelia 
after coitus yielded 61.1% positive colposcopy findings, thus suggesting the need for 
lubricants during sexual intercourse (Norvell et al., 1984). Microbicide vehicles, particularly 
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gels can be rheologically tailored to mitigate epithelial disruption. The gp120 envelope 
glycoprotein studded on the infectious HIV-1 has been reported to reduce the transepithelial 
resistance (TER) of genital epithelia (Nazli et al., 2010). The mechanism of this phenomenon 
is based on the HIV-1’s ability to induce inflammatory factors in the epithelial cells leading to 
down-regulation of tight junction mRNA and protein levels resulting in increased epithelial 
permeability. Tight junction genes known to be affected include; claudin 1, 2, 3, 4, 5, ocludin 
and ZO-1 which were 2-17 times variably down-regulated (Nazli et al., 2010; Bai et al., 
2008). Figure 2.4 illustrates the epithelial tight junction down-regulatory effects of exposing 
genital epithelia to a gp120-carrying HIV-1 (wildtype) strain as compared to gp120-deficient 
HIV-1 (mutant) strain. 
 
 
Figure 2.4: Epithelia monolayers showing tight junction down-regulation on exposure to different HIV-1 strains 
that include; a) normal unexposed epithelia, b) wildtype HIV-1 strain exposed epithelia and c) gp120-lacking 
mutant HIV-1 exposed epithelia (adapted from Nazli et al., 2010). 
 
Nazli and co-workers standardized that in order for a microbicide to enhance its chances of 
effectiveness, it must neutralize HIV-1 before it reaches the epithelial layer. Vital work in this 
direction has been done by Geonnotti and Katz of Duke University in determining the crucial 
parameters in the dynamics of HIV-1 neutralization by a microbicide gel (Geonnoti and Katz, 
2006). Using a Cyanovirin-N (CV-N) as a model microbicide agent, they concluded that 
effective pre-epithelial HIV-1 neutralization can be achieved with a postcoital vaginal 
epithelial gel-coating thickness of ~100µm that is extensively and exclusively distributed 
intravaginally. A similar principle could be a prerequisite in designing other forms of 
microbicide delivery systems such as vaginal tablets, rings and films where the primary goal 
and momentous achievement of a microbicide formulation would be to extensively and 
exclusively cover the vaginal epithelia and to enhance epithelia HIV-1 deterrent properties. A 
conventional battleground-illustration of intraluminal HIV-1 in the seminal layer drifting 
towards a microbicide covered vaginal epithelial mucus layer is depicted in figure 2.5.  
 
 28 
 
 
Figure 2.5: Illustration of microbicide-HIV-1 virus confrontation in the vaginal cavity (Adapted from Geonnoti and 
Katz, 2006). 
 
Ways of enhancing vaginal epithelial integrity should be pursued. One such way involves the 
use of water soluble fibre pectin in microbicide delivery systems. Pectin has been reported to 
have trophic effects on the intestinal epithelia (Fukunag et al., 2003), warranting the 
investigation of its effects on the vaginal epithelia. Mucoadhesive delivery systems can help 
improve residence time of the anti-HIV-1 agent and may aid in maintaining a uniform 
microbicide layer covering the epithelia (Woolfson et al., 2010). Mucoadhesive delivery 
systems are generally composed of synthetic polymers or biological macromolecules with 
the ability to attach to the mucus layer lining the vagina epithelia. Polymers that have been 
employed in vaginal delivery systems include poly(acrylates), chitosan, cellulose derivatives, 
hyaluronic acid derivatives, pectin, tragacanth, starch, poly(ethylene glycol), sulfated 
polysaccharides, carageenan, sodium alginate and gelatine (Valenta, 2005).  
 
2.4.4. Vaginal subepithelia targeting 
Thomas and co-workers disputed the commonly held view that the majority HIV-1 particles 
are non-infections. They went further to demonstrate experimentally that the apparent HIV-1 
non-infectivity, commonly reported maybe a result of infrequent occurrences of successful 
HIV-1-target cell interactions (Thomas et al., 2007; Gray et al., 2001). They highlighted the 
danger that comes with HIV-1 penetration into the CD4+ cell-rich sub-epithelia. HIV-1 
vulnerable target cells in the subepithelia including; DCs, T cells and 
macrophages/monocytes, that generally express CXCR4 and/or CCR5 co-receptors 
essential for HIV-1 infection, are concentrated in the lamina propria (Zhang et al., 1998; 
Zoeteweij and Blauvelt, 1998; Miller and Shattock, 2003). The increased number of CD4+ 
and DC-SIGN expressing cells in the subepithelia enhances HIV-1 transmission (Van de 
Wijgert et al., 2001; Cunningham et al., 2007), making it a serious concern for microbicide 
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developers. It is therefore important for the microbicide agents to be able to access the 
subepithelia. Use of agents with high genital tissue bioavailability such as Pfizer’s CCR5 
blocking viral entry inhibitor, maraviroc, may be useful in this respect (Dumond et al., 2009).  
 
Another concern that arises in the subepithelia is the ability of HIV-1 to hide in the local 
macrophages, away from the reach of microbicide agents. Recent discoveries reveal that 
macrophage-bound HIV-1 could be targeted based on the fact that the scarcity of 
deoxynucleoside triphosphate (dNTP) in macrophages leads HIV-1 to use abundant 
rebonucleoside triphosphate (rNTP) for its replication (Kennedy et al., 2010). Kennedy and 
co-workers discovered that by blocking HIV-1–rNTP interactions, viral replication plunged by 
90% (Kennedy et al., 2010). Therefore, an agent that blocks HIV-1-rNTP interaction such as 
cordycepin may be used as an add-on microbicide agent to reduce post-epithelial HIV-1 
transmission by minimizing intra-macrophage HIV-1 viral replication (Kennedy et al., 2010). 
 
2.4.5. Microbicide multi-targeting 
With the complex nature of HIV-1 infection and the variability of viral invasion pathways, 
many microbicide developers are advocating the use of agents that target either more than 
one receptor on HIV-1 and on the vulnerable target cells or a combination of agents in order 
to efficiently prevent HIV-1 transmission. Table 2.5 summarizes some of the microbicide 
combinations that have been developed to date. A smart choice of an anti-HIV-1 agent 
combination would be required to mitigate viral attachment, fusion, replication and other 
important steps in the infection sequence. When trying these combinations a complete 
pathotoxicity or safety study has to be performed to rule out any chances of epithelial barrier 
disruption or inflammation to avoid the danger of not only allowing free passage for the HIV-
1, but inflammation-driven recruitment of target cells as well. 
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Table 2.5: Microbicide combination formulations (Alliance for Microbicides Development, 
2007; Liu et al., 2005). 
Microbicide combination  Developer/Researcher 
 
BufferGel® + dentrimers  
(SPL7013 + optimized dentrimers) 
 
 
ReProtect , Starpharma 
CAP + UC781 or NCp7 nucleoside/zinc finger 
inhibitors 
 
New York Blood Centre , NIH 
CVN-12pl chimeras and combinations, HNG-
105 
 
Drexel 
Dolabellane diterpene Instituto Oswaldo Cruz (FIOCRUZ) 
Universidade Federal Fluminense, Fundacão 
Atanipho de Paiva 
M167+ BMS+ other ARV 
 
IPM 
PC-710 (Carraguard + zinc) ,  
ZCM ( Carraguard + zinc + MIV-150) 
 
Population Council 
SJ3366 
 
ImQuest 
Tri-molecular microbicidal–immunising 
construct (MHC antigents + microbial HSP70 
+CCR5 peptides) 
 
Allomicrovac 
Cellulose acetate 1,2-Benzenedicarboxylate + 
UC781 
 
Liu S, Lu H, Neurath R, Jiang S (Liu et al., 
2005) 
mAb b12 and CV-N 
 
Sexton A, Harman S, Shattock RJ, Ma K-C 
(Sexton et al., 2009) 
WHI-07 and vanadocene dithiocarbamate D’Cruz OJ, Uckun FM (D’Cruz and Uckun  
2007) 
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2.5. Quantitative microbicide targeting 
Post-exposure cervicovaginal HIV-1 population in humans is difficult to quantify due to 
ethical and experimental constrains. However by sequentially analyzing simian 
immunodeficiency virus (SIV) quantities after intravaginal inoculation in Indian rhesus 
macaques, researchers have been able to measure viral populations at each stage in the 
HIV-1 infection process (Miller et al., 1989).  An important finding from these SIV studies 
discovered that after intravaginal inoculation of the order of 1 billion virons, only a small 
fraction of the inoculum was detected 2-24 hours later in the cervicovaginal tissues (Miller et 
al., 2005). Therefore, only a small fraction of the virons gets to cross into the subepithelia to 
establish the founder population (Miller et al., 2005). 
 
This founder viral population cannot solely establish systemic infection because local viral 
population expansion is a prerequisite for systemic infection (Alliance for Microbicide 
Development, 2007; Lukashov and Goudsmit, 1997). The relatively low number of virons at 
this stage of infection provides a rare opportunity for microbicides to prevent systemic HIV-1 
infection. Microbicides must target this stage of HIV-1 transmission since the virus will be at its 
quantitative weakest. Here, microbicide agents that can cross the epithelial barrier and be 
active in the subepithelia can play a major role. Figure 2.6 depicts the quantitative viral post-
exposure profile with eclipse, exponential growth, peak viral replication and decline at different 
stages in the infection sequence. A microbicide delivery system should prolifically deliver the 
anti-HIV-1 agent within the first few days to take advantage of this quantitative-vulnerability of 
the virus. In figure 2.6 we have referred this opportune arbitrary time necessary to counteract 
the virus as the “Microbicide Critical Activity Window” (MCAW). 
 
 32 
 
 
Figure 2.6: Post-exposure HIV-1 virus census in cervicovaginal epithelia (adapted from Miller et al., 2005; Haase, 
2005). 
 
After the MCAW, viral dynamics become complicated as the founder HIV-1 population 
attacks the ‘resting’ CD4+ cells, CD4+ T-cells, macrophages and DCs in the subepithelia 
followed by replication, leading to dissemination to draining lymph nodes. Lymph nodes hold 
high concentration of CD4+ cells, hence once the virus reaches the lymph nodes, there is 
rampant replication and broadcasting of HIV-1 leading to an exponential growth in viral 
population as depicted in figure 2.6 (Haase, 2005). Viral replication reaches a peak 
concentration in 10-14 days then declines steadily (Miller et al., 2005). For microbicides, 
fortunes diminish drastically after the exponential growth stage due to increased number of 
virons, production of mutant viruses that may present an extraordinary challenge to anti-HIV-
1 agents and the ability of the HIV-1 to hide in cells such as macrophages. However, Anti-
HIV-1 agents released from microbicide delivery systems should surpass this peak viral 
concentration [designated as “Microbicide Critical Concentration” (MCC) in figure 2.6] to 
have a chance of deterring systemic viral infection (Richman et al., 2003). Microbicide 
success depends on a comprehensive quantitative excess of the microbicide agent/s to HIV-
1 from the introitus to the cervix in the vagina (Hendrix et al., 2009; Lacey et al., 2006). The 
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variability in semen-borne HIV-1 quantities further adds to this quantitative complexity, as the 
semen viral quantity depends upon the individual’s stage of HIV-1 infection and the seminal 
volume, which in turn depends on ones ejaculation frequency (Vernazza et al., 1997; Tachet 
et al., 1999). 
 
Various microbicide delivery systems with different anti-HIV-1 agent release profiles can be 
formulated in the form of gels, films, rings, tablets or sponges (Pillay et al., 2012). Their 
common goal should be to deliver the anti-HIV-1 agent in sufficient quantity to prevent 
infection. The majority of delivery systems are quick release formulations applied prior to 
sexual intercourse for exclusive and extensive distribution within the vaginal or rectal cavity 
before exposure to HIV-1 during sexual intercourse. Extensive in vitro and in vivo studies 
need to be performed to determine the ability of the delivery system to release the anti-HIV-1 
agent thus ensuring complete and sufficient vaginal distribution of the anti-HIV-1 agent. 
Figure 2.7.b displays a failed typical microbicide quick release profile. Such delivery systems 
usually fail to stay at inhibitory concentrations for a long enough time to avert transmission 
that may be a result of viral shedding, typical observed in acute HIV-1 infection. This 
limitation may be resolved by employing sustained and extended release delivery systems 
with a typical profile shown in figure 2.7.c. In addition to preventing infection due to viral 
shedding, these systems can improve compliance and ensue that an inhibitory anti-HIV-1 
agent concentration is always available in situ. The major disadvantage of these extended 
microbicide delivery systems is the toxic or inflammatory effects that may occur as a result of 
sustained exposure to the anti-HIV-1 agent and the delivery system, making pathotoxicity 
studies mandatory to exclude inflammation and breach of the vaginal epithelia (Cone et al., 
2006). 
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Figure 2.7:  HIV-1 neutralization schematics by microbicide formulations with different anti-HIV-1 release profiles; 
a) acute HIV-1 intravaginal infection: no microbicide, b) quick release microbicide formulation and c) sustained 
release microbicide formulation (Gupta, 2008). 
 
In designing a microbicide delivery system, a lot of other aspects should be considered such 
as how the anti-HIV-1 agent interacts with the virus, the means by which HIV-1 enters target 
cells, and the ways by which it can be neutralized (Chan and Kim, 1998). However, more 
knowledge is required regarding the quantitative aspects of both viral entry and 
neutralization. Advanced microscopy has shown that HIV-1 is surrounded by lipid coated 
bilayer studded with heterodimeric envelop proteins made up of three transmembrane 
subunits (gp41) which are capped by extensively glycosylated triple surface moieties 
(gp120) (Zhu et al., 2006; Zhu et al., 2003). Gp120 has been identified as an integral 
component in the viral entry mechanism  where it binds to CD4 of the target cells causing 
conformational changes that allow co-receptor binding leading to a rearrangement in the 
transmembrane gp41 thus triggering viral-cellular fusion (Poignard et al., 2001; Chan et al., 
1997). 
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The number of trimers needed for infection, stoichiometry of entry (Yang et al., 2005; Yang 
et al., 2006), as well as those of blocking the HIV-1, stoichiometry of neutralization (Magnus 
et al., 2009; Magnus and Regoes, 2010; Klaase, 2007; O’keefe et al., 2000), has been a 
subject of controversy among researches. Inspired by this, Yang and co-workers arrived at 
an experimental conclusion that just one trimer is capable of enabling HIV-1 entry. Whilst an 
incremental model elaborates that all trimers contribute equally to HIV-1 entry, the laminal 
model postulates that a threshold number of gp120s should be available for viral entry to 
occur (Yang et al., 2005; Yang et al., 2006; Magnus et al., 2009; Magnus and Regoes, 2010; 
Klaase, 2007; O’keefe et al., 2000). The determination of which part of the virus should the 
anti-HIV-1 agents target and how many of them are required is yet to be determined for an 
appropriate microbicide delivery system to be developed. With proper modeling and use of 
Yang and co-workers’ stoichiometric conclusion, which provides the worst case scenario, the 
appropriate quantity of anti-HIV-1 agent that is to be utilized in the microbicide formulation 
can be determined and seriously considered when developing microbicide delivery systems. 
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2.6. Concluding remarks 
The prevention of vaginal HIV-1 transmission requires the employment of a multiple-front 
strategy. Primarily, the evasive HIV-1 has to be intraluminally neutralized before it reaches 
the epithelial layer. Maintenance of the integrity of the epithelial layer is of paramount 
importance and can be achieved by deliberately avoiding agents that may instigate 
inflammation whilst increasing lubrication to minimize microtrauma during sexual intercourse. 
Anti-HIV-1 agents should not only be extremely potent but should also be in a quantitative 
excess in relation to HIV-1, and their distribution intraluminally has to be extensive and 
exhaustive. Use of agents that can penetrate the vaginal epithelia and remain active in the 
subepithelia to further protect HIV-1 susceptible cells may help prevent HIV-1 transmission. 
In addition, being able to have the anti-HIV-1 agents at the site (vaginal cavity) for a 
prolonged period reduces HIV-1 transmission. 
 
An appropriate strategy would be to design a microbicide delivery system capable of: 
maintaining the luminal acidic micro-environment by employing acidifying biodegradable and 
biocompatible polymers such as poly(D,L-lactide), polylactic-co-glycolic acid, polyanhydrides 
including poly(sebacic) anhydride and poly(ortho-esters) as matrices for either vaginal 
tablets, rings, sponges or films  which degrade to their respective acids and diacids in a rate 
controlled manner without destroying the normal vaginal flora. Polymeric macromolecules 
such as pectin may be used to enhance epithelial integrity. Proper scientific experimentation 
and mathematical modeling may result in the sustained and extended delivery of the active 
agents from the appropriately engineered polymers or polymer blends that may be 
mucoadhesive.  
 
These innovative microbicide delivery systems have the potential to enhance patient 
compliance and ensure optimum anti-HIV-1 agent concentration whilst reducing side effects 
normally caused by frequent dosing. Use of multiple anti-HIV-1 agents with different 
mechanisms of action may further enhance microbicide efficacy. Engineering rheological 
properties of the delivery systems to achieve extensive and exhaustive target-epithelial 
coverage is necessary, particularly in gels. In the following chapters a composite polymeric 
delivery system which aims to address the concerns raised in this chapter is formulated and 
tested in vitro and in vivo as a potential anti-HIV-1 microbicide delivery system. In 
conclusion, researchers might discover countless highly potent anti-HIV-1 agents to be used 
as microbicides, but unless they deliver them effectively and efficiently to the appropriate 
site, their work will be far from translational. 
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CHAPTER 3 
CHARACTERIZATION AND PREFOMULATION ANALYSIS OF DRUG (AZT AND BP36) 
AND POLYMER (PECTIN, MUCIN AND POLY ETHYLENE GLYCOL) INTENDED FOR 
SUBMICROSPHERE PREPARATION  
 
3.1. Introduction 
Research into microbicides that prevent HIV-1 transmission has led researchers to consider 
different chemical agents of varying potency and mechanisms of action against HIV-1. 
These anti-HIV-1 agents range from; vaginal acidifying agents (polyacrylic acid), virus 
inactivators (monocaprin and myristamine oxide), agents that adsorb to HIV-1 and inactivate 
it (cellulose acetate phthalate), broad spectrum antimicrobials such as cetyl betaine, viral cell 
membrane disrupting agents (nonoxynol-9 and napthalene sulphonate), viral fusion inhibitors 
(polysterene sulfornate, cyanovirin-N and sodium lauryl sulfornate) and HIV-1 replication 
inhibitors such as dapivirine, stapidine, tenofovir disproxil fumarate and theophen thiourea 
(Pillay et al., 2012). Research has also been carried out on plant extract agents such as 
praneem whose mechanism of action is not yet clearly understood. 
 
The apex of microbicide research thus far has been the relative success of a study (phase 
IIb CAPRISA 004 tenofovir gel trial) performed using a 1% tenofovir gel (nucleoside reverse 
transcription inhibitor) which showed 39% efficacy in preventing vaginal HIV-1 transmission 
thus proving right the viability of the concept of using microbicides as a HIV-1 transmission 
prevention tool (Abdool karim et al., 2010). There is also scope in using a combination of 
different anti-HIV-1 agents with different mechanisms of action (Pillay et al., 2012). 
 
The study reported in this dissertation employs a combination of two anti-HIV-1 agents, 
zidovudine and BP36. Zidovudine was the first antiretrovirals to be developed and used to 
treat HIV/AIDS. It is a nucleotide reverse transcriptase inhibitor (NRTI), which means that it 
prevents HIV-1 from replicating. It was chosen in this study to reduce the viral load thus 
reducing the risk of transmission since HIV-1 that initially infects a person has to reach a 
quantitative threshold for transmission to occur (Pillay et al., 2012). The second anti-HIV-1 
agent is an experimental herbal extract (leaves and sterm) from a South African plant 
identified as BP36. BP36 has been studied and patented for its anti-HIV-1 properties by the 
Council for Scientific and Industrial Research (CSIR) BioSciences, South Africa. 
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Scientists at CSIR BioSciences, South Africa, found the composition of BP36 to be a 
percentage carbohydrate content of; arabinose 11.5%, rhamnose 5.5%, xylose 1.9%, 
mannose 4%, galactose 10.5%, glucose 26%, glucuronic acid 4.3% and galacturonic acid 
36.3%. On its anti-HIV-1 properties, BP36 was reported to be active against HIV-1 subtype 
C pseudoviruses, with an IC50 of 0.1–7.9µg/mL as compared to T20:0.1 – 7.5µg/mL and 
tenofovir:0.2 – 1.2µg/mL (van den Berg et al., 2011). In addition BP36 was found to act 
within 8 hours thus proposing that its mechanism of action was probably viral fusion 
inhibition. Therefore, BP36 was employed together with zidovudine because its mechanism 
against HIV-1 is different and complimentary to that of zidovudine. 
 
 In this chapter zidovudine and BP36 are identified and characterized using attenuated 
Fourier transform infrared microscopy and their physical properties are elucidated through 
differential scanning calorimetry, and thermogravimetric analysis. This study involved dual 
encapsulation of zidovudine and BP36 in submicrospheres prepared from biodegradable 
and biocompatible macromolecules porcine gastric mucin, pectin, and polyethylene glycol, of 
which submicrospheres are then embedded within a polymeric caplet matrix. Therefore, this 
chapter also focused of elucidating the physicochemical, thermal and thermodynamic 
properties of porcine gastric mucin, pectin and polyethylene glycol and their interaction in 
aqueous media in an effort to understand and predict how they would form submicrospheres 
that would encapsulate zidovudine and BP36. 
 
Mucin, a glycosylated protein that forms the major structural component of the mucus gel 
that covers most human body cavities (urogenital, gastrointestinal, eye, lungs and other 
mucosal membranes) plays a major role in various frontline interactions with different 
materials from the external environment (Dekker et al., 2002; Bansil and Turner, 2006). 
Mucus is composed of approximately 95% water, about 2% lipids (fatty acids, phospholipids 
and cholesterol) and electrolytes with the remaining 3% being mucin. Research has shown 
interest in mucin as the structural backbone of the gel-like layer that serves various functions 
such as; lubrication of mucosal membranes to avoid abrasions, protection of mucosal lining 
from self digestion as in the case of gastric mucus and it also acts as a gate keeper, keeping 
at bay unwanted external environmental materials and organisms such as bacteria and 
viruses (Patel et al., 2003; McGuckinet al., 2011).  
 
The major functions of mucus are owed to the structure and molecular properties of mucin. 
Mucin is a large (0.5-20MDa) glycoprotein consisting of a protein core composed of 4-5 
amino acids (proline, serine, threonine, glycine and glutamate) arranged in detached 
regions, namely, a bulky (60%) central repeating serine, threonine and proline (STP) region. 
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Interspaced within this STP region and at the terminals are N-linked oligosaccharides and 
von Willebrand factor (vWF)-like cysteine rich regions (Dekker et al., 2002; Bansil and 
Turner, 2006). The STP region is linked to oligosaccharide side-chains made up of 5-15 
sugars such as N-acetylglucosamine, fucose, N-acetylneuramic acid, N-
acetylgalactosamine, mannose and sulfate that account for approximately 80% by weight of 
mucin and are responsible for mucin’s hydrophilic properties through its sialic acid content 
(Bansil and Turner, 2006). The cysteine rich regions form disulfide bonds responsible for 
mucin’s dimeric structure (Dekker et al., 2002; Bransil and Turner, 2006). Therefore mucin is 
a complex biomaterial with peculiar structural and chemical properties to interact with a 
diverse range of materials of external origin. Of particular interest in this chapter was the 
manner in which mucin interacts with a biocompatible and biodegradable macromolecule, 
pectin, under different conditions and how these macromolecular interactions can be 
demonstrated through diverse techniques.  
 
Pectin, a plant cell wall constituent, is a linear polysaccharide composed of (1-4)-α-D-
galacturonic acid units randomly interrupted by (1,2)-linked L-rhamnoside-chains and other 
neutral sugars (Rolin, 1993; Sriamornasak et al., 2008). Chemical and physical properties of 
pectins are mostly defined by the degree of methyl esterification (DE) and the degree of 
amidation (DA) of its carboxylic groups. The DE is used as a pectin classification system 
with pectins having less than 50% DE referred to as low methoxy pectins and those with DE 
greater than 50% regarded as high methoxypectins (Rolin, 1993). Pectin is used as a 
thickener or gelling agent in the food industry (Thakur et al., 1997). In the cosmetic industry it 
has been employed to encapsulate fragrances in microspheres as well as being utilized in 
various formulations such as gels, films and as a stabilizer in emulsions, suspensions and 
foams (Thakur et al., 1997; Liu et al., 2005). Pectin’s use extends to the pharmaceutical 
industry where it is used as a binding agent, gelling agent and in conventional and modified 
drug delivery to modulate the release of the active pharmaceutical ingredient from 
nanoparticles, microspheres, beads and tablets (Wong et al., 2002; Liu et al., 2005; Vaidya 
et al., 2009; Srivastava et al., 2010). In tissue engineering and biotechnology it finds 
applications as a wound dressing and cell regeneration matrix (Munarin et al., 2011). In the 
majority of these applications pectin interacts with the mucus layer and hence interacts with 
mucin.  
 
Several techniques have been developed over the years to assess the type and extent of 
mucin-pectin interactions. Among them, the rheological technique has demonstrated 
viscosity and dynamic moduli synergism involved in mucin-pectin aqueous dispersions 
(Hassan and Gallo, 1990; Liu et al., 2005; Sriamornsak et al., 2008; Sriamornsak and 
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Wattanakorn, 2008; Thirawong et al., 2008). This technique has been widely utilized to 
determine and explain mucoadhesion of pectin (Sriamornsak et al., 2008; Thirawong et al., 
2008). Scanning electron microscopy and atomic force microscopy have also been 
employed to demonstrate mucin-pectin interactions (Liu et al., 2005; Sriamornsak et al., 
2008; Sriamornsak et al., 2010). This chapter further demonstrates mucin pectin interactions 
using full attenuated total reflection Fourier transform infrared (ATR-FTIR) spectroscopy 
analysis, ultraviolet (UV) spectrophotometric analysis, thermal and thermodynamic analysis 
as well as in silico static lattice atomistic simulations of mucin-pectin interactions. In addition, 
an investigation of the effect of calcium ions (Ca2+), the mucin:pectin ratio and a plasticizer 
polyethylene glycol 400 (PEG 400), on the formation of a mucin-pectin interpenetrating 
macromolecular network was investigated. 
 
3.2. Materials and Methods 
3.2.1. Materials  
Zidovudine (AZT) was purchased from GlaxoSmithKline, Middlesex, UK and BP36 was 
supplied by the department of BioSciences, Council for Scientific and Industrial Research, 
South Africa. Porcine gastric mucin type III (MUC) with 1-1.5% bound sialic acid (Mw ~22 000 
000 gmoL-1) and polyethylene glycol 400 (PEG Mw 400) were purchased from Aldrich® 
(Sigma–Aldrich Inc., St. Louis, USA). Three commercially available grades of citrus pectin 
having different degrees of esterification (DE) and different degrees of amidation (DA) were 
purchased from CP KelcoApS, Lille Skensved, Denmark: GENU® pectin type USP/100 
(PECUSP)[DE 55-65%Mw~120-130 000 gmoL-1, average density ρPEC-USP~0.7gmL-1]; GENU® 
pectin type LM-101 AS (PECAS) [DE 35%, DA 15%]and GENU® pectin type LM-104 AS 
FS(PECAS-FS), [DE 28%, DA 20%]. All other chemicals employed were of analytical grade 
and were used as purchased. 
 
3.2.2. Attenuated total reflection Fourier transform infrared spectroscopic (ATR-FTIR) 
analysis of the drugs and polymers 
Powder samples of zidovudine, BP36 and lyophilized samples of MUC, PEC and MUC-PEC 
aqueous dispersion combinations (MUC:PEC ratios: 1:0, 1:1, 1:4, 1:9 and 0:1) were 
analysed by ATR-FTIR. Dilute aqueous dispersions of (1%w/v); MUC, PEC and their 
combinations at different MUC:PEC ratios of 1:0,1:1,1:4,1:9 and 0:1 were prepared by 
dispersing the macromolecules in deionized water whilst stirring at 25°C for 30 minutes. The 
dispersions were frozen overnight below -72°C before being lyophilized for 48 hours. 
Thereafter samples were analyzed using a Perkin Elmer Spectrum 2000 FTIR spectrometer 
that was fitted with a MIRTGS detector (PerkinElmer Spectrum 100, Llantrisant, Wales, UK), 
that used a diamond crystal internal reflection element containing an ATR-FTIR cell. 
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Samples were analyzed at a wave number range of 650-4000cm1 with a resolution of 4 cm−1 
and 64 scans per spectrum at a direct contact force of 112 N. AZT, BP36 , MUC and PEC 
were characterised. In addition, MUC-PEC interactions were elucidated and interpreted from 
the various structural transformations observed on comparing the MUC-PEC ATR-FTIR 
spectra to that of the native MUC and PEC. 
 
3.2.3. Morphological characterization of lyophilized samples of MUC, PEC and MUC-
PEC blends 
Lyophilized aqueous dispersions of (1% w/v); MUC, PECUSP and MUC-PECUSP combinations 
with weight ratios of 1:0,1:1,1:4 1:9 and 0:1 were mounted on specimen stubs and gold 
coated using a SPI-ModuleTM sputter coater (SPI Supplies, STRUCTURE PROBE INC, West 
Chester, Pennsylvania, USA) and then observed at 510X magnification under a scanning 
electron microscope (SEM) (PHENOMTM Desktop SEM, FEI Company, Oregon, USA) 
operated at 10KV in the electron imaging mode.   
 
3.2.4. Thermogravimetric analysis of AZT and BP36 
Thermal degradation analysis was performed on 10-20mg samples of AZT and BP36 
samples, put in ceramic pans and under nitrogen atmosphere, using a TGA 4000 
thermogravimetric analyzer (PerkinElmer Inc, Massachusetts, USA). Thermograms obtained 
and their first derivatives revealed the thermal degradation properties of the AZT and BP36. 
 
3.2.5. Thermal and thermodynamic analysis of AZT and BP36 powder samples, MUC, 
PECUSP and MUC-PECUSP lyophilized samples 
Dry powder samples were used to elucidate the thermal properties of AZT and BP36 through 
differential scanning calorimetry.  MUC-PECUSP aqueous dispersions were prepared by 
adding PECUSP and MUC to deionized water then stirring them at 25°C for 30 minutes. Each 
aqueous dispersion had a total macromolecule concentration of 3.33%w/v composed of 
different MUC:PECUSP ratios of 1:0, 1:9, 1:4, 1:1 and 0:1. The dispersions were cast into 
films on Petri dishes and left to dry at ambient temperature for 48hours. The resultant films 
were pulverized and used as samples for differential scanning calorimetry (DSC) 
measurements (Mettler Toledo, DSC1, STARe System, Schwerzenback, Switzerland). 
Calibration of temperature and enthalpy on the instrument were done using indium and zinc. 
Heating rate was set at 10°Cmin-1 under a dry nitrogen atmosphere (Afrox, Germiston, 
Gauteng, South Africa) with a flow rate of 200mLmin-1 acting as the purge gas in order to 
reduce oxidation. Samples (10mg) were added into 40µL aluminium pans and heated from -
10°C to 110°Cand kept at 110°C for 3 minutes. This was done to evaporate any moisture in 
the sample and to eliminate any thermal history. The samples were then quenched from 
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110°C to -10°C at a rate of 20°C min-1. The midpoint melting point (Tm) and heat of fusion 
(∆H) obtained from the melting point depression were determined according to the peaks 
generated on the experimental DSC curves on heating the samples from -10 to 250 °C.  To 
determine the interaction and miscibility of MUC and PECUSP, analysis of the thermal and 
thermodynamic properties of MUC and PECUSP were elucidated according to the Nishi-Wang 
and Flory-Huggins theories (Harris et al., 1983; Xie et al., 2002). 
 
3.2.6. Ultraviolet (UV) spectrophotometry analysis of MUC, PEC and MUC-PEC 
combination aqueous dispersions 
Ultraviolet (UV) absorbance of MUC, PEC and MUC-PEC combination dispersions in 
deionized water were assessed by passing UV light through a standard quartz cuvette at 
600nm wavelength, thereafter UV absorbance was measured using a nanophotometer 
(NanoPhotometerTM,Implen GmbH, Munchen, Germany) at ambient temperature (25°C). 
Dilute aqueous dispersions of MUC-PEC were prepared at a concentration of 0.2%w/v. MUC-
PEC weight ratios examined were 1:0, 1:1, 1:4, 1:9, 0:1, 4:1, and 9:1. Three different types 
of pectin were used to assess the effect of the DE and DA on MUC-PEC combination UV 
absorbance. UV absorbance was used in this study as a measure of MUC-PEC interactions 
by computing and comparing the UV absorbance difference (∆A), of pristine MUC, PEC and 
combination MUC-PEC dispersions. Absorbance difference (∆A) was regarded as the 
difference of the UV absorbance obtained for the MUC-PEC combination (AMUC-PEC) and that 
of the summation of the UV absorbance obtained when individual pristine dispersions of 
MUC (AMUC) and pectin (APEC) were measured as in equation 3.1. 
 
∆A= AMUC-PEC - (APEC + AMUC)                                                                                  Equation 3.1 
 
3.2.7. Rheology analysis of MUC, PEC and MUC-PEC combination aqueous 
dispersions 
Viscosity (ƞ), storage modulus (G’) and loss modulus (G’’) of (3.333% w/v) of dilute aqueous 
dispersions of MUC, PEC and different MUC:PEC combinations were measured using a 
modular advanced rheometer (HAAKE MARS Modular Advanced Rheometer, Thermo 
electron Corporation, Karlsruhe, Germany) with a C35/1° Ti sensor. The tests were 
performed employing the rheometer parameters shown in table 3.1. 
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Table 3.1: Rheometer parameters 
Parameter Value 
Cone and plate gap 0.0051mm 
Driver version  0.29 
Inertia 1.721 10-06 Kgm2 
A-factor 89051.00 Pa 
M-factor 57.010 rad/s 
Temperature 25°C 
Damping  30.00 
 
Viscosity was measured on a 0.5mL sample for 60s and 180s. Dynamic oscillatory rheology 
measurements of the storage and loss moduli of 0.5mL samples were performed over a 
small frequency range of 0.1-1.0Hz which fell within the shear independent plateau of the 
corresponding strain amplitude sweep. All samples were prepared by dispersing PEC, MUC 
or MUC-PEC combinations in 15mL of deionized water. The samples were allowed to stand 
for 5minutes prior to testing. Rheological synergy expressed by the equations below was 
investigated and used as a signifier of the interpenetrating macromolecular interactions 
between PEC and MUC (Equations 3.2-3.4). 
 
∆ƞ= ƞMUC-PEC – (ƞPEC + ƞMUC)                                                                                  Equation 3.2 
 
∆G’= G’MUC-PEC – (G’PEC + G’MUC)                                                                            Equation 3.3 
 
∆G’’= G’’MUC-PEC – (G’’PEC + G’’MUC)                                                                         Equation 3.4 
 
Where: 
∆ƞ – Difference of the viscosity of MUC-PEC (ƞMUC-PEC) and the sum of the viscosities of 
individual MUC (ƞMUC) and PEC (ƞPEC). 
∆G’- Difference of the storage modulus of MUC-PEC (G’MUC-PEC) and the sum of the storage 
moduli of individual MUC (G’MUC) and PEC (G’PEC). 
∆G’’- Difference of the loss modulus of MUC-PEC (G’’MUC-PEC) and the sum of the loss moduli 
of individual MUC (G’’MUC) and PEC (G’’PEC). 
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3.2.8. Static lattice atomistic simulations of MUC PEC interactions 
Molecular mechanics simulations were performed using commercial software: HyperChemTM 
8.0.8 Molecular Modeling System (Hypercube Inc., Gainesville, Florida, USA) and 
ChemBio3D Ultra 11.0 (CambridgeSoft Corporation, Cambridge, UK).The structure of pectin 
(PEC; 4 saccharide units) was built from standard bond lengths and angles using the sugar 
builder module on HyperChemTM 8.0.8 while the structure of the glycoprotein analogue 
(MUC) was generated using the sequence editor module. The models were energy-
minimized using a progressive-convergence-strategy where initially the MM+ force field was 
used followed by energy-minimization using the Amber 3 (Assisted Model Building and 
Energy Refinements) force field. The conformer having the lowest energy was used to 
create the MUC-PEC complexes. A complex of one macromolecule with another was 
assembled by disposing the macromolecules in a parallel way, and the same procedure of 
energy-minimization was repeated to generate the final models: PEC, MUC, and MUC-PEC 
(1:1 to 1:4). Full geometry optimization was carried out in vacuum employing the Polak–
Ribiere conjugate gradient algorithm until an RMS gradient of 0.001kcal/mol was reached. 
For molecular mechanics calculations in vacuum, the force fields were utilized with a 
distance-dependent dielectric constant scaled by a factor of 1. The 1-4 scale factors 
employed were, electrostatic=0.5 and van der Waals=0.5 (Kumar et al., 2011). 
 
3.3. Results and Discussion 
3.3.1. ATR-FTIR spectroscopy of AZT, B36, MUC, PEC and MUC-PEC 
The AT-FTIR spectrum of zidovudine showed strong band from ~3200-3500cm-1 which was 
likely a result of stretching vibration of the hydroxyl (O-H) group in AZT (Figure 3.1). The 
weak bands observed in figure 3.1 at about 1200cm-1 may be a result of the stretching 
vibrations of the amine group of AZT (Figure 3.1). The distinctive peak at ~2100cm-1 was 
due to the stretching vibrations of the azide group (-N=C=N-) in AZT (Figure 3.1). A strong 
absorption peak (~1600cm-1) was observed on the AZT spectrum which may have been 
contributed to by the strong stretching vibrations of the amide I bond (Ravi et al., 2008). The 
ATR-FTIR spectrum of AZT (Figure 3.1) also depicted several peaks in the finger print 
region (1450-650cm-1) which were consistent with what has reported in literature (Ravi et al., 
2008). 
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Figure 3.1:  ATR-FTIR absorbance spectrum of zidovudine (AZT) 
 
Figure 3.2 depicts the FTIR absorption spectra of BP36 which shows a broad peak from 
~2800-3600cm-1 which was likely a result of the overlapping stretching vibration of alkane 
and hydroxyl groups found in BP36. A strong band at ~1700cm-1 may have been caused by 
hydrogen bonded carboxyl (C=O) groups of the BP36 (Figure 3.2). The BP36 spectrum also 
depicted a few peaks in the finger print region (1450-650cm-1). 
 
 
Figure 3.2: ATR-FTIR absorbance spectrum of BP36 
 
Full ATR-FTIR split absorption spectra of the three different types of citrus pectins; PECUSP, 
PECAS and PECAS-FS, are shown in figure 3.3 with characteristic peaks identified. The broad 
peaks between 3000 and 3650cm-1 identified in all three types of pectin were due to an 
overlap of strong stretching vibrations of the -O-H bond of the pectin carboxylic groups and 
the free -O-H bond of the hydroxyl groups found in pectin. Absorption peaks at 2933cm-1 for 
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PECUSP, 2932cm-1 for PECAS and 2926cm-1depict sp3 stretching vibrations of the -C-H alkane 
groups of the different types of pectin. Absorption peaks observed at 1736cm-1 for PECUSP, 
1740cm-1 for PEC AS and PECAS-FS correspond to stretching vibrations of the -C=O ester 
bond.  
 
The strength of the peaks signified the degree of esterification of the three different types of 
pectin. PECUSP which is typically 55-65% esterified displayed the strongest peak followed by 
PECAS, 35% and PECAS-FS, 28%. PECAS-FS displayed strong peaks at 1672cm-1 and 1594cm-1 
identifying amide I and amide II -C=O stretching vibrations respectively. Amide I and amide II 
peaks of PECAS observed at around 1670cm-1 and 1599cm-1 were weaker than those of 
PECAS-FS. This confirmed that the degree of amidation of PECAS-FS (typically 20%) was higher 
than that of PECAS (typically 15%). PECUSP did not show any amide peaks thus confirming 
that it was not amidated, however a strong peak at 1607cm-1was observed which might have 
been a result of -C=O stretching of the carboxylic groups. All three types of pectin displayed 
typical absorption bands in the carbohydrate region (1200-900cm-1) (Sriamornsak et al., 
2008).    
 
Figure 3.4 compares the FTIR absorption spectra of MUC, PECUSP and that of MUC-PECUSP. 
MUC is a glycosylated protein whose characteristic absorption peaks depicted in figure 3.4 
1(b) included a broad peak spanning from 3000cm-1to 3650cm-1 which was likely due to an 
overlap of carboxylic -O-H with primary and secondary amine -N-H stretching vibrations. An 
absorption peak at 2919cm-1 was a typical -C-H stretching vibration corresponding to the 
alkane groups found in glycosylated mucin. Other typical MUC peaks occurred at 1638cm-1 
due to -C=O amide I strong stretching vibration and at 1544cm-1 resulting from -C=O amide II 
stretching vibration. The gylcosylation of MUC was revealed by the typical peaks observed in 
the carbohydrate region of 1200cm-1 to 900 cm-1. 
 
The absorption spectra of MUC-PECUSP showed peaks attributed to by both PECUSP and 
MUC, with a very broad peak extending from 3000cm-1 to above 3650cm-1 as a result of -O-
H stretching of the carboxylic groups in PECUSP and the carboxylic groups in MUC 
overlapping the -N-H stretching bond of the primary amine. The band with its peak at 
3363cm-1 appeared much broader than the respective peaks of PECUSP and MUC which 
signified the occurrence of PECUSP and MUC macromolecular interactions through hydrogen 
bonding. MUC-PECUSP absorption peaks at 2932cm-1 belonged to -C-H alkane stretching 
vibrations of both PECUSP and MUC. The peak at 1737cm-1 showed that the ester bond in the 
PECUSP remained intact when PECUSP and MUC interacted. Disappearance of the peaks at 
1638cm-1 and 1544cm-1 from MUC when combined with PECUSP may have been a result of 
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macromolecular interactions or due to masking by PECUSP. MUC-PECUSP spectrum showed 
a  broad peak at 1614cm-1 which was likely a result of the -C=O bond stretching vibrations of 
carboxylic groups of PECUSP and this may be attributed to hydrogen bonding involved in the 
IMN.   
 
A clear view of the relative spectra peak changes is depicted in figure 3.5, which is an 
overlay ATR-FTIR absorption spectra displays of MUC-PECUSP at different MUC:PECUSP 
ratios of 1:1, 1:4 and 1:9. As the MUC-PECUSP ratio changes from 1:1 through 1:4 to 1:9, the 
peaks from 3000cm-1 to 3650cm-1 (due to -O-H,-N-H stretching) and the ester -C=O bond 
around 1736cm-1 become broadened and intensified as a result of extensive intermolecular 
hydrogen bonding. The peaks between 1600cm-1 and 1630cm-1 shifted to the right and 
decreased in intensity for a PEC-PECUSP ratio of 1:1 through 1:4 to 1:9 as a result of PECUSP 
and MUC molecular interactions. The shoulder to the right of these peaks increasingly 
disappeared as the ratio of MUC:PECUSP changed from 1:1 through 1:4 to 1:9. MUC, being a 
larger glycoprotein molecule as compared to PECUSP, had much more groups that could 
participate in hydrogen bonding. These included amine, amide groups of the protein 
backbone, the extensive hydroxyl and carboxylic groups of the carbohydrate side chains. 
Consequently, there was an increase in MUC-PECUSP macromolecular interactions with 
changing MUC:PECUSP ratio from 1:1, 1:4 to 1:9. 
 
Figure 3.3:  Split ATR-FTIR absorbance spectra of lyophilized aqueous dispersions of different types of pectin; 
PECAS-FS, PECAS and PECUSP 
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Figure 3.4:  Split ATR-FTIR absorbance spectra of lyophilized aqueous dispersions PECUSP, MUC and MUC-
PECUSP 
 
 
Figure 3.5: Overlay ATR-FTIR absorbance spectra of lyophilized aqueous dispersions of porcine gastric mucin 
(MUC) and pectin (PECUSP) that compares the different MUC:PECUSP ratios in MUC-PECUSP lyophilized aqueous 
dispersions, thus depicting the type and extent of macromolecular interactions between MUC and PECUSP. 
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3.3.2. Morphological characterization by scanning electron microscopy of lyophilized 
samples of MUC, PECUSP and MUC-PECUSP 
Electron micrographs of MUC and PECUSP and their various combinations at different ratios 
revealed the surface morphology and relative structural integrity of lyophilized scaffolds as 
depicted in figure 3.6. Figure 3.6(a) depicts a MUC scaffold showing a thin multidirectional 
membranous scaffold with less defined edges and a thin outlook with pores and micropores 
characterizing its membranous surface. MUC, with its bottle-brush structure composed of a 
protein core and random carbohydrate side chains, would most likely result in uneven 
surfaced, porous membranes with multidirectional edges as depicted in figure 3.6(a) (Patel 
et al., 2003, Bansil and Turner 2006). In contrast, the PECUSP scaffold depicted in figure 
3.6(b) was composed of a thicker, unidirectional rigid-looking scaffold with well defined 
edges and a smoother surface as compared to that of MUC.  
 
PECUSP has a linear structure with relatively well defined (1-4)-α-D-galacturonic acid repeat 
units which could explain its smooth unidirectional rigid structure shown in figure 3.6(b) 
(Rolin 1993). The MUC-PECUSP combination scaffolds exhibited intermediary characteristics 
owing to contributions from both MUC and PECUSP. The MUC-PECUSP 1:1 scaffold depicted 
in figure 3.6(c) displayed more MUC characteristic thinness, was multidirectional and even 
appeared filamentous at the edges. The rigidity and smoothness of the scaffold membranes 
increased with changing MUC:PECUSP ratio from 1:1 through 1:4 to 1:9 as they assumed a 
more unidirectional and thicker PECUSP morphology. The morphological presentations 
exhibited in figure 3.6 were possibly a result of the molecular structures of MUC and PECUSP. 
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Figure 3.6: SEM images, taken at 510X magnififation, depicting membranous scaffolds of lyophilized MUC-
PECUSP combinations; (a) MUC, (b) PECUSP, (c) MUC-PECUSP1:1, (d) MUC-PECUSP1:4 and (e) MUC-PECUSP1:9. 
Bar =50.0µm 
 
3.3.2. Thermogravimetric analysis of AZT and BP36  
Thermogravimetric analysis of AZT yielded the thermogram depicted in figure 3.7 (solid line) 
and its first derivative (derivative thermogravimetric analysis, DTGA (dotted line). The first 
derivative reveals that AZT thermally degraded in two major steps depicted by the DTGA 
peaks at 244.10°C (first step) and 310.70°C (second step). Degradation of AZT started at 
the extrapolated onset of 230.14°C, then the second degradation step began before the first 
degradation step ended. The extrapolated end of the degradation of AZT was at 331.48°C 
and the total AZT weight loss on heating from 50-500°C was about 78%. 
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Figure 3.7: TGA (solid) and DTGA (dotted) thermogram of AZT obtained when AZT was analyzed from 50ºC to 
500ºC 
 
The TGA thermogram of BP36 [Weight (%) against Temperature (°C), 25-500°C, figure 3.8] 
depicts the first derivative with peak at 68.52°C that corresponds to the first thermal event 
and a peak at 304.02°C that corresponds to the second thermal event. The first thermal 
event calculations gave an extrapolated onset at 50.54°C, an inflection point at 65.70°C, an 
end at 98.63°C and a BP36 degradation weight loss of 10.119% measured from 25-150°C. 
This weight loss was most probably due to evaporation of the moisture from BP36. The 
second thermal event calculations showed an extrapolated onset at 251.34°C, an inflection 
point at 306.04°C, an end at 351.15 and a BP36 degradation weight loss of 33.393%. BP36 
ash value was calculated to be 40.340%. 
 
 
Figure 3.8: TGA (solid) and DTGA (dotted) thermogram for BP36 obtained when BP36 was analyzed from 25ºC 
to 500ºC 
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3.3.4. Thermal and thermodynamic analysis of AZT, BP36, MUC, PECUSP, MUC-PECUSP 
DSC thermogram of AZT run from -10ºC to 500ºC revealed an onset melting point 
(endothermic peak) of 115ºC and a double crystallization point (exothermic peak) at 230ºC 
and 240ºC before degrading (Figure 3.9). 
 
 
Figure 3.9: First run DSC thermogram of AZT measured from -10ºC to 500ºC 
 
Running DSC for AZT from -10ºC to 200ºC, quenching the sample and then running it again 
from -10ºC to 200ºC revealed an onset zidovudine onset grass transition (Tg) of 35ºC as 
depicted in the 2nd run AZT thermogram in figure 3.10. 
 
 
Figure 3.10: First and second run DSC thermograms of AZT measured from -10ºC to 200ºC 
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The BP36 DSC thermogram showed a midpoint melting point of ~105ºC which was a broad 
endothermic peak consistent with carbohydrate macromolecules (Figure 3.11). The 
thermogram showed an exothermic peak at about 390ºC that was not very sharp before 
degradation (Figure 3.11). This exothermic peak could be ascribed to crystallization of BP36. 
BP36 also showed a grass transition at ~80ºC as depicted by the 2nd run DSC thermogram 
of BP36 in figure 3.12. 
 
 
Figure 3.11: First run DSC thermogram of BP36 measured from -10ºC to 500ºC 
 
 
Figure 3.12: First and second run DSC thermograms of BP36 measured from -10ºC to 250ºC 
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Typical broad endothermic peaks were observed for MUC at 111.100°C and PECUSP at 
105.280°C (Sharma and Ahuja 2011). MUC-PECUSP blends conformed to the same outline 
with melting point peaks becoming broader and shifting towards the left as the MUC:PECUSP 
ratio changed from 1:9 through 1:4 to 1:1. The melting temperature (Tm) and the heat of 
fusion (∆Hm) of the MUC-PECUSP blend increased with the content of PECUSP as depicted in 
Figure 3.13 and table 3.2. 
 
 
Figure 3.13: DSC thermogram of; MUC, MUC-PECUSP (ratio 1:1, 1:4 and 1:9) and PEC evaluated from -10°C to 
250°C. 
 
Table 3.2: Midpoint melting point and heat of fusion of different MUC:PECUSP weight and 
volume fractions. 
MUC:PECUSP weight ratio 1:0 1:1 1:4 1:9 0:1 
Φ1 1.000 0.318 0.104 0.050 0.000 
ϕ2 0.000 0.682 0.896 0.950 1.000 
Peak Tm/ °C 105.280 106.630 107.280 109.770 111.100 
∆Hm/Jg-1 207.580 206.500 212.190 222.810 250.290 
 
To determine the miscibility and interaction of MUC and PECUSP by differential scanning 
calorimetry (DSC) using the melting point depression, the Flory-Huggins lattice theory and 
Nishi-Wang theory of thermodynamics were employed (Harris et al., 1983; Xie et al., 2002). 
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Equation 3.5 and 3.6 related to the thermodynamic relationship of the melting point 
depression of MUC, PECUSP and MUC-PECUSP according to the Nishi-Wang theory. Equation 
3.7 gives B, the MUC-PECUSP interaction energy density.  
 
Tm=Tm0+Tm0 (V2/∆H2) Bϕ12                                                                                        Equation 3.5 
 
Tm=Tm0+Tm0 (V2/∆H2) B (1-ϕ2)2                                                                               Equation 3.6 
 
B= (12TR)/V                                                                                                          Equation 3.7 
 
Where, Tm and Tm0 are the melting temperatures of PECUSP in the blend and pure PECUSP 
respectively. V1 and V2 are the corresponding molar volumes of MUC and PECUSP whilst ϕ1 
and ϕ2 are volume fractions of MUC and PECUSP respectively, where ϕ1+ϕ2 =1. R is the molar 
gas constant, T is the absolute temperature and 12 is the Flory-Huggins interaction 
parameter computed at 25°C. ϕ1 and ϕ2 were computed from the mass of MUC and PECUSP 
used to prepare the blends and their respective densities (ρMUC)~1.500gmL-1 and (ρPEC-
USP)~0.7gmL-1 (Nordman et al., 1997). V1 and V2 were calculated from the average molecular 
weights and the densities of MUC (Mw-MUC~22 000 000 gmoL-1) and PECUSP (Mw-PEC-USP~125 
000 000 gmoL-1). Table 3.3 displays calculated values of the MUC-PECUSP interaction 
energy density (B) and the Flory-Huggins interaction parameter, 12, of the three different 
ratios of MUC-PECUSP. The 12 values for the MUC:PECUSP ratios examined were all negative 
which indicated that aqueous dispersions of MUC and PECUSP were miscible as a result of 
possible macromolecular interactions such as hydrogen bonding of hydroxyl and carboxyl 
groups in both macromolecules and the amine and amide groups of the MUC. The more 
negative the 12 value was, the stronger the interactions between MUC and PECUSP. 
 
The data in table 3.2 showed that macromolecular interactions between MUC and PECUSP 
strengthened with decreasing MUC:PECUSP ratio (from 1:1 through 1:4 to 1:9) and this may 
be explained by the fact that the MUC is a larger macromolecule as compared to PECUSP 
hence one MUC macromolecule could accommodate and interact with more than one 
PECUSP macromolecule. MUC, with its bottle brush structure had carbohydrate side-chains 
whose hydroxyl and carboxyl groups were available to interact via hydrogen bonding with 
those of PECUSP (Patel et al., 2003; Bansil and Turner, 2006). The trend in the 12 value from 
MUC:PECUSP 1:1 through 1:4 to 1:9 revealed that although the macromolecular interactions 
became strengthened gradually, MUC it appears would reach a point of saturation with the 
number of PECUSP macromolecules that it would able to interact with. Determination of the 
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optimum MUC:PECUSP ratio was not the subject of this study however this trend revealed 
and may have resulted from the increased steric hindrance and depletion of interaction 
functional groups as consequence of the  increase in the number of PECUSP molecules. 
 
Table 3.3: Thermodynamic interaction energy density (B) and the Flory-Huggins interaction 
parameter (12) which were determined at 25°C of MUC-PECUSP blends at different 
MUC:PECUSP ratio; 1:1, 1:4 and 1:9. 
MUC:PECUSP B/Jcm-3 12 
1:1 - 4.607x10-4 - 2.726 
1:4 - 34.225x10-4 -20.250 
1:9 - 49.790x10-4 -29.459 
 
3.3.5. Ultraviolet spectrophotometry analysis 
Both MUC and PEC could be dispersed in deionized water; however the ease and extent at 
which they dispersed or solubilised varied depending on their molecular structures, the type 
of functional groups they possessed and how these functional groups interacted with water 
molecules. The ultraviolet spectroscopic experiment measured the amount of UV light 
absorbed by the dispersed MUC and PEC macromolecules. The more the macromolecule 
was solubilized the less the UV light it absorbed. MUC was shown to be less soluble in 
deionized water than PECUSP as presented in table 3.3. MUC:PECUSP (1:0) absorbed more 
UV light than MUC-PECUSP (0:1) and as the weight fraction of MUC in the aqueous 
dispersions was increased there was an increase in UV absorbance.  
 
MUC as a glycoprotein has hydroxyl and carboxylic groups on the branched carbohydrate 
side chains as well as amine and amide groups in its protein core (Dekker et al., 2002; 
Bransil and Turner, 2006). These groups were involved in hydrogen bonding with water 
molecules leading to solubilization. However, MUC’s protein core which was mostly 
hydrophobic prevented complete solubilization and led to conformational changes in MUC 
with folds being formed to protect its hydrophobic regions. This resulted in the formation of a 
MUC random coil that had greater absorbance of UV when dispersed in deionized water 
than PECUSP, which has hydroxyl and carboxylic groups that interact with water molecules to 
form hydrogen bonds that aid in solubilization. This phenomenon is comparable to a micelle 
system that appears clear visually as a result of the hydrophobic core being encapsulated in 
the hydrophilic outer layer. Conversely, the PECUSP macromolecules are much smaller, are 
linear and have no major hydrophobic moiety which made them more approachable by water 
molecules as compared to MUC macromolecules. This is reflected in table 3.4 by the lower 
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UV absorbance value of the aqueous dispersion of pristine PECUSP (MUC-PECUSP::0:1) as 
compared to that of pristine MUC (MUC:PECUSP1:0). 
 
Table 3.4: UV absorbance of dilute aqueous dispersions of MUC, PEC and MUC-PEC 
combinations  
MUC:PECratio PEC MUC MUC-PEC ∆A 
APEC A MUC AMUC-PEC 
MUC:PECUSP1:0 0.084±0.008 0.000±0.000 0.084±0.004 0.000±0.000 
MUC:PECUSP 1:9 0.070±0.001 0.064±0.001 0.168±0.010 0.034±0.008 
MUC:PECUSP 1:4 0.067±0.008 0.074±0.009 0.303±0.003 0.162±0.009 
MUC:PECUSP1:1 0.037±0.009 0.348±0.009 0.511±0.002 0.126±0.009 
MUC:PECUSP4:1 0.009±0.002 0.547±0.007 0.631±0.009 0.075±0.006 
MUC:PECUSP9:1 0.002±0.000 0.569±0.004 0.579±0.002 0.008±0.001 
MUC:PECUSP0:1 0.000±0.000 0.630±0.000 0.630±0.006 0.000±0.000 
MUC:PECAS1:4 0.028±0.006 0.074±0.009 0.121±0.001 0.019±0.006 
MUC:PECAS-FS 1:4 0.036±0.005 0.074±0.009 0.120±0.004 0.010±0.004 
 Data expressed as mean values (± SD); n = 3. 
AMUC-PEC – UV absorbance of MUC-PEC aqueous dispersions 
APEC – UV absorbance of aqueous PEC 
AMUC – UV absorbance of aqueous MUC 
UV absorbance was measured at 600nm where neither MUC nor PEC has their λ max 
 
Dispersing MUC and PEC together in deionized water may lead to intermolecular and 
intramolecular hydrogen and electrostatic interactions between the two macromolecules that 
may alter solubilization of the macromolecules and hence UV absorbance. In this study, the 
absorbance difference (∆A) was used as a parameter to signify the presence and extent of 
molecular interactions between MUC and PEC. ∆A was computed as the difference in the 
UV absorbance of the MUC-PEC dispersion and the summation of the UV absorbance of 
individual dispersions of MUC and PEC as in Equation 3.1. A positive value for ∆A signified 
UV absorbance synergy. The extra UV absorbance may be attributed to the intermolecular 
interactions between MUC and PEC (Cai and Arntfield, 1997). It can be asserted that MUC 
and PEC would have formed hydrogen bonds, interpenetrated and electrostatically 
interacted with each other, in addition to interacting with the surrounding water molecules, 
leading to a decrease in solubility and thus an increase in UV absorbance. 
 
Table 3.4 shows that ∆A values for all MUC-PEC combinations were positive. This signified 
the occurrence of intermolecular interactions between MUC and PEC that are stronger than 
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either macromolecule’s interactions with water molecules. These intermolecular interactions 
included hydrogen bonding, chain interpenetration and electrostatic interactions as 
explained further in the molecular mechanics section. ∆A changed with the change in 
MUC:PECUSP ratio. According to results shown in table 3.4, ∆A generally increased with the 
change in MUC:PECUSP ratio from 1:0 through 1:4 and 1:9 to 0:1. However, MUC:PECUSP 1:4 
showed the greatest absorbance as compared to ratios 1:0, 1:1, 1:9 and 0:1. In general, 
more than one PECUSP molecule may interact with one MUC molecule given MUC’s 
multiblock copolymer structure, size and potential functional groups capable of 
intermolecular interactions. Although this study’s aim was not to find out the optimum 
number of PECUSP molecules that could potentially interact with MUC in aqueous media, the 
results revealed that there may be a certain ratio that would result in optimum MUC-PECUSP 
interactions to give a stable polyelectrolyte. In this experiment the MUC:PECUSP ratio 4:1 
resulted in the greatest intermolecular interactions. 
 
A ∆A comparison was made of three different types of pectin; PECUSP, PECAS and PECAS-FS 
which had different degrees of esterification (DE) and degrees of amidation (DA) at a 
MUC:PEC ratio of 4:1. It was found that ∆A increased with an increase in the degree of 
esterification in the order PECAS-FS (DE 28%)<PECAS(DE 35%)<PECUSP (DE 65%). ∆A 
increased with a decrease in the degree of amidation in the order PECAS-FS (DA 20%)<PECAS 
(DA 15%)<PECUSP (DE 0%). The higher PEC was esterified, the more it interacted with MUC 
and this may have been a result of the predominance of macromolecular chain 
interpenetration between MUC and PEC when PEC had more ester side groups leading to 
the formation of an IMN. The corresponding ester side-groups are aliphatic groups which are 
hydrophobic and thus can interact with the hydrophobic part of MUC to form more stable 
MUC-PEC interpenetrating networks. This decreased the aqueous solubility of the 
macromolecules and increased the UV absorbance of their aqueous dispersions. Amidation 
added to the hydrophilicity of PEC thus increased its hydrophilic interaction with water 
molecules and PEC, resulting in increased solubility and decreased UV absorbance as 
observed in the PECAS-FS (DA 20%)<PECAS(DA 15%)<PECUSP (DE 0%) trend. 
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3.3.6. Rheological characterization of porcine gastric mucin (MUC), pectin (PEC) and 
their respective combination aqueous dispersions 
The viscosity of the aqueous PEC dispersion was found to be greater than that of MUC for 
all the three different types of PEC studied (Table 3.5). The viscosity of MUC-PECUSP 
increased as the ratio of MUC-PECUSP changed from 1:1 through 1:4 to 1:9 signifying the 
major role played by PECUSP in the overall viscosity of the MUC-PECUSP combination. In 
addition, the viscosities of the three different types of pectin were in the order of MUC-
PECUSP>MUC-PECAS-FS>MUC-PECAS which meant that highly esterified pectin PECUSP (DE 
65%) underwent stronger molecular interactions with MUC. This corroborated well with the 
previously reported work by Thirawong and co-workers, where they observed that the more 
pectin became esterified the higher its molecular weight became and this in-turn increased 
its interactions with MUC. PECAS (DE 35%) and PECAS-FS (DE 28%) are both low methoxy 
pectin types therefore their molecular weights are much smaller than that of the higher 
methoxy pectin type PECUSP, thus translating to lower molecular interactions with MUC as 
compared to PECUSP (Thirawong et.al., 2008). One would expect MUC-PECAS to have shown 
a greater viscosity than MUC-PECAS-FS because of its higher DE, however the opposite was 
observed in this study.  
 
The greater viscosity of MUC-PECAS-FS as compared to MUC-PECAS may be explained by 
the higher degree of amidation of MUC-PECAS-FS (DA 20%) as compared to MUC-PECAS (DA 
15%). The amide groups in the low methoxy pectin types might have taken part in hydrogen 
bonding with the hydroxyl, carboxyl, amine and amide groups present in MUC, therefore the 
greater the DA, the more the pectin interacted with the MUC which translated into a higher 
viscosity for MUC-PECAS-FS as compared to MUC-PECAS-FS. The viscosity difference (∆ƞ), 
which was regarded as the difference between the viscosity of the MUC-PEC dispersion and 
the sum of the individual viscosities of MUC and PEC dispersions, was greater than zero for 
all MUC-PEC ratios studied and for all the three different pectin types used (Sriamornsak 
and Wattanakorn, 2008; Thirawong et al., 2008). This signified that there was viscosity 
enhancement and thus rheological synergy when MUC and PEC were co-dispersed in 
deionized water. The enhancement in viscosity could be regarded as a result of the 
macromolecular interactions between MUC and PEC to produce a stronger gel (Hassan and 
Gallo, 1990; Rossi et al., 1995; Thirawong et al., 2008). 
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Table 3.5: Viscosity of MUC-PEC dispersions of three different pectin types at different 
MUC: PEC ratios  
MUC:PEC ratio 
 
PEC MUC MUC-PEC ∆ƞ 
Viscosity 
ƞPEC 
Viscosity 
ƞMUC 
Viscosity 
ƞMUC-PEC 
MUC:PECUSP1:9 151.738±0.144 1.687±0.042 179.625±0.274 22.200 
MUC:PECUSP1:4 101.733±0.899 2.635±0.056 141.671±0.761 37.306 
MUC:PECUSP1:1   29.586±0.056 8.008±0.055 93.188±0.144 55.406 
MUC:PECAS1:4   51.690±0.076 2.635±0.056 83.290±0.537 28.965 
MUC:PECAS-FS1:4   46.640±0.066 2.635±0.056   96.941±0.217 47.135 
 
3.3.7. Effect of plasticizer (PEG 400) and calcium ions on the viscosity and dynamic 
moduli of dilute MUC-PECUSP aqueous dispersions  
 Rheology data obtained from performing viscosity and dynamic oscillatory rheology tests on 
MUC-PECUSP aqueous dispersions showed that the viscosity, the storage, and the loss 
moduli of MUC-PECUSP; decreased on addition of PEG 400 (1%v/v), increased on 
crosslinking with calcium ions and further increased on addition of both PEG 400 and  
subsequent crosslinking with calcium ions.  Table 3.6 reveals that the values of the viscosity 
difference (∆ƞ) were positive when; PEG 400 was employed, after crosslinking with Ca2+ and 
when PEG 400 was added with subsequent crosslinking with Ca2+. This demonstrated the 
occurrence of rheological enhancement when MUC and PECUSP were co-dispersed as 
compared to the individual rheology characteristics.  
 
Table 3.6 and figure 3.15 revealed that (ƞ) and (∆ƞ) of PEG-MUC-PECUSP were less than 
that of MUC-PECUSP. PEG 400 being a non-ionic polymer did not interact electrostatically 
with neither MUC nor PECUSP, instead it may have adsorbed onto the surfaces of MUC and 
PECUSP reducing their charge distribution and intensity which might have lowered the 
rheology parameters such as viscosity. The PEG 400 effect on MUC-PECUSP dispersions 
was not shown to cause the “depletion effect” commonly reported and employed in 
biochemistry to precipitate and extract proteins (Wang and Annunziata, 2007). This is when 
PEG 400 was expected to attract water molecules away from MUC-PECUSP thereby 
increasing MUC PEC macromolecular interactions which would have been observed as an 
increase in viscosity and dynamic moduli. Another possible explanation is that PEG 400 
might have drawn water molecules away from MUC-PECUSP which in turn reduced the 
mobility of MUC and PECUSP macromolecular chains leading to a decrease in 
macromolecular interpenetration.  
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In addition, the two macromolecules were dispersed in aqueous media at neutral pH 
resulting in them carrying similar charges. Therefore, by depleting the surrounding water 
macromolecules the macromolecules would be brought closer together and this may have 
caused some electrostatic repulsion since at neutral pH both MUC and PECUSP may have 
ionized carboxyl groups causing electrostatic repulsion of the two macromolecules, 
manifesting in a decrease in macromolecular interactions and hence lowering of viscosity 
and the dynamic moduli. PEG 400 may lie in between the MUC and PECUSP chains and this 
might have sterically hindered macromolecule’s mobility which resulted in decreased 
macromolecular interactions.  
 
Table 3.6: Viscosity of MUC-PECUSP: effect of addition of PEG 400 and crosslinking with 
calcium ions on aqueous dispersions of MUC-PECUSP at MUC: PECUSP ratio 9:1. 
MUC:PEC ratio 
 
MUC PEC MUC-PEC ∆ƞ 
ƞMUC ƞPEC ƞMUC-PEC 
MUC 2.138 ± 0.084 n/a     2.138 ± 0.084  
PECUSP n/a 168.662 ± 
1.402 
168.662 ± 1.402  
MUC-PECUSP   196.440 ±1.688 25.640 
PEG-MUC-PECUSP   189.559 ± 1.378 18.759 
cl-MUC-PECUSP   211.798 ± 0.854 40.998 
cl-PEG-MUC-PECUSP   225.912 ± 1.331 55.112 
 
Crosslinking MUC-PECUSP in the neutral aqueous media using Ca2+ caused an increase in 
(ƞ) and (∆ƞ). Divalent cations like Ca2+ have been reported to interact with mucin via 
electrostatic interactions, particularly in neutral and basic media when the sialic acid groups 
found in mucin are ionized. This would cause the MUC to attain an aggregated structure 
(Espinosa et al., 2002). PECUSP has ionized carboxyl groups at neutral pH capable of 
partaking in electrostatic interactions with Ca2+ resulting in an egg-box conformational 
structure (Braccini and Péres, 2001). Thus calcium ions  at neutral pH cause electrostatic 
homo-crosslinking of MUC and PECUSP leading to an increased MUC-PECUSP gel strength 
and enhanced rheology parameters such as viscosity and the dynamic moduli as shown in 
figures 3.15 and 3.16 as well as in tables 3.5 and 3.6. The homo-crosslinking of MUC and 
PEC upon addition of Ca2+ created an IMN whereby the classic egg-box pectin network was 
intricately entangled with the MUC aggregated network, creating a thermodynamically stable 
macromolecular network that yielded synergistic characteristics exemplified by the 
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enhancement of the viscosity in table 3.5 and figure 3.15, as well as the synergistic increase 
in dynamic moduli as shown in table 3.7 and figure 3.16.  
 
The addition of PEG 400 and then crosslinking with calcium ions caused a marked increase 
in viscosity and dynamic moduli and this might have been due to PEG adsorbing on MUC 
and PECUSP surfaces causing the macromolecules to be more flexible for interpenetration as 
well as depleting the surrounding water molecules. In the presence of Ca2+ there was 
enhanced electrostatic interactions that caused the rheological synergy observed. 
Incorporation of PEG 400 and the subsequent addition of Ca2+ created a IMN that 
corresponded to a pseudo interpenetrating network (PDIPN) whereby PEG 400 remained 
linear whilst MUC and PEC were electrostatically crosslinked around it resulting in an 
entanglement with further enhancement in rheology characteristics than those of the Ca2+ 
crosslinked MUC-PEC IMN without PEG 400 as illustrated in table 3.7 and figure 3.16. The 
MUC-PEC interactions, as measured by rheological synergy were previously studied, 
therefore this study confirms and expands on their work (Hassan and Gallo, 1990; 
Mortazavi, 2003; Liu et al., 2005; Thirawong et al., 2008; Sriamornsak and Wattanakorn, 
2008) 
 
 
Figure 3.14:  Rheology profile properties of MUC, PECUSP and MUC-PECUSP 9:1 illustrating non-Newtonian shear 
thinning (pseudoplastic) flow and rheological synergism. 
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Figure 3.15: Rheological pseudoplastic flow and viscosity profiles of MUC, PECUSP and MUC-PECUSP 9:1 
illustrating the effect of addition of PEG 400 and crosslinking with calcium ions on viscosity. 
 
Table 3.7: Effect on dynamic moduli of PEG 400 and crosslinking with calcium ions 
Dispersed components Dynamic moduli 
Storage modulus (G’) Loss modulus (G’’) 
MUC 0.002± 0.000 0.031± 0.003 
PECUSP 0.034 ± 0.002 0.515 ± 0.016 
MUC-PECUSP 0.035 ± 0.001 0.593 ± 0.027 
PEG-MUC-PECUSP 0.036 ± 0.005 0.584 ± 0.033 
cl-MUC-PECUSP 0.050 ± 0.004 0.654 ± 0.064 
cl-PEG-MUC-PECUSP 0.149 ±  0.011 0.808 ± 0.073 
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Figure 3.16:  Effect on dynamic moduli of PEG 400 and crosslinking with calcium ions as measured by dynamic 
oscillatory rheology 
 
3.3.8. Molecular mechanics assisted model building and energy refinements 
A molecular mechanics conformational searching procedure was employed to acquire the 
data employed in the statistical mechanics analysis, and to obtain differential binding 
energies of a Polak–Ribiere algorithm, as well as to potentially permit application to 
macromolecular composite assemblies. MM+ is a HyperChem modification and extension of 
Norman Allinger’s Molecular Mechanics program MM2 (Warhurst et al., 2003), whereas 
AMBER is a package of computer programs for applying molecular mechanics, normal mode 
analysis, molecular dynamics and free energy calculations to simulate the structural and 
energetic properties of molecules (Pearlman et al., 1995)  
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3.3.9. MMER analysis 
Molecular mechanics energy relationship (MMER), a method for analytico-mathematical 
representation of potential energy surfaces, was used to provide information about the 
contributions of valence terms, non-covalent coulombic terms, and non-covalent van der 
Waals interactions for polysaccharide/mucopolysaccharides interactions. The MMER model 
for potential energy factor in various molecular complexes can be written as: 
 
Emolecule/complex= VƩ + Vb + VƟ + Vφ + Vij+ Vhb +Vel                                                                                   Equation 3.8  
 
where, VƩ is related to total steric energy for an optimized structure, Vb corresponds to bond 
stretching contributions (reference values were assigned to all of a structure’s bond lengths), ZƟ denotes bond angle contributions (reference values were assigned to all of a structure’s 
bond angles), Vφ represents torsional contribution arising from deviations from optimum 
dihedral angles, Vij incorporates van der Waals interactions due to non-bonded interatomic 
distances, Vhb symbolizes hydrogen-bond energy function and Vel stands for electrostatic 
energy. 
 
In addition, the total potential energy deviation, ∆ETotal, was calculated as the difference 
between the total potential energy of the complex system and the sum of the potential 
energies of isolated individual molecules, as follows:  
 
∆ETotal= ∆ETotal (MUC-PEC) – [∆ETotal (MUC) + ∆ETotal (PEC)                                                Equation 3.9 
 
The molecular stability can then be estimated by comparing the total potential energies of 
the isolated and complexed systems. If the total potential energy of a complex system is 
smaller than the sum of the potential energies of isolated individual molecules in the same 
conformation, the complexed form is more stable and its formation is favoured (Yu et al., 
2008). In the present SLAS study, different concentrations of pectin in forms of increasing 
number of molecules were disposed in close vicinity of the glycoprotein to represent 
MUC:PEC ratios of 1:1 (MUC-PEC1), 1:2 (MUC-PEC2), 1:3 (MUC-PEC3), and 1:4 (MUC-
PEC4) (Figure 3.17 and 3.18). The global energy relationships for the various complexes 
derived after assisted model building and energy refinements were as follows: 
 
EMUC=-166.812 VƩ= 5.474Vb + 70.351Vθ + 55.173Vφ – 29.066Vij – 7.096Vhb – 261.649Vel 
 
                                                                                                                            Equation 3.10                                
 
EPEC= 6.539 VƩ= 2.316Vb + 11.957Vθ + 10.407Vφ + 13.335Vij – 31.477Vel          Equation 3.11 
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EMUC-PEC1= -222.143 VƩ=8.556Vb + 111.66Vθ + 104.151Vφ – 45.460Vij – 13.159Vhb-
387.892Vel 
[∆E= -61.87kcal/mol]                                                                                            Equation 3.12 
 
EMUC-PEC2= -299.723 VƩ= 10.725Vb + 132.77Vθ + 137.173Vφ – 61.557Vij – 20.086Vhb – 
498.747Vel 
[∆E= -139.45kcal/mol]…                                                                                      Equation 3.13 
 
EMUC-PEC3= -347.445 VƩ= 14.440Vb + 151.128Vθ + 193.723Vφ – 54.800Vij – 24.668Vhb -
27.268Vel  
[∆E= -187.172kcal/mol]                                                                                        Equation 3.14 
 
EMUC-PEC4= -385.041VƩ= 20.132Vb + 170.443Vθ + 231.344Vφ – 55.159Vij – 25.026Vhb -
26.775Vel [∆E= -224.768kcal/mol]                                                                        Equation 3.15 
 
3.3.10. Elucidation of MUC and PEC molecular interactions and the simulation of a 
MUC-PEC submicrosphere  
For the elucidation of the mechanism inherent to the MUC-PEC complex formation, invariant 
factors common to mathematical description of binding energy and substituent 
characteristics have been ignored. The monomer length for pectin was determined on the 
basis of equivalent grid surface area covered by the macromolecule so that the inherent 
stereo-electronic factors at the interaction site can be perfectly optimized at different 
concentrations. The set of low-energy conformers that were in equilibrium with each other 
was identified and portrayed as the lowest energy conformational model. Molecular 
modelling studies may account for specific interactions between macromolecular segments 
and provide an estimate whether the two macromolecules will form a stable combination 
(favourable interaction) by fulfilling the necessary condition of having a negative free energy 
of mixing (Tiller and Gorella, 1994).  
 
As evident from equations 3.10-3.12, a potential and steric energy stabilization of -
61.87kcal/mol was accompanied with the formation of MUC-PEC1. This confirmed the 
favourable formation and stability of the macromolecular complex in dried state. The energy 
computations involved significant contributions from the bonding interactions (towards 
destabilization) as well as non-bonding interactions (towards stabilization). While the 
bonding, angle and torsional contributions destabilized the complex by inflicting strains in the 
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polymeric architecture, hydrogen bonding, van der Waals forces and electrostatic energy 
tended to balance the strain resulting in a geometrically stabilized conformation. 
 
The formation of MUC-PEC2, MUC-PEC3, and MUC-PEC4 displayed a further energy 
minimization with an increase in the number of pectin molecules interacting with mucin. An 
interesting trend was observed here. According to equations 3.10-3.15, bond stretching and 
bond angle contributions displayed an upward but small increment. However, the torsional 
energy played a significant role in destabilizing the macromolecular complex with large 
increase in inherent steric energy. Similarly, for non-bonding interactions, hydrogen bonding 
and van der Waals forces displayed downward small increments with the electrostatic 
interaction playing the major stabilizing role. The above findings can be summarized as 
follows:  
1. The energy destabilization seemed inherent from rotation of saccharide and amino 
acid residues creating strain due to steric interactions and this strain was further aggravated 
by the inclusion of bond length and angle adjustment with respect to the degrees of freedom 
of the system. 
2. The changes in macromolecular strain above may have led to the formation of H-
bonds between pectin molecules and mucin, as displayed in figure 3.19. In addition, the 
steric interactions might have caused pendent functional groups of pectin (-OH and –COOH) 
and mucin (-OH, -COOH, and –NH2) to overcome torsional barriers thus presenting a larger 
accessible potential energy surface.  
3. The above two steps may have led to the formation of an interconnected 
macromolecular network structure that provided the necessary physicomechanical 
properties to the mucin-pectin complex (Kumar et al., 2011). 
4. A close look at the equations 3.12-3.15 revealed a decrease in the difference in 
energy values between each subsequent addition of a pectin macromolecule. This implies 
that the addition of pectin may have reached a maximum after which further addition might 
not have made any significant contribution. This was corroborated by the experimental 
findings where mucin:pectin::1:9 proved to be the ratio that portrayed the maximum mucin-
pectin interaction.  
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Figure 3.17: Energy minimized molecular structures of, (a) glycosylated MUC and (b) PEC generated by 
HyperChemTM 8.0.8 Molecular Modeling System (Hypercube Inc., Gainesville, Florida, USA). Colour codes: C 
(cyan), O (red), N (blue) and H (white). 
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Figure 3.18: Visualization of geometrical preferences of; (a) MUC:PEC::1:1, (b) MUC:PEC::1:2, (c) 
MUC:PEC::1:3 and (d) MUC:PEC::1:4 along with H-bonds after molecular simulation in vacuum. MUC is 
rendered as stick model (red) with coiled (yellow) secondary structure. Colour codes: C (cyan), O (red), N (blue) 
and H (white). 
 
The MUC PEC interaction energy was computed according to equation 3.16 and the MUC 
PEC interaction energy values for MUC:PEC ratios; 1:1, 1:2, 1:3 and 1:4 are provided in 
table 3.8. The interaction energy increased when the number of pectin molecules interating 
with one mucin molecule increased with the energy when the MUC:PEC ratio was 1:4 being 
the higest (Table 3.8). A further increase in the pectin molecules involved would probably 
increase the interaction energy between MUC and PEC. Connolly molecular electrostatic 
potential surfaces added to the simulated MUC PEC molecular interactions of the MUC:PEC 
ratio 1:4 (Figure 3.18d) revealed in wire mesh display mode a simulated microsphere (Figure 
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3.19). This in silico simulated microsphere is evidence that it is possible to form 
microspheres or submicrospheres using the macromolecules mucin and pectin.  
 
∆E(x:y) = VΣ MUC-PEC (x:y) – (x.VΣ MUC + y.VΣ PEC)                                                         Equation 3.16 
 
Where; ∆E(x:y) is the MUC PEC interaction energy of x molexules of MUC and y molecules of 
PEC, VΣ MUC-PEC (x:y) is the total potential energy of the MUC-PEC complex, VΣ MUC is the total 
potential energy of MUC and VΣ PEC is the total potential energy of PEC. 
 
Table 3.8: Total potential energies of MUC, PEC, MUC-PEC and the MUC PEC interation 
energies at MUC:PEC ratios of; 1:1, 1:2, 1:3 and 1:4 
MUC:PEC ratio 1:1 1:2 1:3 1:4 
Total potential Energy of MUC, 
VΣ mucin (kcal/moL) 
-1.668 
Total potential energy of PEC,  
VΣ pectin (kcal/moL) 
6.540 
Total potential energy of MUC-PEC,  
VΣ pectin-mucin (x:y) (kcal/moL) 
-222.143 -299.723 -247.446 -385.042 
Total MUC PEC interaction energy,  
∆E (kcal/moL) 
-61.871 -139.451 -187.173 -224.679 
 
 
Figure 3.19: Connolly molecular electrostatic potential surfaces of a simulated submicrosphere in wire mesh 
display mode 
 
In chapter 4 zidovudine loaded mucin-pectin-polyethylene glycol submicrospheres were 
formulated guided by the preformulation information devived from this chapter. 
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3.4. Concluding remarks 
AT-FTIR spectroscopy, thermal and thermogravimetric characterisation of AZT and BP 36 
were performed. All the techniques employed in this study demonstrated mucin-pectin 
interactions when the two macromolecules were co-dispersed in aqueous media. The 
interactions occurred in the form of hydrogen bonding, chain interpenetration, electrostatic 
interactions and also due to van de Waal’s forces. The extent and strength of the 
interactions were shown to increase with the degree of esterification as well as when 
crosslinked with Ca2+ as a result of the formation of a MUC-PEC intermacromolecular 
network. The macromolecular interactions also decreased with an increase in the degree of 
amidation and upon addition of a plasticizer, PEG 400. Mucin-pectin interactions increased 
significantly on addition of PEG 400 and subsequently crosslinking using Ca2+ as a result of 
the formation of a MUC-PEC-PEG IMN that corresponds to a PDIPN. The ratio of mucin to 
pectin played a major role in their macromolecular interactions, with more and stronger 
macromolecular interactions observed on increasing the number of PEC macromolecules as 
compared to those of MUC in the aqueous dispersions. This was attributed to the relatively 
larger size of the MUC macromolecule compared to that of PEC, whereby the multi-
oligosaccharide branches of mucin provided multiple hydroxyl and carboxyl functional 
groups to interact with pectin.  
 
In addition, the formation of a MUC-PEC IMN and a MUC-PEC-PEG IMN on crosslinking 
with Ca2+ resulted in synergistic enhancement of the physicomechanical properties such as 
demonstrated in the rheological analysis in this chapter. These enhanced properties of the 
MUC-PEC IMN that results when both MUC and PEC are employed as biomaterials may be 
beneficially utilized in various pharmaceutical applications such as enhancing gel strength, 
increasing encapsulation efficiency of drugs and modulating drug release from different 
formulations including microspheres, nanoparticles, tablets, wafers and gels. However, 
MUC-PEC macromolecular interactions may also result in problems such as decreased 
permeability of drug and molecules through mucosal membranes where pectin and mucin 
would have formed an IMN barrier. A MUC-PEC microsphere was successfully simulated at 
a MUC:PEC ratio of 1:4. This chapter formed the basis for the in vitro experimentation 
performed in chapter 4, for the preparation of drug-loaded pectin-mucin-polyethylene glycol 
submicrospheres. 
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CHAPTER 4 
FORMULATION AND CHARACTERIZATION OF DRUG LOADED PECTIN-MUCIN-POLY 
ETHYLENE GLYCOL SUBMICROSPHERES  
 
4.1. Introduction 
Focus on preventing vaginal HIV-1 transmission has led to the development of several 
different microbicides with a keen interest taken in using antiretroviral drugs as microbicides 
as given by their success in treating HIV/AIDS (Klaase et al., 2008). Although microbicides 
hold much promise and their concept is sound, clinical trials conducted up-to-date have 
failed to demonstrate efficacy (Hendrix et al., 2009). Several questions have been raised and 
some answers postulated to try and explain why anti-HIV-1 agents, effective in vitro, have 
mostly failed at different clinical stages. One common possible explanation given is that 
microbicide formulations did not take into consideration and did not address some 
fundamental anatomical, physiochemical and physiological principles involved in vaginal 
HIV-1 transmission. Such factors include; the presence of the anti-HIV-1 agent in 
appropriate quantities in the vaginal cavity where it has to be distributed extensively and 
exhaustively on the vaginal epithelia and having the microbicide stay at the site for a longer 
duration than HIV-1 (Hendrix et al., 2009).  
 
Various formulations have been prepared to try and mitigate these concerns, among them; 
gels, creams, films, tablets and rings (Hendrix et al., 2009). This chapter focuses on the 
formulation of drug-loaded macromolecular submicrospheres (SMs) which are to be 
embedded within a polymeric drug delivery system in the form of a caplet as a potential 
microbicide drug delivery system. The submicrospheres were formulated from biocompatible 
materials; pectin, porcine gastric mucin and polyethylene glycol. These polymers formed the 
framework structure of the submicrospheres, enabling the encapsulation and controlled 
release of the anti-HIV-1 agent (zidovudine, one of the model antiretroviral agents used in 
this study). The submicrospheres were envisaged to be pH responsive and to have the 
ability to extend drug release by approximately 24 hours. In addition, the submicrospheres 
would also serve as reservoir units for the anti-HIV-1 agent, thus ensuring that there would 
be enough of the anti-HIV-1 agent available for the entire duration of use of the microbicide 
formulation. 
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4.2. Materials and Methods 
4.2.1. Materials 
Commercial grade pectin (PEC), GENU® pectin type USP/100 [Degree of esterification (DE) 
55-65%] was purchased from CP Kelco ApS, Lille Skensved, Denmark. Porcine gastric 
mucin type III (MUC) with 1-1.5% bound sialic acid and polyethylene glycol of Mw 400 (PEG) 
were purchased from Aldrich® (Sigma–Aldrich Inc., St. Louis, USA). The model anti-HIV-1 
active pharmaceutical ingredient (API), zidovudine (AZT), was purchased from 
GlaxoSmithKline, Middlesex, UK. Other materials and excipients including; calcium chloride 
and cyclohexane were of analytical grade and were utilized as purchased. Simulated vaginal 
fluid (SVF, pH 4.5) was prepared from analytical grade reagents in accordance to Owen and 
Katz’s formulation (Owen and Katz, 1999).  
 
4.2.2. Box-Behnken design optimization for the preparation of AZT-loaded PEC-MUC-
PEG SMs 
A three-factor, three-level (33) Box-Behnken statistical design on MINITAB® (V14, State 
College, Pennsylvania, USA) was employed to optimize the preparation of AZT-loaded 
MUC-PEC-PEG SMs (Karnachi and Khan, 1996; Box and Behnken, 1960). Upper and lower 
levels of three independent parameters that included; ultrasonication time (ST), surfactant 
concentration (SC) and drug:polymer (D:P) ratio were chosen due to their high significance 
in the fabrication of the SMs. The dependent parameters or responses that comprised; 
particle size (PS), zeta potential (ZP) and mean dissolution time (MDT) were sought, as 
presented in table 4.1. Fifteen formulations were generated from the Box-Behnken design 
(Table 4.2). These formulations were prepared and experimentally tested and the results 
obtained were fed into the MINITAB® design software which were then computed the 
optimized formulation’s independent parameter and expected response values. 
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Table 4.1: Independent parameters and responses from the Box-Behnken statistical design 
used to optimize AZT-loaded PEC-MUC-PEG SMs 
Independent parameter Levels 
Lower Upper 
ultrasonication time (min) 5 10 
surfactant concentration %(v/v) 1.5 2 
drug:polymer ratio 0.5 1 
   
Response Objective 
particle size (nm) minimize 
zeta potential (mV) minimize 
mean dissolution time (hours) maximize 
 
Table 4.2: Formulations generated using a Box-Behnken statistical design for the 
optimization of AZT-loaded PEC-MUC-PEG SMs 
Formulation 
number 
Ultrasonication time 
(min) 
Surfactant 
concentration % (v/v) 
Drug:polymer ratio 
1 10 1.75 0.5 
2 10 1.5 0.75 
3 5 1.5 0.75 
4 10 2 0.75 
5 5 2 0.75 
6 7.5 2 1 
7 5 1.75 1 
8 7.5 1.75 0.75 
9 7.5 1.75 0.75 
10 10 1.75 1 
11 7.5 1.5 0.5 
12 5 1.75 0.5 
13 7.5 1.5 1 
14 7.5 2 0.5 
15 7.5 1.75 0.75 
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4.2.3. In vitro preparation of AZT-loaded PEC-MUC-PEG SMs. 
AZT-loaded PEC-MUC-PEG SMs where prepared using a crosslinking-emulsion technique. 
PEC, MUC, PEG and AZT(300mg) were subsequently dispersed and dissolved in MilliQ 
water obtained from a MilliQ® gradient water purification system (Millipore SAS, Molsheim, 
France) whilst stirring for 15min to form an aqueous phase which was then crosslinked by 
drop-wise addition of a calcium chloride solution. The PEC:MUC ratio used was 9:1, PEG 
was 0.1mLs and drug (AZT):polymer (MUC, PEC and PEG) ratios used were in accordance 
with the Box-Behnken-design. A water-in-oil (W/O) emulsion was prepared by ultrasonication 
using a high intensity ultrasonic processor (Sonics Vibracell VCX 130, Sonics Materials INC, 
Newtown, CT, USA) with the crosslinked PEC-MUC-PEG-AZT dispersion acting as the 
aqueous phase and cyclohexane as the oil phase. The W:O ratio was 1:4 and span 85 was 
added as the surfactant in accordance with the Box-Behnken design. The emulsion was 
centrifuged at 4000rpm for 1min. Thereafter, excess cyclohexane was decanted. The 
remaining concentrated SM emulsion was frozen at -80°C for 12hrs before being lyophilized 
for 48hrs.  
 
4.2.4. Determination of the stability of the optimized SM emulsion  
The dispersion state of the W/O emulsion obtained in the formulation of SMs  was measured 
using a Turbiscan Lab® (Turbiscan LabTM, Formulaction SA, L’Union, France) which 
assessed the degree of reversible colloidal phenomena such as creaming and sedimentation 
as well as irreversible phenomena such as coalescence and flocculation (Celia et al., 2009). 
The Turbiscan Lab® Expert software was used to analyze transmitted (T) and backscattered 
(BS) light according to equation 4.1 and in reference to the Mie theory represented by 
equation 4.2. 
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Where λ* is the photon transport mean free path, Ф is the volume fraction of the particles, d 
is the particle mean diameter and g (asymmetry factor) and Qs (light scattering efficiency 
factor)
 
are optical parameters given by the Mie theory. A disposable flat bottomed cylindrical 
glass cell was carefully filled to approximately 42mm height with the optimized SM emulsion 
(20mLs) then placed into the Turbiscan® Lab instrument for synchronous dual measurement 
of light that transmitted through and light that was back-scattered at a 45º angle in reference 
to the incident light. Pulsed near infrared light (λ 880nm) was emitted from the source and 
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optical detectors (photodiodes) received the transmitted and the backscattered light. 
Measurements were performed at 25ºC and the Turbiscan® Lab was configured to perform 
continuous scans, performing a scan every 6 minutes, over a 55mm cell length from bottom 
to top for an hour. Variation in particle volume fraction (Ф) on particle migration 
(sedimentation of creaming) and the mean particle diameter (d) due to coalescence resulted 
in variation in the quantity of transmitted and backscattered light. The measured amount of 
transmitted and backscattered light was then interpreted and used to describe the dispersion 
state (stability) of the emulsion (Mengual et al., 1999; Lemarchand et al., 2003; Celia et al., 
2009). 
 
4.2.5. Characterization of the SMs 
The shape and surface morphology of the SMs were determined using a transmission 
electron microscope (TEM) (JEOL S100 Transmission Electron Microscope, Tokyo, Japan) 
set at 40 000X magnification. The particle size of the SMs was determined by measuring 
particle diameter through a process of dynamic light scattering using a Zetasizer (Zetasizer 
Nano ZS, Malvern Instruments Ltd, Worcestershire, United Kingdom). Particle surface 
charge was evaluated by measuring the zeta potential of the SMs using the zetasizer 
(Garcia et al., 2011). SM powder (5mg) samples were each dispersed in 30mLs of MilliQ 
water and passed through 0.22µm Minisart® non-pyrogenic single use filters (Sartorius 
Stedim Biotech, Goettingen, Germany) into quartz cuvettes and specialized zeta potential 
containers respectively which were then inserted into the zetasizer to determine SM particle 
size and zeta potential (Garcia et al., 2011). 
 
4.2.6. Drug encapsulation and release from SMs 
The percentage encapsulation efficiency (EE) of the optimized SMs was determined 
according to equation 4.3 (Garcia et al., 2011). 
 	% = 	 	!"#	"$	%&	'#	() ℎ+",+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 	!"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Where the actual amount of AZT in SMs was measured on a 100mg SM sample. SMs 
(100mg) were added to 100mL of MilliQ water, ultrasonicated for 10 minutes, vortexed for 5 
minutes and then allowed to release the remaining AZT form the SMs over 48 hours whilst in 
an orbital shaker bath that rotated at 20rpm and was set at 37ºC. The amount of AZT that 
was encapsulated in the SMs was then computed form the UV absorbance values measured 
using a nanophotometer (NanoPhotometerTM, Implen GmbH, Munchen, Germany) at 
ambient temperature (25°C) and at a UV absorbance lambda max of 267nm. Determination 
of EE was performed in triplicate. The theoretical amount of AZT was taken as the 
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proportional amount of AZT in 100mg of SMs in reference to the loading dose. AZT release 
from PEC-MUC-PEG SMs was performed using the dialysis membrane technique over 24 
hours in a 100mL container filled with SVF (Gupta et al., 2011; Woolfson et al., 2010; Shaikh 
et al., 2009). The dissolution media (simulated vaginal fluid, SVF), was prepared according 
to Owen and Katz’s as presented in table 4.3 (Owen and Katz, 1999). 
 
Table 4.3: Simulated vaginal fluid (SVF), 1L (Owen and Katz 1999) 
SVF component Quantity (g) 
Sodium chloride (NaCl) 3.510 
Potassium hydroxide (KOH) 1.400 
Calcium hydroxide Ca(OH)2 0.222 
Bovine serum albumin (BSA) 0.018 
Lactic acid 2.000 
Acetic acid 1.000 
Glycerol 0.160 
Urea 0.400 
Glucose 5.000 
 
Drug release was also performed in phosphate buffered saline (PBS pH 7.4) which acted as 
simulated semen (Gupta et al., 2011; Woolfson et al., 2010; Owen and Katz, 2005). The 
AZT-loaded SMs and 2mLs of SVF or PBS (similar medium as the bulk 100mL dissolution 
medium) were added into a dialysis tubing which had a molecular weight cut-off of 12kDa 
obtained from Sigma [(Sigma–Aldrich Inc., St. Louis, USA); Gupta et al., 2011; Shaikh et al., 
2009]. The tubing was securely tied at both ends and then suspended in a dissolution media 
filled container (100mL) that was placed in an orbital shaker incubator (Orbital Shaker 
Incubator, LM-530D, Yihder Technology CO., LTD, Jhonghe City, Taipei County, Taiwan, 
Republic of China) which was set at 37°C and rotated at 20rpm (Woolfson et al., 2010). 
Dissolution media aliquots (200µL) were withdrawn at predetermined time intervals and 
ultraviolet (UV) quantification of the amount of drug released was performed using the 
nanophotometer. Dissolution tests were performed in triplicate.  
 
Dissolution profiles were generated from the amounts of AZT released over 24 hours and 
these profiles were used to characterize in vitro AZT release kinetics from the SMs. The 
ability of the macromolecular SMs to modulate AZT release was evaluated by determining 
the mean dissolution time (MDT) according to equation 4.4 and the dissolution efficiency 
(DE) which is the area under the dissolution curve up to a certain time, t, expressed as a 
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percentage of the rectangular area described by 100% dissolution in the same time, was 
computed according to equation 4.5 (Khan, 1975; Costa and Lobo, 2001; Garcia et al., 
2011). 
 
(0& =	∑ 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Where Mt is the fractional dose released in time ti= (ti+ti-1)/2 and M∞ corresponds to the 
loading dose 
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Where y is the percentage of drug dissolved at time t. The pH responsiveness of the SMs 
was tested by comparing the dissolution efficiencies, MDTs and computing the similarity 
factor (f2) and the difference factor (f1) of the dissolution profiles obtained in SVF and PBS 
according to equations 4.6 and 4.7 (Moore and Flanner, 1996; O’Hara et al., 1998; Costa et 
al., 2001; Zhang et al., 2010). 
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Where n is the number of sampling points, Wt is an optional weight factor, Rt is the reference 
assay at time t and Tt is the test assay at time t. The dissolution profile of the PEC-MUC-
PEG SMs in SVF and PBS was fitted into 14 different kinetic models and the best fit 
parameter, the adjusted coefficient of determination (R2adjusted), regarded as the goodness of 
fit parameter, was obtained. R2adjusted was viewed as a measure of how close the dissolution 
profile of the SMs followed the chosen kinetic model, with values of R2adjusted that increasingly 
approached 1 showing the closest model fit as opposed to values smaller than 1 (Zhang et 
al., 2010).  
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4.2.7. Attenuated total reflectance Fourier transform infrared (ATR-FTIR) spectroscopy 
analysis 
ATR-FTIR spectra of native PEC, MUC, PEG, AZT and the AZT-loaded PEC-MUC-PEG 
SMs were obtained using a Perkin Elmer Spectrum 2000 FTIR spectrometer fitted with a 
MIRTGS detector (PerkinElmer Spectrum 100, Llantrisant, Wales, UK). Dry powder samples 
directly analyzed over a wave number range of 650-4000cm-1 with a resolution of 4 cm−1 and 
10 scans per spectrum were performed at a direct contact force of 120N on a universal 
diamond ATR top-plate. Distinct absorption peaks were used to verify the constitution of the 
SMs by comparing them to the peaks on the native MUC, PEC, PEG and AZT.  
 
4.2.8. Thermal analysis using differential scanning calorimetry (DSC)  
The thermal properties of PEC, MUC, AZT and the AZT-loaded SMs were analyzed by DSC. 
The analysis was conducted on a differential scanning calorimeter (Mettler Toledo, DSC1, 
STARe System, Schwerzenback, Switzerland) which was dually calibrated for temperature 
and enthalpy using indium and zinc. All experiments were performed at a heating rate of 
10°C min-1 under a dry nitrogen atmosphere (Afrox, Germiston, Gauteng, South Africa) 
which flowed at a rate of 200mLmin-1 acting as the purge gas in order to reduce sample 
oxidation. Samples were placed in 40µL aluminium pans and heated from -10°C to 110°C 
and kept at 110°C for 3 minutes. This was done to evaporate any moisture in the sample 
and to eliminate any thermal history. The samples were then quenched from 110°C to -10°C 
at a rate of 20°C min-1. The midpoint melting point (Tm) and heat of fusion (∆H) which were 
used for characterization were obtained from the melting point depression of the peaks 
generated on the experimental DSC curves on heating the samples from -10 to 300°C.  
 
4.2.9. Thermogravimetric analysis (TGA)  
Thermal degradation analysis was performed on 10-20mg samples of PEC, MUC, AZT AZT-
loaded PEC-MUC-PEG SMs which were contained in ceramic pans under nitrogen 
atmosphere using a TGA 4000 thermogravimetric analyzer (PerkinElmer Inc, 
Massachusetts, USA). The experiments were run at 10°Cmin-1 from 50-500°C. 
Thermograms obtained and their first derivatives revealed the thermal degradation 
properties of the samples. 
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4.2.10. X-ray diffraction (XRD) analysis 
The crystalline and amorphous nature of the AZT-loaded SMs and their individual 
compositional components was investigated using a Rigaku MiniFlex600 Benchtop X-ray 
Diffractometer (Rigaku Corporation, Tokyo, Japan) fitted with; a 600W (40Kv-15mA) X-ray 
generator, a counter monochromator to cut X-rays other than Cu Kα X-rays and a high 
intensity D/tex ultra high speed 1D detector. Experimental temperature was maintained at 
19ºC. The diffractometer was operated using the Rigaku MiniFlex Guidance software, 
version 1.2.0.0 and data was analyzed using the Rigaku PDXL Basis software able to 
perform integrated intensity calculations. Measurement parameters included a divergence 
slit (DS) of 1.25º, scattering slit (SS) of 1.25º, a 0.3mm receiving slit (RS) and a goniometer 
radius of 150mm. Each powder sample of PEC, MUC, AZT and AZT-loaded PEC-MUC-PEG 
SMs was pressed flat onto a square grooved glass slide sample holder. Measurements were 
performed by scanning each sample at 0.01-100º/min over a diffraction angle range of 3º-
60º 2θ. The XRD diffractograms generated were used to evaluate the crystallinity of the 
respective samples (Santos et al., 2003; Mishra et al., 2008; Kumar et al., 2011; Raviolo and 
Briñόn, 2011). 
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4.3. Results and Discussion 
4.3.1. Preparation and optimization of the macromolecular SMs 
All 15 formulations from the design template produced SMs of varying particle size, zeta 
potential that had different MDTs (Table 4.4). The obtained results were inputted into the 
MINITAB® software to yield four possible optimized formulations and the most appropriate 
optimized formulation had a composite desirability (D) of 0.865, PS desirability (dPS) of 
1.000, ZP desirability (dZP) of 0.825 and MDT desirability (dMDT) of 0.785. Independent and 
dependent parameters that had a desirability of 1,000 were regarded as the most optimum 
and those that had a desirability of 0.000 as the least optimum parameters. The optimal 
formulation had independent parameters; ST of 6.28 minutes, SC of 1.64 (% v/v) and a D:P 
ratio of 1:1 which gave predicted SM responses of; PS 215.19 nm, ZP -39.13mV and a MDT 
of 5.52 hours. Linear regression of independent parameters and responses using MINITAB® 
generated relationships described by the polynomial equations 4.8, 4.9 and 4.10 (Karnachi 
and Khan, 1996). Where the coefficient of determination of PS (R2PS) was 51.4%, ZP (R2ZP) 
was 90.1% and that of MDT (R2MDT) was 85.6% (Karnachi and Khan, 1996).            
       
PS=-1719.600+163.070[ST]+1247.470[SC]+637.950[D:P]-3.900[ST]2-158.33[SC]2-
127.530[D:P]2-66.800[ST*SC]+24.600[ST*D:P]-227.200[SC*D:P]                       Equation 4.8 
 
ZP=40.125-4.925[ST]+13.250[SC]-189.100[D:P]+0.580[SC]2-20.400[SC]2-26.400[D:P]2-
4.160[ST*SC]+3.000[ST*D:P]+122.800[SC*D:P]                                                  Equation 4.9 
 
MDT=-34.951+3.267[ST]+41.139[SC]-20.998[D:P]-0.093[ST]2-11.896[SC]2-4.624[D:P]2-
0.921[ST*SC]-0.415[ST*D:P]+10.104[SC*D:P]                                                   Equation 4.10 
 
The correlation of the independent parameters; ST, SC and D:P ratio to the responses; PS, 
ZP and MDT was further illustrated as response mesh plots presented in figure 4.1 
(Karnachi and Khan, 1996).  
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Table 4.4: Responses obtained from in vitro testing of the 15 design formulation’s 
independent parameters 
Formulation number Particle size (nm) Zeta potential (mV) MDT (hours) 
1 186.1±4.267 -42.7±2.350 4.852 
2 311.0±13.360 -35.4±0.503 4.825 
3 143.6±21.110 -33.7±1.460 3.572 
4 229.1±52.030 -40.2±1.400 3.845 
5 228.7±12.510 -28.1±0.894 4.895 
6 220.0±4.768 -29.7±0.144 5.612 
7 223.2±12.390 -30.5±0.193 6.300 
8 262.9±3.964 -33.1±0.535 5.339 
9 203.1±2.989 -41.6±0.671 5.952 
10 231.3±4.634 -32.4±0.618 5.209 
11 220.6±6.202 -34.2±0.948 5.958 
12 239.5±9.255 -33.3±0.415 4.906 
13 228.1±5.899 -47.4±0.536 4.349 
14 269.3±13.450 -47.2±0.860 4.695 
15 321.1±17.370 -35.4±0.501 5.533 
 
 
Figure 4.1: Response mesh plots correlating dependent formulation parameters/responses; PS, ZP and MDT to 
their independent parameters; ST, SC and D:P ratio  
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4.3.2. Submicrosphere emulsion stability  
The delta transmission and delta back scattering profiles of the optimised SM emulsion 
depicted in figure 4.2 show that the SM emulsion was generally stable with some local 
destabilization (sedimentation) as observed by the gradual decrease in the delta 
backscattering (DeltaBS) signal at the top end of the glass cell. The middle and the bottom 
of the profile was relatively unchanged which meant that the emulsion was stable over the 
hour long test duration and no global destabilization (coalescence) and no creaming 
occurred to the SM emulsion during the total experimentation duration. 
  
 
Figure 4.2: Delta transmission and delta backscattering profiles of an optimized SM emulsion obtained through 
continuous scans every 6 minutes for 1 hour  
 
During the SM preparation the emulsion was centrifuged within an hour followed by freezing 
at -80 degrees for 24 hours then lyophilized for 48 hours, therefore a small degree of 
sedimentation observed does not significantly affect the AZT-loaded PEC-MUC-PEG SM 
formulation.  
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4.3.3. Morphological characterization of AZT-loaded PEC-MUC-PEG SMs 
Well defined spherical SMs were observed under TEM (Figure 4.3). The mean particle size 
of the SMs prepared from the 15 design formulations ranged from 143.6±21.110nm, F3, to 
321.1±17.370nm, F15, (Table 4.4). The optimized formulation had a mean particle size of 
270.6±5.53nm and a stable polydispersity index (PDI) of 0.303±0.028 as depicted in figure 
4.4a which also shows zeta potential for the 15 design formulations that ranged from -
28.1±0.894mV to -47.4±0.536mV (Table 4.4). The optimized formulation had a zeta potential 
of -34.4±0.539mV signifying that the SMs were not agglomerated (Figure 4.4b).  
 
 
Figure 4.3: Transmission electron micrograph of AZT-loaded MUC-PEC-PEG SMs observed at 40 000X 
magnification using a JEOL S100 transmission electron microscope 
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Figure 4.4:  Showing, (a) particle size distribution with intensity and (b) zeta potential distribution profile of the 
optimized SMs obtained using a zetasizer 
 
4.3.4. Drug release from PEC-MUC-PEG SMs 
The release of AZT from SMs in SVF occurred mostly within 24 hours for the 15 Box-
Behnken design formulations as depicted in the dissolution profiles in figures 4.5a-c. All 15 
formulations had similar drug release profiles (Figures 4.5a-c). The ability of the 
macromolecular SMs to retain drug and prolong drug release was evaluated by the MDT.  
MDT varied from 3.573 hours for formulation F3 to 6.300 hours for formulation F7 (Table 4.4) 
and was a resultant of the contribution of the independent parameters as observed in figures 
4.1g, 4.1h and 4.1i. For example, the dissolution profiles observed in figure 4.4a for 
formulations F3 and F4 showed that the drug was relased faster from the submicrospheres 
and this was corroborated by the computed low MDT values (Table 4.4).  Independent 
parameters for F3 (Table 4.2) were; minimum ST (5min), medium SC (1.75%) and medium 
D:P ratio (0.75) which resulted in the formation of the smallest submicrospheres 
(PS=1.436±21.110nm). The low MDT of F3 submicrospheres was likely because the small 
submicrospheres provided a large dissolution surface area. Conversly relatively larger F7 
submicrospheres had the highest MDT and were a product of; minimum ST (5min), medium 
SC (1.75%) amd maximum D:P ratio (1) as presented in table 4.2. In this case a higher D:P 
ratio probably contributed more to the high MDT as the submicrospheres could better retard 
the dissolution of the encapsulated AZT. The optimized formulation had a MDT of 5.974 
hours. Comparative drug release of the optimized formulation in PBS pH 7.4 yielded a MDT 
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of 5.389 hours (Figure 4.5d).  Drug release from the optimized SMs within 24 hours in SVF 
pH 4.5 was approximately 91% as compared to approximately 94% in PBS (Figure 4.5d). 
The dissolution characteristics of drug from the submicrospheres was therefore a summation 
of the contribution of all the 3 independent variables; ST, SC and D:P ratio. 
 
Figure 4.5: SM dissolution profiles of; (a) formulations F1-F5, (b) formulations F6-F10, (c) formulations F11-F15 
and (d) the optimized formulation in SVF and PBS  
 
An increase in pH from acidic (pH 4.5 SVF) to alkaline (pH 7.4 PBS) might have caused a 
destabilization in the architecture of the SMs leading to increased leakage of the 
encapsulated drug as shown by the increase in the fractional release in PBS as compared to 
that observed in SVF (Figures 4.5d and 4.6a). Additionally, the mean dissolution time for the 
drug released from the SMs was shorter in PBS as compared to SVF. This variation in drug 
release in dissolution media of a different pH may be explained by the presents of carboxyl 
groups in pectin and mucin which are neutral in an acidic environment (SVF pH4.5) and 
which are then ionized in an alkaline environment (PBS pH 7.4) which would lead to 
repulsion of the negatively charged moieties thus causing the architectural destabilization of 
the SMs thereby leading to increased drug release and a decreased mean dissolution time. 
However, the effect appeared not too pronounced possibly because pectin and mucin were 
interpenetrated and crosslinked. This was also confirmed by the similarity of the SM 
dissolution profiles obtained in SVF and in PBS as specified by the closeness of their 
dissolution efficiencies (DE =69.097% in SVF and DE=73.568% in PBS) and according to 
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the computed similarity and difference factors (f2 =63.132 and f1=8.099) (Moore and Flanner, 
1996; O’Hara et al., 1998; Costa et al., 2001; Zhang et al., 2010). 
 
From the dissolution profiles in figure 4.6b, it was noted that ionic crosslinking PEC with Ca2+ 
reduced the amount of drug released in 24 hours and this may be a result of the formation of 
an egg-box network structure when the Ca2+ electrostatically interacted with the carboxylic 
moieties of the macromolecular PEC (Yu et al., 2009). This egg-box structure condenses the 
PEC chains encapsulating AZT leading to reduced dissolution. PEG caused a slight increase 
in the amount of drug released and this may have occurred because PEG draws water 
molecules towards the SMs by forming hydrogen bonds with the surrounding water 
molecules of the dissolution media (SVF or PBS). There was no major difference in the 
dissolution profile observed for PEC-MUC-PEG submicrospheres and that for PEC-MUC or 
PEC-PEG submicrospheres (Figures 4.6c and 4.6d) suggesting that PEC was the main 
constituent that contributed to the dissolution of the submicrospheres. 
 
Modeling of AZT-loaded SM dissolution in SVF and PBS showed that AZT release kinetics 
fitted with most kinetic models tested as given by the values of the adjusted coefficient of 
determination (R2 adjusted) with the exception of zero order kinetic model as shown in table 4.5. 
The highest goodness of fit parameter (R2adjusted) was attained using the Logistic and Makoid-
Banakar models for the dissolution profiles obtained in SVF and PBS respectively. The 
closeness of the best fit parameters and R2adjusted underline the similarity in the SMs 
dissolution kinetics and profiles when dissolution was performed in SVF (pH 4.5) as 
compared to dissolution in PBS (pH 7.4).  
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Figure 4.6: Comparison of AZT release from; (a) PEC-MUC-PEG SMs in SVF pH 4.2 to AZT release in PBS pH 
7.4, (b) crosslinked PEC SMs to release from uncrosslinked PEC SMs both in SVF, (c) PEC-MUC-PEG SMs to 
AZT release from PEC-MUC SMs both in SVF and (d) PEC-MUC-PEG SMs to AZT release in PEC-PEG SMs 
both in SVF. 
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Table 4.5: Goodness of fit and best fit parameters obtained by fitting the SM dissolution profiles (obtained in SVF and PBS) to different kinetic 
models 
Dissolution model Best-fit parameter Goodness of fit parameter 
R2adjusted  
Parameter 1 Parameter 2 Parameter 3 pH 4.5 pH 7.4 
pH 4.5 pH 7.4 pH 4.5 pH 7.4 pH 4.5 pH 7.4 
Zero order k0=4.922 k0=5.172     0.5871 0.4341 
First order k1 =0.136 k1=0.170     0.9768 0.9675 
Higuchi kH=20.733 kH=21.984     0.9607 0.9384 
Korsmeyer-Peppas kKP=25.198 kKP=30.806 n=0.426 n=0.372   0.9692 0.9769 
Hixson-Crowell kHC=0.037 kHC=0.046     0.9378 0.9238 
Hopfenberg kHB=0.000 kHB=0.000 n=1791.481 n=7236.567   0.9744 0.9642 
Baker-Lonsdale kBL=0.013 kBL=0.016     0.9808 0.9933 
Makoid-Banakar kMB=19.709 kMB=26.024 n=0.691 n=0.573 k=0.028 k=0.023 0.9933 0.9973 
Peppas-Sahlin k1=20.905 k1=27.709 k2=-1.216 k2=-2.058 m=0.683 m=0.597 0.9926 0.9971 
Quadratic k1=-0.003 k1=-0.003 k2=0.102 k2=0.112   0.9382 0.8882 
Weibull α=4.455 α=3.552 β=0.761 β=0.725 Ti=0.110 Ti=0.000 0.9944 0.9983 
Logistic α=-1.717 α=-1.298 β=2.751 β=2.584   0.9941 0.9918 
Gompertz α=2.290 α=1.632 β=2.2029 β=1.877   0.9817 0.9750 
Probit α=-1.027 α=-0.2772 β=1.651 β=1.546   0.9935 0.9928 
k0, k1, kH, kKP, n, kKP, kHC, kHB, kBL, k, k2, α and β are best fit parameters of the respective dissolution models 
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4.3.5. ATR-FTIR analysis of PEC, MUC, PEG, AZT and AZT-loaded PEC-MUC-PEG SMs 
FTIR spectrum of AZT-loaded PEC-MUC-PEG SMs (Figure 4.7a) revealed a broad 
absorption peak extending from approximately 3000 to 3600cm-1 which may have been a 
result of the overlapping stretching vibrations of hydroxyl (–OH) groups found in MUC, PEC, 
AZT and  PEG and the carboxyl (–COOH) groups of PEC and MUC (Kumar et al., 2010). 
The broadening of this peak as compared to the ones in PEC (Figure 4.7c), MUC (Figure 
4.7b), PEG (Figure 4.7e)  and AZT (Figure 4.7d)  was probably due to the participation of the 
–OH and COOH groups in H-bonding. The SM absorption peaks observed at 2933cm-1 and 
2854cm-1 may be attributed to strong stretching vibrations of the alkane groups; –CH3, -CH2, 
and –CH that are found in PEC (peak 2935cm-1), MUC (peak 2917cm-1), PEG (peak 
2867cm-1) and AZT (peak 2814cm-1).   
 
AZT encapsulation in PEC-MUC-PEG SM was confirmed by the presence of the absorption 
peak at 2105cm-1 which may be attributed to the stretching vibrations of the azide (-N3) 
group of AZT (Figure 4.7a). The reduction in intensity of this peak as compared to the one 
observed on the AZT ATR-FTIR spectrum (Figure 4.7d) may be a result of the shielding of 
AZT as it was encapsulated within the PEC-MUC-PEG SMs and possibly due to the 
participation of the –N3 group in hydrogen bonding with -OH and –COOH groups found in 
PEC, MUC and PEG.  The peak that was observed at 1742cm-1 on the AZT-loaded PEC-
MUC-PEC SM ATR-FTIR spectra (Figure 4.7a) may have resulted from the contribution 
made by strong stretching vibrations of the ester bond found in PEC which was 
approximately 55-65% esterified (GENU® pectin USP/100, CP Kelco ApS, Lille Skensved, 
Denmark). A strong amide I (-C=O) peak (1682cm-1) was observed on the SM spectrum 
which may have been dually contributed to by the strong stretching vibrations of the amide I 
bond in MUC (peak 1636cm-1) and  AZT, peak 1641cm-1 and 1670cm-1 (Patel et al., 2003, 
Tam et al., 2005). The ATR-FTIR spectra of SMs, PEC, MUC, PEG and AZT depicted 
several peaks in the finger print region (1450-650cm) which were consistent with what is 
reported in literature and expected for the AZT-loaded SMs (Mishra et al., 2008; Patel et al., 
2003; Ravi et al., 2008). 
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Figure 4.7:  ATR-FTIR spectra of; (a) AZT-loaded PEC-MUC-PEG SMs, (b) MUC, (c) PEC, (d) AZT and (e) PEG 
 
4.3.6. Differential scanning calorimetry (DSC)  
DSC thermograms of AZT-loaded PEC-MUC-PEG SMs, MUC, PEC and AZT are depicted in 
figure 4.8.  AZT-loaded PEC-MUC-PEG SMs had a broad endothermic peak with melting 
point peak maxima at 113.67°C and a measured heat of fusion of 9.75Jg-1 as well as an 
exothermic crystallization peak at 230.81°C (Figure 4.8a). SM components; MUC had an 
melting point represented by an endothermic peak maxima at 101.36°C (Figure 4.8b), PEC 
had a melting endothermic peak at 120.73°C as well as an exothermic crystallization peak at 
236.17°C (Figure 4.8c) and the model drug, AZT, had an onset melting point at 122.88°C 
and an exothermic crystallization peak at 240.34°C (Figure 4.8d) that were consistent with 
results reported in literature (Araújo et al., 2003). The thermal DSC thermogram of AZT-
loaded PEC-MUC-PEG SMs confirmed the SM composition and was a result of the thermal 
contribution of PEC, MUC, PEG and AZT. 
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Figure 4.8: DSC thermograms of; (a) PEC-MUC-PEG +AZT, (b) MUC, (c) PEC and (d) AZT 
 
4.3.7. Thermogravimetric analysis of AZT loaded SMs and their native constituents 
The thermal degradation of AZT-loaded PEC-MUC-PEG SMs as measured by TGA 
produced the thermogram depicted in figure 4.9a (solid). The SM TGA thermogram depicts a 
one-step degradation with weight loss of approximately 84% on heating from 50-500°C. 
However, its first derivative TGA (DTGA, dotted) revealed that the SMs degraded in three 
major steps as revealed by DTGA peaks at 239.60°C, 287.90°C and 409.77°C that 
correspond to the points of inflection on the SM TGA thermogram. It is vital to compare the 
SM TGA thermogram with that of all the components from which the SMs were formulated 
i.e. PEC, MUC, PEG and AZT as presented in figure 4.9b. Figure 4.9c shows the TGA 
(solid) and DTGA (dotted) thermograms of PEC. Thermal degradation of PEC was shown to 
take place in two steps; the first was a minor step that took place from 50-150°C resulting in 
7.919% weight loss and a point of inflection at 95.03°C which may have been a result of 
dehydration. The second and major PEC degradation step had an extrapolated onset and 
end at 233.54°C and 276.92°C respectively with its point of maximum degradation 
represented by the DTGA (peak 246.01°C). This second degradation step resulted in a 
weight loss of approximately 59% and was most likely due to the depolymerization of PEC 
carbohydrate chains (Kumar et al., 2010). PEC weight loss of approximately 66.98% 
occurred from 50-500°C. The first DTGA peaks of the SMs, 239.60°C (Figure 4.9a) and 
PEC, 246.01°C (Figure 4.9c) are observed to be close; therefore, PEC degradation might 
have contributed to the initial degradation of the SMs (Figure 4.9a). 
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Thermal degradation of MUC was also observed to occur in two steps, with the first minor 
step occurring from 50-150°C which resulted in a corresponding DTGA peak at 90.63°C that 
resulted in weight loss of approximately 9.14% (Figure 4.9d). This step was likely a result of 
the evaporation of bound water molecules from the MUC macromolecules. This first step 
was then followed by a major degradation step which had an extrapolated onset and end at 
264.58°C and 330.64°C respectively with its point of inflection corresponding to the DTGA 
peak at 286.50°C. This major degradation step was possibly a result of the depolymerization 
of oligosaccharide side-chains in MUC. Overall, there was a total weight loss of 66.17% on 
heating MUC from 50-500°C. Due to the closeness of the DTGA peaks of the corresponding 
second degradation steps of MUC, peak at 286.50°C (Figure 4.9d) and SMs, peak at 
287.90°C  (Figure 4.9a), MUC was likely a contributor to the second degradation step of the 
AZT-loaded PEC-MUC-PEG SMs (Figure 4.9a). 
 
The model drug, AZT, thermally degraded in two major steps depicted by the DTGA peaks 
at 244.10°C (first step) and 310.70°C (second step) which might have contributed to the first 
and second SM degradation steps (Figures 4.9a and 4.9e). Degradation of AZT started at 
the extrapolated onset of 230.14°C then the second degradation step began before the first 
degradation step ended. The extrapolated end of the degradation of AZT was at 331.48°C 
and the total AZT weight loss on heating from 50-500°C was 77.935%. The third degradation 
step of the SMs, DTGA peak 409.77°C (Figure 4.9a) was likely due to the degradation of 
PEG which degraded almost completely (99.084%) in one major step with an extrapolated 
onset and end of 338.89°C and 393.97°C respectively (Figure 4.9f). The point of maximum 
degradation of PEG corresponds to the DTGA peak at 395.15°C (Figure 4.9f).  
 
All the three degradation steps of the SMs were shifted to the right as compared to the 
corresponding degradation steps of the respective components of the SMs (PEC, MUC, AZT 
and PEG) signifying SM thermal stability. The SM thermal stability might have been brought 
about by the macromolecular ionic crosslinking using Ca2+ done during the formulation of the 
SMs as well as the intermolecular interactions possibly due to hydrogen bonding of the 
carboxyl, hydroxyl, amide, amine and azide groups of the SM components. 
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Figure 4.9: The TGA (solid) and DTGA (dotted) thermograms of: (a) PEC-MUC-PEG+AZT SMs; (b) (i) MUC, (ii) 
PEC, (iii) AZT, (iv) PEC-MUC-PEG+AZT MS and (v) PEG; (c) PEC; (d) MUC; (e) AZT and (f) PEG 
 
4.3.8. X-ray diffraction (XRD)  
Figure 4.10 depicts the XRD diffractograms of; AZT-loaded PEC-MUC-PEG SMs , PEC, 
MUC and that of AZT. The diffractogram of AZT-loaded PEC-MUC-PEG SMs shows several 
sharp peaks that include major peaks at 2θ equal to; 8.725º, 14.535º, 15.374º, 15.726º, 
16.987º, 21.265º, 22.093º, 24.064º, 26.825º, 27.677º, 29.181º and 29.181º which signify the 
crystalline nature of the AZT-loaded PEC-MUC-PEG SMs (Figure 4.10a). The diffractogram 
of PEC depicts a broad peak at 2θ equal to 21.274º indicating the amorphous nature of PEC 
(Figure 4.10c) and the difractogram of MUC depicts a broad peak at 2θ equal to 21.525º 
illustrating also the amorphous nature of MUC (Figure 4.10b). AZT was shown to be 
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crystalline due to several sharp peaks that include major peaks at 2θ equal to 9.000º, 
14.891, 15.725º, 16.040º, 17.304º, 21.41º, 21.640º, 24.513º, 27.140º, 28.050º and 29.500º 
observed on its diffractogram shown in Figure 4.10d which are similar to the ones previously 
reported by Raviolo and Briñόn (Raviolo and Briñόn, 2011). The observed patten in the 
diffractograms in Figure 4.10 shows that the crystallinity of AZT-loaded PEC-MUC-PEG SMs 
was a result of the contribution by the highly crystalline AZT. The peaks observed in the 
diffractogram of AZ-loaded PEC-MUC-PEG SMs were sharp as those observed for  AZT but 
were shifted slightly to the left by less than 1º and peak intensities were lower that those of 
observed for AZT which was probably because of the formation of a less crystaline complex 
when AZT was ecapsulated in the amorphous MUC and PEC based SMs (Banthia et al., 
2008; Mishra et al., 2008; Santos et al., 2003; Shaikh et al., 2009).  
 
 
Figure 4.10: Three dimensional X-ray diffractograms of; (a) AZT-loaded PEC-MUC-PEG SMs (black), PEC 
(green), MUC (blue) and AZT (red) 
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4.4. Concluding remarks 
AZT-loaded MUC-PEC-PEG submicrospheres were successfully designed and optimized 
using the Box-Behnken design. The optimised submicrospheres prepared by a crosslinking-
emulsion technique were spherical and not agglomerated. Drug release studies performed 
over 24 hours showed that approximately 91% and 94% of AZT was released in SVF and 
PBS (which acted as simulated semen) respectively. There was no major difference 
between the submicrosphere AZT dissolution profile in SVF and the one in PBS. Drug 
release kinetics of the submicrospheres were found to fit most models tested with the 
highest goodness of fit parameter (R2adjusted) being observed with the Logistic and Makoid-
Banakar models for the dissolution profiles obtained in SVF and PBS respectively. 
 
In conclusion, submicrospheres which act as a reservoir for an anti-HIV-1 agent and capable 
of delivering it over a 24 hour duration were successfully formulated from biocompatible 
materials and tested in vitro. These AZT-loaded submicrospheres embedded in a polymeric 
matrix, as in chapter 5, and used in vivo in the human vaginal cavity, would likely ensure that 
there is enough of the anti-HIV-1 agent present in the vaginal cavity to counter HIV-1 in the 
seminal fluids interposed into the vaginal cavity during coitus, with no frequent dosing 
required prior to or after each coital act. Further studies including in vivo animal studies and 
toxicity studies necessary would be presented in chapter 6 to test the performance of these 
submicrospheres embedded within a composite polymeric delivery system and used in vivo 
in the pig model. 
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CHAPTER 5 
FABRICATION, OPTIMIZATION AND IN VITRO TESTING OF A COMPOSITE 
POLYMERIC DELIVERY SYSTEM  
 
5.1. Introduction 
Heterosexual HIV-1 transmission from males to females occurs mostly via the vaginal route 
where free and/or cell bound HIV-1 from the seminal fluid transcytose the vaginal epithelia to 
enter the subepithelium where they target CD4+ cells such dendritic cells, macrophages and 
T cells (Haase, 2010). Scientists and researchers have recognized that the human vaginal 
cavity is an important port of entry of HIV-1 thus contemporary thought and experimentation 
has been directed at trying to prevent HIV-1 infection by targeting the vaginal cavity as a site 
for anti-HIV-1 agent delivery with the hope that by intervening at this early stage of infection 
there would be greater chances of success in preventing HIV-1 transmission. 
 
Motivation for targeting vaginal HIV-1 transmission has been heightened by the success in 
the development and usage of a physical polymeric barrier/sheath commonly known as a 
condom, which is worn during coitus to prevent the mixing of male and female genital fluids 
thus preventing HIV-1 infection. Though largely effective in preventing HIV-1 transmission, 
the condom has been hampered by inappropriate (leading to breakage), infrequent usage 
and to some extent it has suffered problems of cultural and religious unacceptability. As an 
alternative to the condom, microbicides have failed to demonstrate efficacy in vivo yet they 
are potent in vitro (Hendrix et al., 2009).  Possible reasons for current microbicide 
formulations failure may lie in their inability to; maintain or augment the vaginal mucosal 
barrier properties, sustain the HIV-1 prohibitive acidic pH (~4.5) of the vaginal cavity, deliver 
appropriate quantities of the anti-HIV-1 agent/s in the vaginal cavity where it has to be 
distributed extensively and exhaustively on the vaginal mucosa, ensure presence of the anti-
HIV-1 agent/s in the subepithelia to counteract HIV-1 that would have transcytosed the 
vaginal epithelia and deliver and ensure bioavailability of the anti-HIV-1 agent over longer 
duration to outlast HIV-1 in the vaginal cavity (Hendrix et al., 2009).  
 
Formulations prepared thus far that include gels, creams, films, tablets and rings have tried 
to mitigate these microbicide formulation shortcomings but have often fallen short (Hendrix 
et al., 2009). Gels, creams and films were found to be indiscrete, sticky and short acting thus 
require frequent application before and after every coital act whilst tablets and rings are 
discrete and may be formulated to deliver the anti-HIV-1 agent over an extended duration 
(Klaase et al., 2008).  
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This chapter discusses the formulation of a composite polymeric drug delivery system in the 
form of a caplet embedded with drug-loaded submicrospheres. The delivery system was 
tested in vitro as a potential microbicide drug delivery system. The submicrospheres were 
formulated from biocompatible materials; pectin, porcine gastric mucin and polyethylene 
glycol which formed the framework structure of the submicrospheres enabling the 
encapsulation and controlled release of zidovudine and BP36, the model antiretroviral 
agents used in the study. The polymeric matrix part of the delivery system was mostly 
formed from poly(D,L-lactide), a hydrophobic, biocompatible and biodegradable polymer. 
Poly(D,L-lactide) was chosen to ensure extended drug release from the caplet in line with 
the principle of having the microbicide outlasting HIV-1. The choice of poly(D,L-lactide) helps 
maintain the HIV-1 prohibitive acidic environment since it hydrolyses to form lactic acid 
which is in itself the acidifying agent normally produced by the anaerobic breakdown of 
glucose in the human vagina. The polymeric caplet is intended to be inserted into the 
posterior human vaginal fornix where it would be resident for an extended duration of time 
whilst releasing the anti-HIV-1 agent (Ndesendo et al., 2010). Only zidovudine and not BP36 
was used in the formulation and testing of the composite delivery system in this chapter 
since BP36 is a herbal extract of low purity which was difficult to standardize and utilize in 
the experiments performed. 
 
5.2. Materials and Methods 
5.2.1. Materials 
Polyvinyl acetate/polyvinylpyrolidone [Kollidon® SR (KSR)] and phosphate buffered saline 
(PBS, pH 7.4) were purchased from Aldrich® (Sigma–Aldrich Inc., St. Louis, USA). Poly(D,L-
lactide) was purchased from Boehringer Ingelheim, Ingelheim, Germany. Poly(acrylic acid) 
(Carbopol 794P NF) was purchased from Noveon Inc, Cleveland, OH, USA. The optimised 
zidovudine-loaded pectin-mucin-polyethylene glycol submicrospheres were prepared as 
provided in chapter 4. Other materials and excipients including magnesium stearate (MS) 
were of analytical grade and were utilized as purchased. Simulated vaginal fluid (SVF, pH 
4.5) was prepared from analytical grade reagents in accordance to Owen and Katz’s 
formulation (Owen and Katz, 1999).  
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5.2.2. Box-Behnken design optimization of the composite polymeric drug delivery 
system (caplet) 
A three-factor, three-level (33) Box-Behnken statistical design was employed to optimize the 
fabrication of the composite polymeric caplet. The upper and lower levels of three 
independent parameters; mass of PDLL, mass of MS and the mass of KSR are shown in 
table 5.1 (Karnachi and Khan, 1996; Box and Behnken, 1960). The responses; fractional 
mass increase (FMI) after 7 days of caplet dissolution in SVF, caplet matrix hardness (H) 
and fractional drug released (FDR) after 7 days of caplet dissolution in SVF were sought 
(Table 5.1). The 15 formulations generated by the Box-Behnken design (Table 5.2) were 
experimentally tested and the results obtained were fed into the MINITAB® software which 
then computed the optimized formulation’s independent parameters and expected 
responses. 
 
Table 5.1: Box-Behnken design independent parameter limits and response objectives 
Variable Limits (mg) 
 Lower Upper 
mass of poly(D,L-lactide) 1102.5 937.5 
mass of magnesium stearate 7.5 22.5 
mass of polyvinyl acetate/polyvinylpyrolidone 75  
   
Response Objective 
fractional drug release after t7 days minimize 
hardness (N) maximize 
fractional  mass increase after t7days minimize 
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Table 5.2:  Box-Behnken design template of the 15 polymeric caplet formulations 
Formulation Mass of PDLL  Mass  of MS Mass  of KSR 
F1 1102.5 15 225 
F2 1102.5 7.5 150 
F3 1020 22.5 225 
F4 937.5 15 225 
F5 1020 7.5 225 
F6 1102.5 22.5 75 
F7 1020 22.5 75 
F8 937.5 22.5 150 
F9 1020 705 225 
F10 937.5 7.5 150 
F11 1020 15 150 
F12 1102.5 15 75 
F13 1020 15 150 
F14 937.5 15.0 75 
F15 1020 7.5 75 
 
5.2.3. Polymeric caplet matrix texture profiling 
Caplet matrix hardness was tested using a calibrated texture analyzer (Texture Analyzer 
TA.TX plus, Stable Microsystems, Surrey, UK) fitted with a 5kg load cell and set according to 
the parameters shown in table 5.3. The peak compression force was measured in triplicate 
on three different locations along the caplet length using a 2mm flat cylindrical probe and the 
mean peak compression force value was computed and regarded as a measure of the 
matrix hardness of the caplet. Measurements were performed on all the caplets fabricated 
according to the 15 Box-Behnken design template formulations (Table 5.2) and on the 
optimized caplet. In addition, the percentage caplet matrix resilience was also determined 
(Pillay and Danckwerts, 2002). 
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Table 5.3: Texture analyzer parameters used in caplet matrix texture analysis 
Parameter Value 
test mode compression 
pre-test speed 1.00mm/sec 
test speed 2.00mm/sec 
post- test speed 10.00 mm/sec 
target mode force 
force 4N 
trigger type auto force 
trigger force 0.05N 
 
5.2.4. Effect of the quantity of poly(acrylic acid) on the caplet matrix dimensions  
The effect of the amount (percentage of the total caplet mass) of poly(acylic acid) on the 
dimensional increase of the polymeric caplet after exposure to SVF for a month were 
measured at 1%, 2% and 3% poly(acrylic acid) content in the caplet. Caplets were immersed 
for 30 days in 100mL SVF filled containers which were then put in an orbital shaker 
incubator (Orbital Shaker Incubator, LM-530D, YIHDER TECHNOLOGY CO., LTD, Jhonghe 
City, Taipei County, Taiwan, Republic of China) which was kept at 37°C and rotated at 
20rpm. The dimensional increase of the caplet was then computed according to equation 
5.1.  
 
%	'!+#)'"# 	'#,+)+ = opKomom × 100																																																																																		]'"#	5.1   
 
Where D1 is the length, width or thickness of the caplets before being immersed in SVF for 
30 days and D2 is the length, width or thickness of the caplet after it was immersed in SVF 
for 30 days 
 
5.2.5. Polymeric caplet friability determination 
The uniformly blended powder of the optimized formulation composed of poly(acrylic acid) 
(1%), PDLL (62.50%), MS (0.5%), KSR (5%) and AZT-loaded PEC-MUC-PEG SMs (20%) 
was used to directly compress 10 caplets at a compression force of 2.5 tonnes using a 
hydraulic Carver Press (Carver Inc, Wabash, IN, USA). The mass of each caplet was above 
650mg and the mean caplet mass was 1266.61±9.50mg. Caplet friability was determined 
according to a USP 23 method using an Erweka friability apparatus made of a transparent 
smooth-surfaced polymer drum that had an internal diameter of 285mm and a depth of 
39mm attached to a horizontal axis. The 10 caplets were dusted then placed in the drum 
 102 
 
through the removable side of the apparatus. The drum was rotated 100 times at a constant 
rate of 25rpm and the caplets were tumbled at each turn of the drum by a curved projection 
from the middle of the drum to the outer wall. Caplets were then removed from the drum, 
dusted and reweighed. The caplet friability was then calculated according to equation 5.2. 
S,'T' '<	% = (5 −(>(5 × 100																																																																																																]'"#	5.2 
Where M1 is the total mass of the 10 caplets before the experiment and M2 is the total mass 
of the 10 caplets after the experiment 
 
5.2.6. Drug release studies of the composite polymeric drug delivery system   
Drug release studies were performed for the AZT containing composite polymeric caplet. 
The caplet was placed in a container filled with 100mL of SVF (pH 4.5) dissolution media 
(Gupta et al., 2011; Woolfson et al., 2010; Owen and Katz, 1999). The container was then 
placed in an orbital shaker incubator (Orbital Shaker Incubator, LM-530D, YIHDER 
TECHNOLOGY CO., LTD, Jhonghe City, Taipei County, Taiwan, Republic of China) which 
was kept at 37°C and rotated at 20rpm.  An aliquot (200µL) was withdrawn at predetermined 
time intervals and an equal volume of fresh SVF was replaced after each withdrawal. The 
fraction of drug released from the caplet was then computed from the UV absorbance values 
measured on 4µL of the withdrawn samples at 25°C using a nanophotometer which was set 
to detect UV absorbance at λmax of 267nm. Drug release studies were performed in triplicate.  
 
Drug release studies were also performed in phosphate buffered saline (PBS pH 7.4) which 
acted as a simulant for semen (Owen and Katz, 2005). The MDT computed from the drug 
release data revealed the extent to which AZT release from the composite polymeric caplet 
could be sustained. A comparison was made of dissolution of AZT in SVF and in PBS by 
noting their calculated dissolution efficiencies (DE) according to equation 4.5 and through 
the determination of the similarity factor (f2) and the difference factor (f1) according to 
equations 4.6 and 4.7 (Moore and Flanner, 1996; O’Hara et al., 1998; Costa et al., 2001; 
Zhang et al., 2010). The coefficient of determination (R2adjusted) obtained from fitting the 
dissolution profile of the caplet into 14 different kinetic models gave an indication as to which 
model drug release from the caplet followed (Zhang et al., 2010). 
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5.3. Results and Discussion 
5.3.1. Fabrication and optimization of the composite polymeric delivery system 
The polymeric caplets fabricated by direct compression (using a custom made punch and 
die set depicted in figure 5.1) according to the 15 Box-Behnken design formulations had 
variable masses and dimensions depending on the amount of material that was used to 
fabricate them. The optimized formulation caplet had an approximate length of 25mm, width 
of 10mm and thickness of 6mm. Experimental procedure yielded varying results of, FMI, H 
and FDR (Table 5.4). These results were then inputted into the MINITAB® software to yield 
an optimized formulation with a composite desirability (D) of 0.997, fractional mass increase 
desirability (dFMI) of 1.000, hardness desirability (dH) of 1.000 and fractional drug release 
desirability (dFDR) of 0.991.The optimum independent parameters were computed to be; 
PDLL mass of 937.50mg, MS mass of 7.5mg and KSR mass of 75mg. These independent 
parameters yielded computed responses; FMI of 0.279, H of 21.849 FDR of 0.401. The 
relationships between the independent parameters and responses assessed by linear 
regression using MINITAB® were described by the polynomial equations; 5.3, 5.4 and 5.5 
(Karnachi and Khan, 1996). Where the coefficient of determination of FMI (R2FMI) was 
87.30%, H (R2H) was 61.70% and that of FDR (R2FDR) was 77.90% (Karnachi and Khan 
1996).   
 
FMI=1.616-0.002[PDLL]+0.668[MS]-0.001[KSR]                                                  Equation 5.3 
 
H=-14.465+0.101[PDLL]-0.706[MS]-0.109[KSR]-0.005[MS*MS]+0.001[PDLL*MS]+ 
0.001[MS*KSR]                                                                                                     Equation 5.4   
                                                                                                                                       
FDR=3.964-0.008[PDLL]+0.009[MS]+0.007[KSR]                                               Equation 5.5 
 
The correlation of the responses, FMI, H and FDR to the independent parameters, PDLL, 
MS and KSR was also illustrated as response surface plots (Figure 5.2).  
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Figure 5.1: Digital photographs of the steel punch and die set and a polymeric caplet punched using the set. 
Table 5.4: Experimental responses to the 15 design formulations used in the optimization for 
the polymeric caplet 
Formulation Fractional mass 
increase after 7days  in 
SMVa 
Hardness (N) Fractional drug release 
in SVF after 
7 days 
F1 0.320 20.152 0.227 
F2 0.314 18.438 0.245 
F3 0.678 21.634 0.346 
F4 0.502 18.400 0.376 
F5 0.474 19.849 0.369 
F6 0.358 19.634 0.332 
F7 0.394 19.997 0.274 
F8 0.635 20.977 0.419 
F9 0.314 18.636 0.264 
F10 0.404 21.473 0.320 
F11 0.386 21.384 0.288 
F12 0.330 20.158 0.330 
F13 0.366 21.286 0.261 
F14 0.507 21.031 0.328 
F15 0.284 20.164 0.243 
a - simulated vaginal fluid 
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Figure 5.2: Response surface plots correlating responses; fractional of mass increase (FMI), matrix hardness (H) 
and fractional drug release (FDR) to independent parameters; masses of magnesium stearate (MS), polyvinyl 
acetate/polyvinylpyrolidone (KSR) and poly(D,L-lactide) (PDLL) used in fabricating the polymeric caplet. 
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5.3.2. Effect of the quantity of poly(acrylic acid) on caplet matrix swelling 
The amount of poly(acrylic acid) in the caplet determined the degree of SVF or PBS uptake 
and hence the caplets’ percentage dimensional increase (swelling; increase in length, width 
and thickness). Figure 5.3a depicts digital photographs of the polymeric caplets containing; 
1%, 2% and 3% poly(acrylic acid) before and after being immersed in SVF for a month. The 
percentage dimensional increase in length, width and thickness of the caplet are illustrated 
by the bar graph in figure 5.3b. An increase in the content of poly(acrylic acid) meant an 
increase in the hydroxyl and carboxyl groups in the caplet which would lead to more SVF or 
PBS being drawn into the caplet through the possible formation of hydrogen bonds between 
the hydroxyl and carboxyl groups of poly(acrylic acid) and the water molecules in SVF or 
PBS resulting in caplet matrix swelling. The alkaline PBS (pH 7.4) caused the ionization and 
repulsion of carboxyl groups resulting in more swelling than in the acidic SVF (pH 4.5) where 
the carboxyl groups remained neutral as depicted in figures 5.4 and 5.5. The same 
phenomena are expected in vivo where normal vaginal fluid is acidic and seminal fluid is 
alkaline (Owen and Katz, 1999; Owen and Katz, 2005). In addition, increase in poly(acrylic 
acid) concentration would therefore affect the drug release rate (Khan and Zhu, 1998).  
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Figure 5.3: Depicts (a) digital photographs of polymeric caplets, from left to right; before the 30 day dissolution in 
SVF and after dissolution for the caplets containing 1%, 2% or 3% of poly(acrylic acid) and (b) a bar graph 
illustrating the different percentage dimensional increases in length, width and thickness of the polymeric caplet 
containing 1%, 2% and 3% poly(acrylic acid) that was measured after 30 days of caplet dissolution in SVF. 
 
Figure 5.4 shows a digital photograph and SEM micrographs of the cross-sectional area of 
the caplet before and after dissolution in SVF or PBS for 30 days. Figure 5.4a clearly 
illustrates the positive effect of poly(acrylic acid) on the swelling of the polymeric caplet, with 
the caplets containing more poly(acrylic acid) (2% and 3%) having larger cross-sectional 
areas. SEM micrographs (Figure 5.4c-e) reveal that there were pores formed within the 
caplet in addition to the swelling of the caplet. The pores observed might have been due to 
the bulk erosion of the caplet matrix that possibly involved the hydrolytic degradation of 
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poly(D.L-lactide) and the solubilization and leaching out of the polyvinylpyrolidine part of 
polyvinyl acetate/polyvinylpyrolidone, KSR (Li and McCarthy 1999, Siepmann et al., 2010). 
 
 
Figure 5.4: Depicts; (a) digital photograph of the caplet’s cross-section (from left to right); before dissolution and 
after 1% poly(acrylic acid) containing caplet’s dissolution in SVF and PBS then 2% and  3% poly(acrylic acid) 
containing caplet’s dissolution in SVF respectively (b) SEM micrograph acquired at 500X magnification of the 
caplet’s cross-section before dissolution and (c-f ) SEM micrograph of the caplet cross-section after a 30 day 
dissolution of the caplet containing, (c) 1% poly(acrylic acid) in SVF (d)  1% poly(acrylic acid) in PBS (e) 2% 
poly(acrylic acid) in SVF and (f) 3% poly(acrylic acid) in SVF. 
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5.3.3. Polymeric caplet matrix texture profile 
Caplet matrix hardness (H) values for the 15 design formulations were measured and are 
presented in table 5.4. Caplet hardness varied from 18.400N in Formulation F11 to 21.634N 
in Formulation F15 (Table 5.4). The optimized formulation had a Box-Behnken computed 
caplet matrix hardness of 21.849N whilst the experimentally measured hardness was 
22.061±0.261N (Figure 5.5). From the response surface plots in figure 5.2d, e and f as well 
as the hardness response values of the 15 design formulations in table 5.4, it was observed 
that hardness decreased with increasing percentage content of PDLL and generally 
increased with increase in the percentage content of the plastically deforming KSR (El-
Bragory et al., 2010). The percentage composition of MS in the caplet had an ambiguous 
effect on caplet hardness as previously reported by Matsuda and co-workers (Matsuda et al, 
1976). Both, relatively low and high amounts of MS resulted in decreased caplet hardness 
(Figure 5.2d). 
 
 
Figure 5.5: Force versus time texture analysis profile used to determine the caplet matrix hardness (H) and 
percentage matrix resilience  
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 In addition, the percentage matrix resilience of the caplet was computed from the force 
versus time curve according to equation 5.6 (Pillay and Danckwerts, 2002). 
 
(,'U	,+)' '+#+	% = 	; $V>; $>5 	× 100																																																																											]'"#	5.6 
Where ; $	V> is the area under the curve between the anchors 3 and 2 and ; $>5  is 
the area under the curve between the anchors 2 and 1. The anchors are depicted as red 
vertical lines in Figure 5.5. The mean percentage polymeric caplet matrix resilience was 
62.444±0.583%. 
 
5.3.4. Polymeric caplet friability 
All 10 caplets employed were neither cracked nor broken after the friability test. Their total 
mass before and after the experiment was 12662.9mg and 12656.0mg respectively. Their 
friability was computed to be 0.054%, which is less than 1%.  
 
5.3.5. Drug release from the composite polymeric delivery system 
The fraction of AZT released from the polymeric caplet was measured over 7 days for the 15 
design formulations and results obtained are presented in table 5.4. The fraction of drug 
released varied from 0.227 in formulation F1 to 0.419 in formulation F8 (Table 5.4). The 
optimized formulation had a computed fraction of drug released within 7 days of 0.401. The 
fraction of drug released from the optimised formulation was then experimentally tested in 
both SVF and PBS (acted as a semen simulant) over 30 days to obtain the drug release 
profiles depicted in figure 5.6. The fraction of drug released after 30 days in SVF (pH 4.5) 
was 0.743±0.010 and that released in PBS (pH 7.4) was 0.806±0.210. There was a MDT 
decrease when dissolution was performed in PBS (MDT=7.675 days) as compared to in 
SVF (MDT=10.556 days) as well as a marginal increase in the fraction of drug released in 
PBS (pH 7.4) to that released in SVF (pH 4.5). This may be attributed to the 1% poly(acrylic 
acid) composition of the polymeric caplet. Poly(acrylic acid) is pH responsive due to the 
several carboxylic groups it possesses which are ionized in basic media (PBS pH 7.4) and 
unionized in acidic media (SVF pH 4.5). Therefore, these ionized carboxylic groups, in basic 
media (pH 7.4), might have repelled each other and polarized as well as attracted dissolution 
media’s water molecules resulting in an increase in dissolution media uptake thus leading to 
caplet matrix swelling as depicted in figure 5.3. This matrix destabilization and increase in 
basic dissolution media uptake by the caplet then resulted in an increase in drug release and 
a decrease in MDT (Khan and Zhu, 1998).  
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The effect of the dissolution media pH in conjunction with the 1% poly(acrylic acid) on the 
caplet dissolution kinetics is illustrated in figure 5.6 and confirmed by the similarity factor 
(f2=44,821) and the difference factor (f1=28.738) whose computed values show that the 
dissolution profile obtained in SVF was different from that obtained in PBS. Since f2 values 
from 50-100 relate to the sameness of dissolution profiles and f1 values from 0-15 means 
there is little difference in the dissolution profiles. Values of f2 (44.821) and f1 (28.738) were 
not within these ranges which means that the dissolution profiles were different (O’Hara et 
al., 1998, Costa et al., 2001). The increase in DE when dissolution was performed in PBS 
(DE=59.598%) as compared to dissolution in SVF where DE was 48.125%  also confirmed 
the pH responsiveness of caplet dissolution (Moore and Flanner, 1996; O’Hara et al., 1998; 
Costa et al., 2001; Zhang et al., 2010).  
 
Figure 5.6:  Fraction of AZT released from the optimised caplet in SVF and PBS over 30 days 
 
The drug release mechanism, in both SVF and PBS, from the composite polymeric caplet 
was shown to follow most kinetic models it was fitted into as given by the adjusted coefficient 
of determination, R2adjusted, which was high, ranging from 0.8848 for the zero order kinetic 
model to 0.9973 for the Makoid-Banakar model in SVF and from 0.5021 for zero order 
kinetic model to 0.9947 in PBS Weibull model (Table 5.5). AZT release mechanism from the 
caplet was a sum of the release mechanism from the macromolecular SMs and that from the 
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main polymeric matrix. Drug release from the matrix was extended due to the hydrophobic 
PDLL whose hydrolytic degradation is known to be slow (Li and McCarthy, 1999). The 
dissolution media was drawn into the interior of the caplet by the hydrogen bond forming 
poly(acrylic acid) and the hydrophilic polyvinylpyrolidine part of KSR. Polyvinylpyrolidine was 
then dissolved and leached out of the caplet matrix together with the drug released from the 
SMs leaving pores as depicted in figure 5.4 (Siepmann et al., 2010). The pores formed 
enabled more dissolution media to enter the caplet matrix leading to more percolation based 
AZT release (Siepmann et al., 2010). Drug release from the caplet matrix was therefore 
swelling and diffusion dependent. 
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Table 5.5: Best fit parameters and adjusted coefficients of determination obtained after fitting the optimized caplet drug release profile to 
different kinetic models (Costa and Lobo, 2001; Zhang et al., 2010; Dash et al., 2010). 
Dissolution model Best-fit parameter Goodness of fit parameter 
(R2 adjusted ) 
Parameter 1 Parameter 2 Parameter 3 pH 4.5 pH 7.4 
pH 4.5 pH 7.4 pH 4.5 pH 7.4 pH 4.5 pH 7.4 
Zero order k0=2.839 k0=3.287     0.8848 0.5021 
First order k1 0.050 k1=0.078     0.9903 0.8829 
Higuchi kH=13.294 kH=16.000     0.9772 0.9515 
Korsmeyer-
Peppas 
kKP=9.659 kKP=22.126 n=0.609 n=0.388   0.9908 0.9786 
Hixson-Crowell kHC=0.14 kHC=0.020     0.9725 0.8030 
Hopfenberg kHB=0.000 kHB=0.00 n=3016.319 n=5886.059   0.9891 0.8683 
Baker-Lonsdale kBL=0.004 kBL=0.007     0.9516 0.9865 
Makoid-Banakar kMB=6.985 kMB=18.728 n=0.842 n=0.545 k=0.017 k=0.014 0.9973 0.9885 
Peppas-Sahlin k1=-24.048 k1=19.701 k2=30.807 k2=-1.203 m=0.205 m=0.576 0.9932 0.9889 
Quadratic k1=-0.001 k1=-0.002 k2=0.049 k2=0.072   0.9928 0.8821 
Weibull α=888.973 α=3.619 β=0.566 β=0.513 Ti=0.545 Ti=0.686 0.9917 0.9947 
Logistic α=-0.2973 α=-0.1644 β=2.674 β=1.988   0.9938 0.9920 
Gompertz α=4.457 α=2.032 β=1.715 β=1.375   0.9741 0.9884 
Probit α=-1.783 α=-1.005 β=1.609 β=1.218   0.9904 0.9929 
k0, k1, kH, kKP, n, kKP, kHC, kHB, kBL, k, k2, α and β are best fit parameters of the respective dissolution models  
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5.4. Concluding remarks 
A composite polymeric delivery system in the form of a hard, resilient and non-friable caplet 
embedded with AZT-loaded MUC-PEC-PEG submicrospheres was successfully formulated, 
optimised using a 33 Box-Behnken design and fabricated by direct compression. The drug 
release mechanism from the caplet was likely due to a combination of matrix swelling and 
diffusion. Matrix swelling was proportional to the amount of poly(acrylic acid) in the caplet 
and pores were formed in the matrix as a result of the solubilisation of the polyvinylpyrolidine 
part of polyvinyl acetate/polyvinylpyrolidone (KSR). The dissolution media percolated into the 
matrix through the formed pores and AZT then diffused out. Fractional drug release over 30 
days was 0.743±0.010 in SVF and 0.806±0.210 in SVF. Dissolution of AZT from the caplet 
matrix was observed to be affected by the pH of the dissolution medium. This was confirmed 
by the reduction in the mean dissolution time, the increase in dissolution efficiency and 
computed values of the similarity factor (f2<50) and difference factor (f1>15) for the 
dissolution profiles obtained in SVF and PBS.  Dissolution kinetics of AZT release from the 
composite polymeric caplet fitted best with the Makoid-Banakar model when SVF was used 
as the dissolution medium and with the Weibull model when PBS was used as the 
dissolution media. 
 
 In conclusion a caplet delivery system which was able to act as a reservoir for an anti-HIV-1 
agent and capable of delivering such an agent over an extended duration of a month was 
successfully formulated from biocompatible materials and tested in vitro. This delivery 
system, used discretely in vivo, would likely ensure that there is enough of the anti-HIV-1 
agent present in the vaginal cavity to counter HIV-1 in the seminal fluids interposed into the 
vaginal cavity during coitus, with no frequent dosing required prior to or after each coital act. 
In addition, this delivery system provides for increased anti-HIV-1 agent release when the pH 
of the vaginal cavity is increased as a result of the presence of the normally alkaline seminal 
fluid. Further tests including performance of the composite delivery system in vivo in the pig 
model and pathotoxicity studies necessary to judge the efficacy and safety of the delivery 
system were performed and the results presented in chapter 6. 
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CHAPTER 6 
IN VIVO ANALYSIS OF AN EXTENDED COMPOSITE DRUG DELIVERY SYSTEM IN THE 
PIG MODEL 
 
6.1. Introduction 
The development of topically applied chemical agents that may effectively prevent vaginal 
HIV-1 transmission (microbicides) has been a major challenge for pharmaceutical scientists 
(Hendrix et al., 2009; Adams and Kashuba, 2012; Pillay et al., 2012). The difficulties have 
included; microbicide acceptance as an alternative HIV-1 prevention modality, 
pharmacokinetic inadequacy whereby the microbicide has to be distributed throughout the 
vaginal mucosa in sufficient quantities to prevent HIV-1 transmission and mucosal toxicity 
which diminishes the vaginal mucosa’s barrier properties resulting in easy HIV-1 mucosal 
transcytosis and transmission (Adams and Kashuba, 2012; Pillay et al., 2012). Despite 
having vast potential as a preventative tool against vaginal HIV-1 transmission, research 
conducted thus far has failed to provide an effective anti-HIV-1 microbicide product to the 
market. 
 
Motivation for further research is still present in that, HIV/AIDS is still a pandemic, new 
infections are still occurring each day and the use of microbicides may be advantageous in 
that they may be used discreetly by the female partner thus shifting the control of HIV-1 
prevention from the male to the female (Shattock and Solomon, 2004). Microbicides provide 
a frontline defense approach where HIV-1 is targeted at the vagina mucosal surface when it 
is still vulnerable since the quantity of viruses that initially transcytoses the vaginal mucosa 
(founder population) has been shown to be inadequate to sustain transmission until viral 
replication occurs (Haase, 2010; Shattock and Solomon, 2004; Stone, 2002; Haase, 2005; 
Pillay et al., 2012). Therefore, microbicides may act at this juncture to contain HIV-1 
replication hence prevent transmission. Acting at the mucosal surface where fewer CD4+ 
cells are present as compared to the submucosa, microbicides have the capacity to cub HIV-
1 transmission (Haase, 2005).   
 
The feasibility of the development and use of microbicides to prevent vaginal HIV-1 
trasmission has continuously been hightened by the; discovery of several highly potent anti-
HIV-1 agents, microbicide success stories exemplified by the 39% success rate of the 1% 
tenofovir gel observed in the CAPRISA study and the increase in scientific knowledge 
accumulated thus far including the postulated reasons for the failure of some microbicides, 
for example, vaginal mucosal integrity disruption by microbicides that inturn causes 
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increased HIV-1 transmission (Abdool Karim et al., 2010; Pillay et al., 2012). Microbicide 
research is now focused intensely on microbicide developmental aspects such as 
bioavailability enhancement (targeted and extended release formulations) and Toxicological 
exclusion (Klaase et al., 2008; Pillay et al., 2012; Hendrix et al., 2009). 
 
Future microbicides would therefore be formulated to ensure that enough of the potent anti-
HIV-1 agent is available at the vaginal mucosal interface and distributed throughout the 
entire target site for an extended duration of time to outlast HIV-1 (Pillay et al., 2012). Strict 
toxicology and tolerance protocols using appropriate animal models would have to be 
followed to exclude irritancy and disruption of the vaginal mucosa barrier properties caused 
by the use of microbicides (D’cruz et al., 2005; D’cruz and Uckun, 2008; D’cruz et al., 2003; 
Cone et al., 2006). Microbicide formulations have to satisfy these pharmacokinetic, and 
pathotoxicity preconditions to achieve in vivo microbicide success (das Neves and Bahai, 
2006; Adams and Kashuba, 2012; Pillay et al., 2012). This chapter discusses a study in 
which a composite polymeric drug delivery system intended for intravaginally microbicide 
delivery was tested in vivo over 28 days in the pig model. Large White female pigs were 
chosen as test animals because of their costs, availability and the physiological and 
anatomical resemblance they have with humans. Zidovudine and BP36 which were used as 
model microbicide drugs/agents were encapsulated in pectin-mucin-polyethylene glycol 
submicrospheres which were then embedded within a polymeric caplet shaped matrix which 
was thereafter inserted into the vaginal cavity of Large White female pigs. In vivo 
performance of the delivery system was observed by taking X-ray images and drug 
concentration in vaginal fluid, vaginal tissue and plasma was measured at predetermined 
time points. In addition, histopathological analysis was performed on the pig vaginal tissue 
excised from the euthanized pigs after 28 experimental days. This study aimed at testing an 
alternative microbicide delivery system in vivo, with the possibility of providing extended 
microbicide delivery and to determine the level of vaginal epithelia pathotoxicity that such a 
delivery system might produce. 
 
6.2. Materials and Methods 
6.2.1. Materials 
Poly(D,L-lactide), polyvinyl acetate/polyvinylpyrolidone [Kollidon® SR (KSR)], magnesium 
stearate, porcine gastric mucin, polyethylene glycol 400, barium sulphate, acetonitrile and 
formic acid were purchased from Aldrich® (Sigma–Aldrich Inc., St. Louis, USA). Poly(acrylic 
acid) was purchased from Noveon Inc, Cleveland, OH, USA. Pectin, GENU® pectin type 
USP/100 [Degree of esterification (DE) 55-65%] was purchased from CP Kelco ApS, Lille 
Skensved, Denmark. Active pharmaceutical ingredients (APIs); 1-[(2R,4S,5S)-4-azido-5-
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(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione commonly known as zidovudine 
(AZT) and 2',3'-dideoxy-3'-thiacytidine, commonly known as lamivudine (3TC) were 
purchased from GlaxoSmithKline, Middlesex, UK.  BP36 was obtained from the Council for 
Scientific and Industrial Research (CSIR), South Africa. UPLC grade water was purified 
using a Milli-Q® gradient water purification system (Millipore SAS, Molsheim, France). Other 
materials and excipients employed were of analytical grade and were utilized as purchased. 
 
6.2.2. Preparation of the drug-loaded composite polymeric delivery system 
A composite polymeric delivery system composed of drug-loaded submicrospheres 
embedded within a caplet-shaped polymeric matrix was prepared by first preparing the drug 
loaded microspheres separately (chapter 5) then blended them with other caplet constituent 
materials to prepare the caplet as shown in chapter 5 (Sriamornsak et al., 2010; Brannon-
Peppas, 1992). The drug encapsulated submicrospheres were formulated through a 
crosslinking-emulsion technique where a Ca2+ crosslinked dispersion of pectin, porcine 
gastric mucin, polyethylene glycol 400, BP36 and AZT acted as the aqueous phase whilst 
cyclohexane was the oil phase. The optimized independent parameters of ultrasonication 
time 6.28min, drug:polymer ratio 1:1 and surfactant (span 85) concentration 1.64 (%v/v) were 
utilised in the formulation of the submicrospheres. The caplet shaped polymeric matrix was 
directly compressed from uniformly blended poly(D,L-lactide) (937.50mg), polyvinyl 
acetate/polyvinylpyrolidone (75.00mg), magnesium stearate (7.50mg) poly(acrylic acid) (1% 
w/w) and the drug-loaded submicrospheres (20% w/w). 
 
6.2.3. Transportation and housing of the experimental animals (Large White pigs) 
The pigs were purchased and transported from certified suppliers according to the South 
Africa Laws. Appropriate pre-transportion handling, loading, journeying and unloading at the 
Central Animal services (CAS), University of the Witwatersrand, were performed according 
to CAS standard operating procedures (SOPs). On arrival at CAS the pigs were assessed 
for any signs of disease, injury or distress and then socialized accordingly before the 
experimental procedures were conducted (Grandin, 1997; McEwen, 2002; Grandin, 2007; 
Nanni Costa, 2009). The pigs were housed at the CAS under the care of the researcher with 
the assistance of suitably qualified and trained CAS staff. Initially the delivered pigs were 
housed together in a single pen (Figure 6.1a). Thereafter, each pig was housed separately 
in a pen once the experimental procedures began as portrayed in figure 6.1b (i.e. after 
intravaginal insertion of the composite polymeric delivery system). Separation of each pig 
during experimentation was done for easy identification and monitoring. There was enough 
clean, adequately drained space for all pigs to stand on or lie down (Broom et al., 1995). 
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Figure 6.1: Large White female pigs housed in the Central Animal Services, University of the Witwatersrand (a) 
together in one pen upon delivery and (b) separately in each pen during experimentation. 
 
6.2.4. In vivo experimental design and procedure 
In vivo experimentation involved intravaginal insertion of a composite polymeric drug delivery 
system in 20 Large White female pigs weighing approximately 45kg. For statistical 
significance 20 Large White female pigs were chosen and divided into 4 groups of 5 pigs 
each. A statistical significant level of (p=0.05) was applied (Dell et al., 2002; Festing, 1994). 
This study was approved by the Animal Ethics Screening Committee (AESC) of the 
University of the Witwatersrand, Johannesburg, South Africa (AESC clearance No. 
2011/44/05). The 20 pigs were divided into 4 groups of 5 pigs each, with group A having the 
delivery system with no drug (control) inserted in the vaginal cavity; group B, AZT-loaded 
delivery system inserted in the vaginal cavity; group C, BP36-loaded delivery system 
inserted intravaginally and finally group D which had a combination of AZT and BP36 loaded 
in the composite delivery system and inserted into the pigs’ vaginal cavity as depicted in the 
flow diagram (figure 6.2).  
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* Main study to commence when the pilot study has proven that the BP36 is safe in the pig model. 
** DDS- drug delivery system 
Figure 6.2: Flow diagram depicting a step-by-step in vivo experimental approach 
 
Group A:  
5 pigs 
Placebo-loaded 
**DDS (control) 
Anaesthesia, Insertion of DDS intravaginally, X-raying, blood and vaginal swab sampling  
(Day 0, <45 minutes) 
• Anaesthesia achieved by injection of ketamine (40mg/kg), midazolam (0.3mg/kg) after 
applying topical procaine (5%). Anaesthesia maintained for an hour using inhaled 
isoflurane (2%) and medical oxygen (12%). 
• Insertion of the **DDS into the vagina cavity of the anaesthetized pig. 
• X-ray of the anaesthetized pig to determine the position and physical state of the **DDS 
• 10mL blood sample for drug detection and quantitation, to be drawn from the internal 
jugular vein using a hypodermic needle (done whilst pig is anaesthetized). 
• Whole process to take place in 30-60 minutes 
 
Anaesthesia, X-raying, blood and vaginal swab sampling (< 45 minutes) 
• Anaesthesia, X-raying, blood and vaginal swab sampling to be repeated on day 0, 3, 7, 
14, 21 and 28  
• X-ray to be done to determine bioerosion of the  **DDS 
• Blood sampling from the internal jugular vein using a hypodermic needle  
• Blood plasma samples to be stored at -80°C for analysis using Ultra Performance Liquid 
Chromatography (UPLC) to determine drug release form **DDS 
• Both X-raying and blood sampling to be done whilst pig is anaesthetized 
 
Anaesthesia then Euthanasia 
Pigs to be anaesthetized followed thereafter by injection with intravenous phenobarbital 200mg/kg 
into the internal jugular to euthanize the pigs after day 28 
Harvesting of vaginal mucosa for drug quantitation and histological studies 
Pig vaginal mucosa to be excised from the euthanized pigs for histological analysis on day 28 
Group B: 
 5 pigs 
AZT-loaded 
**DDS (test) 
Pilot Study* 
 Group C:  
5 pigs 
BP36-loaded 
**DDS (test) 
Group D: 
 5 pigs 
AZT and BP36-
loaded **DDS (test) 
One pig each from group A, B, C and D to constitute a single experimental phase 
In vivo animal study 
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All groups including the pilot study underwent the same experimental procedures. Blood 
sampling from the internal jugular vein and X-raying was performed on day: 0, 3, 7, 14, 21 
and 28 whilst the pig is anaesthetized. Study was staggered with only one pig from each 
group undergoing experimentation at a particular stage. 
 
A pilot study was performed to test the experimental procedure and to determine the safety 
of BP36 (a novel anti-HIV-1 herbal extract) in one pig from group C. The pig was 
anaesthetised by an intramuscular injection of ketamine (11mg/kg) and midazolam 
(0.3mg/kg) on the thigh muscle (Figure 6.3a). The pig was then laid in the ventral position on 
an operating table where it was maintained under general anaesthesia using inhalation 2% 
isoflurane and 12% medical oxygen (Kaiser et al., 2006; Ndesendo et al., 2010). The BP36-
loaded drug delivery system was inserted 13cm deep in the vaginal cavity using a metal 
speculum. The drug delivery system was expelled within 2 hours. Therefore, a different 
technique was used whereby the delivery system was tied right round using a silk suture 
material over an engraved shallow groove and then sutured to the vaginal mucosa (Figure 
6.3b). In this case the delivery system was retained for three days but the suture material cut 
through the delivery system leading to the loss of the delivery system. This technique was 
also abandoned. 
 
Finally, the BP36-loaded composite polymeric delivery system was enclosed in a silk 
material pouch that was then secured in the vaginal cavity by suturing the silk pouch onto 
the vaginal mucosa at a position distal to the urethra and proximal to the cervix and this 
technique proved to be the best method to ensure that the delivery system stayed in the 
vaginal cavity for 28 days. Therefore, all the proceeding experimentation was performed 
according to this successful technique achieved during the pilot study. Throughout 
experimentation the pig’s cardiac activity (electrocardiogram), pulse, blood pressure and 
temperature were monitored (Kaiser et al., 2005). In addition, the pig’s weight was measured 
and recorded every week.  
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Figure 6.3: Pig shown, (a) under anaesthesia in the pen before being taken to the procedures room and (b) 
during intravaginal insertion of a delivery system that was tied right round using a silk suture material then 
sutured onto the vaginal mucosa. 
 
6.2.4.1. In vivo X-ray imaging of the intravaginal polymeric delivery system 
The composite polymeric delivery system contained barium sulphate (10% w/w), the radio 
opaque material which enabled X-ray detection of the delivery system in situ. The pig was 
laid on an operating table in the dorsal position whilst under anaesthesia and an X-ray of its 
pelvic region was taken using a Shimadzu MobileArt Evolution X-ray system (model MUX 
200, Shimadzu Corporation, Kyoto, Japan) as depicted in figure 6.4. X-ray images of the 
delivery system were taken on days; 3, 7, 14, 21 and 28 after the delivery system was 
inserted in the vaginal cavity in order to detect its presence and location intravaginally, as 
well as to observe any dimensional changes that may occur to the delivery system in situ 
(Ndesendo et al., 2010). 
 
 
Figure 6.4: Large White female pig lying on the operating table in the dorsal position whilst under anaesthesia 
during the X-ray procedure. 
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6.2.4.2. Vaginal swab collection 
Vaginal swabs were performed to collect vaginal fluids whilst the pig was under anaesthesia 
before the insertion of the delivery system and on days; 0, 3, 7, 14, 21 and 28 after the 
delivery system was insertion. The procedure to collect the vaginal fluids involved the 
insertion of a cotton bud into the vaginal cavity about 4cm deep and allowing it to absorb 
vaginal fluids for approximately 1min (Clark and Friend, 2012). On removal of the cotton bud, 
a swab of the vaginal mucosa was performed with care taken not to contact the delivery 
system. The cotton buds were placed in 2mL Eppendorf tubes and then stored at -80ºC until 
analysis. 
 
6.2.4.3. Blood sample collection 
Blood samples (10mL) were withdrawn directly from the internal jugular vein whist the 
anaesthetized pig lay in the dorsal position starting on the day of delivery system insertion 
(day 0, before delivery system insertion) followed by blood sampling on days; 3, 7, 14, 21 
and 28 after the delivery system was inserted in the vaginal cavity (Clark and Friend, 2012; 
Ndesendo et al., 2010). Withdrawn blood samples were immediately placed in heparinised 
tubes which were centrifuged at 1200rpm and the supernatant was stored in 2mL Eppendorf 
tubes at -80ºC for further analysis.  
 
6.2.4.4. Vaginal tissue sample collection 
On day 28, after X-ray taking, vaginal swab collection and blood sampling, the pigs were 
euthanized by means of an intravenous injection of Phenobarbital (200mg/kg) to one of the 
ear veins to enable vaginal tissue collection. The vaginal tract was excised from the pelvic 
canal after midline dissection through the symphysis pubis. Thereafter the vaginal tract was 
dissected to expose the vaginal mucosa. Two tissue samples were collected from each pig, 
one for quantitative bioanalysis to determine drug tissue concentration and the other for 
histopathology analysis. Tissue samples for quantitative tissue drug determination were 
placed in cryotubes and stored at -80ºC until analysis whist the tissues for histopathology 
assessment were fixed in 10% neutral-buffered formalin and stored at 4ºC until analysis 
(D’cruz et al., 2005, Cone et al., 2006). 
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6.2.5. Quantitative chromatographic determination of drug (AZT and/or BP36) in 
plasma, vaginal fluid and vaginal tissue  
Detection and quantification of AZT and BP36 in porcine plasma samples was performed on 
a Waters AcuityTM ultra performance liquid chromatographic (UPLC) system (Waters 
Corporation, Milford, Massachusetts, USA) consisting of a binary solvent manager, a sample 
manager and fitted with a photodiode array detector (PDA) synchronously controlled using 
the Waters Empower 2 software which collected and processed the chromatography data 
(Iriarte et al., 2009). An Acuity UPLC® HSS T3 1.8µm; 2.1x150mm analytical column (Waters 
Corporation, Dublin, Ireland), fitted subsequent to a VanGuardTM Pre-column 3/Pk 2.1x5mm 
column (Waters Corporation, Dublin, Ireland), was used to detect and separate AZT and 
BP36. 
 
6.2.5.1. Chromatographic detection and quantification of AZT 
AZT was detected and separated from the internal standard (IS), 3TC using the gradient 
method as presented in table 6.1. The eluent was composed of varying proportions of 0.2% 
formic acid in water (A) and acetonitrile (B). 
 
Table 6.1: Chromatographic gradient elution conditions 
Time (min) Flow rate (mL/min) % A % B 
0 0.5 90 10 
1.0 0.5 70 30 
1.5 0.5 90 10 
 
Chromatographic separation was performed at 40ºC column and sample temperature. UV 
detection was carried out at 267nm, the AZT λmax. Samples were filtered through 0.2µm 
membrane filters (GHP Acrodisc® 13mm Syringe Filters, Pall Corporation, New York, USA) 
and placed into 1.5mL Waters glass vials kept at room temperature in the sample 
compartment. Sample volume used during analysis was 2µL and total analysis runtime was 
3 minutes.  
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6.2.5.2. Diluent, stock and working standard solutions preparation 
Acetonitrile:water (50:50 v/v) was prepared and used as the diluent. AZT stock solution 
(100µg/mL) was prepared by dissolving 10mg of AZT into 100mL of the diluent in a 
volumetric flask and the working standard solutions were prepared by serial dilutions of the 
stock solution to obtain solutions of concentrations 10-100µg/mL (n=10).  
 
6.2.5.3. Solid phase extraction and measurement of AZT from plasma 
Plasma samples (500µL) placed in 2mL Eppendorf tubes were pre-treated to remove 
proteins by the addition of 1mL acetonitrile (Polson et al., 2003). The mixture was vortexed 
for 2 minutes then centrifuged for a further 2 minutes at 1200rpm [Table Top High Speed 
Centrifuge (TG16-WS), Hunan Xiangyi Laboratory Instrument Development Co., Ltd, Hunan, 
China]. The supernatant was transferred to new 2mL Eppendorf tubes and zinc sulphate 
(500µL, 0.1%w/v) was added, vortexed and centrifuged again and the supernatant was 
transferred to new 2 mL Eppendorf tubes. Thereafter, the organic phase was evaporated at 
30ºC under a nitrogen stream to obtain samples to be used in the solid phase extraction 
(SPE) procedure (Samanidou et al., 2009).  
 
SPE was performed under vacuum using Waters Oasis® HLB 3cc (60mg) extraction 
cartridges mounted on a 20 hole Waters glass block vacuum manifold processing station 
(Waters Corporation, Milford, Massachusetts, USA). The Oasis® HLB cartridges were 
preconditioned by first passing through methanol (2mL) followed by Milli-Q water (2mL) at 
5psi then the pre-treated plasma samples were passed through the column with minimum 
suction to allow maximum drug adsorption onto the Oasis® HLB cartridge. Finally the drug 
was eluted using different solvents. The solvent with the highest elution efficiency (high drug 
recovery) among methanol, ethanol and acetonitrile was the elution solvent of choice and 
used throughout the study. The eluates were dried at 30ºC under a nitrogen stream and the 
residue was reconstituted with the diluent (1mL), filtered through 0.2µm membrane filters 
(GHP Acrodisc® 13mm Syringe Filters, Pall Corporation, New York, USA) and placed into the 
1.5mL Waters glass vials for UPLC-PDA analysis. 
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6.2.5.4. Chromatography assay validation 
6.2.5.4.1. Selectivity 
The selectivity of the chromatographic assay was assessed by comparing the 
chromatograms obtained using the diluent and blank plasma from five different Large White 
pigs  to those obtained from the diluent and porcine plasma spiked with AZT (final 
concentration, 3µg/mL) and IS (final concentration, 3µg/mL) in an effort to identify and rule 
out interfering peaks. 
 
6.2.5.4.2. Recovery 
Drug recovery was measured by comparing the analyte/IS peak area ratios obtained after 
the blank plasma that was pooled from 5 different pigs was spiked with three different 
concentrations of the analyte (final concentrations; 1, 5 and 10µg/mL) and the IS (final 
concentration, 3µg/mL) before and after the SPE procedure (Iriarte et al., 2009; Samanidou 
et al., 2009). The recovery tests were performed in triplicate.  
 
6.2.5.4.3. Linearity 
Plasma calibration standard solutions were prepared by spiking blank plasma with the 
working standard solution to obtain AZT concentrations of 1-10µg/mL, n=10 and IS (3µg/mL) 
prior to solid phase extraction (Samanidou et al., 2009; Iriarte et al., 2009). A calibration 
curve of analyte/IS peak area ratios against analyte concentration was plotted to validate the 
linearity of the chromatographic assay. Measurement of the analyte/IS area ratio was 
performed in triplicate and the computed mean was used to construct the calibration curves 
on three different days. 
 
6.2.5.4.4. Limit of detection and limit of quantification  
The limit of detection (LOD) and Limit of quantification (LOQ) were computed according to 
the equations 6.1 and 6.2: 
 
 LOD= 3.3σ/S                                                                                                         Equation 6.1 
 
 LOQ=10σ/S  Equation 6.2 
 
Where σ is the standard deviation (SD) of y-intercepts obtained by performing regression 
analysis on the calibration curve and S is the calibration curve slope (Samanidou et al., 
2009). 
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6.2.5.4.5. Precision and accuracy 
The precision/repeatability of the chromatography assay was calculated in terms of the 
percentage relative standard deviation (RSD) examined at three different analyte 
concentrations  levels of; low (1µg/mL),  medium (5µg/mL) and high (10µg/mL) (Samanidou 
et al., 2009, Iriarte et al., 2009, Mason 2007). Accuracy, expressed as the relative error (RE), 
was taken as a measure of the deviation of the mean from the true value (Iriarte et al., 
2009). The three different analyte concentrations were analysed in three replicates on three 
different days in order to determine intra- and inter-day accuracy and precision (Samanidou 
et al., 2009; Iriarte et al., 2009; Mason, 2007). 
 
6.2.5.4.6. Stability of AZT and 3TC in plasma 
Quality control samples (n=3) comprising blank porcine plasma spiked with AZT (final 
concentration, 5µg/mL) working solution and IS (final concentration, 3µg/mL) were injected 
into the UPLC to determine the stability of AZT and the internal standard. Samples were 
exposed to light and kept at ambient temperature (25ºC) and tested at time points; 0, 12, 24, 
48 and 72 hours (Iriarte et al., 2009; Gonzalez et al., 2009).  
 
6.2.5.5. Analysis of AZT concentration in plasma, vaginal fluid and tissue samples of 
group B pigs 
Frozen plasma samples obtained on days; 0, 3, 7, 14, 21 and 28 were allowed to thaw over 
24hrs and then subjected to the SPE phase as described section 2.4.3. Thereafter, UPLC-
PDA AZT detection and quantification was performed. After defrosting vaginal swab samples 
(cotton buds) for 24hrs, 1mL of diluent (acetonitrile:water 50:50) was added to the Eppendorf 
tubes containing the vaginal swab samples to extract AZT. The samples were vortexed for 
5min then centrifuged at 1200rpm and the supernatant was subjected to SPE as described 
in section 2.4.3 before AZT detection and quantification was performed using the UPLC-
PDA. To measure the amount of free AZT in the excised vaginal tissue for each pig in group 
B, frozen samples (1g, n=3) were separately ground in a coffee grinder into a fine tissue 
sample, placed in 2mL Eppendorf tubes then the diluent (1mL, acetonitrile:water 50:50) was 
added as the AZT extraction solvent (Clark and Friend, 2012). The samples were vortexed 
for 10min, centrifuged at 1200rmp and the collected supernatant was subjected to SPE as in 
section 2.4.3 before AZT detection and quantification by UPLC-PDA.  
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6.2.6. Chromatographic detection and quantification of BP36 
Due to the low level of purity of BP36 and the consistency (standardization) within the herbal 
extract, it was difficult to accurately quantify it. However, qualitative analysis that involved 
UPLC detection of BP36 in vaginal fluid, swarbs and plasma using a PDA detector was 
performed using an isocratic method on a UPLC® HSS T3 1.8µm; 2.1 x 150mm column at a 
column temperature of 40°C and eluents, A1 80% acetonitrile and B1 20% 0.2% Formic acid 
water (MilliQ). The runtime was 6min and sample volume that was used was 3µL. 
 
6.2.7. Histopathology analysis of porcine vaginal epithelia 
 Histopathology tests were performed to determine the level of abnormality (such as 
inflammation and toxicity) that may have been caused by the presence of the composite 
polymeric delivery system in the vaginal cavity over 28 days (Ndesendo et al., 2011; D’cruz 
et al., 2003; Clark and Friend, 2012). Excised pig vaginal tissue was fixed in 10% normal 
buffered formalin (Cone et al., 2006; D’cruz et al., 2005; D’cruz and Uckun, 2008; Clark and 
Friend, 2012). Cut vaginal tissue sections were put in and automated tissue processor and 
then stained with haematoxylin and eosin (H/E) for microscopy analysis (Cone et al., 2006; 
D’cruz et al., 2005; D’cruz and Uckun, 2008; Clark and Friend, 2012).  
 
The type of vaginal epithelia, thickness of the epithelial cell layer, degree of inflammation, 
ulceration, fibrosis and mononuclear inflammatory infiltration as well as tissue necrosis, 
fibrosis and the integrity of the lamina propria and the submucosa were examined. Different 
areas (8-10 fields) of the vaginal mucosa were examined, compared with the normal vaginal 
mucosa and then scored for histopathological changes such as epithelial ulceration, 
epithelial proliferation and epithelial exocytosis (inflammatory cell influx into the epithelium), 
subepithelial leukocytic influx, stromal fibrosis, perivascular cell cuffing and tissue necrosis. 
The histopathology scores included: 0, no abnormality; 1, minimum abnormality; 2, mild 
abnormality; 3, moderate abnormality and 4, severe abnormality (D’cruz and Uckun, 2008). 
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6.3. Results and Discussion 
6.3.1. Pilot study using one pig from group C 
The pilot study performed for 7 days using one pig from group C to determine the safety of 
BP36 and to test the experimental procedure before the main study commenced enabled us 
to decide the right procedure which kept the delivery system in the vaginal cavity for a longer 
duration of at least 28 days. The caplet that was inserted into the pig vaginal cavity by 
means of a metal speculum followed by a sponge lined with radio opaque string was 
expelled from the pig vaginal cavity within 3 days (Figures 6.5ai and 6.5aii). Figure 6.5bi and 
6.5bii show the delivery system tested in the pilot study that was tied to a silk suture material 
before being attached to the vaginal mucosa in the pig’s vaginal cavity. This deliver system 
lasted for about 5 days before breaking into two parts along the groove where the suture 
material was tied (Figure 6.5bii).  
 
The technique that managed to keep the delivery system for much longer (in most cases for  
28 days) was the one represented by figures 6.5.ci and 6.5cii where the caplet was enclosed 
in a silk pouch which was then attached to the vaginal wall in the vaginal cavity using silk 
suture material. This technique was then used for all pigs in the in vivo study.  Ideally one 
would like to just insert the delivery system in the vagina and it stays in there for the desired 
duration without having to perform a surgical procedure to secure the delivery system. The 
need for attaching the caplet was a result of the caplet being expelled by the pig. Although a 
mucoadhesive material, poly(acrylic acid), formed part of constituents of the delivery system 
its mucoadhesive properties were diminished because the pig vaginal environment is always 
moist leading to poly(acrylic acid) over hydrating and loosing its mucoadhesiveness.  
 
Another reason why the pig managed to expel the delivery system easily is that there is no 
anatomical place in the pig vaginal cavity where the delivery system may be secured unlike 
in humans where there is the vaginal fornices (especially the posterior vaginal fornix) where 
the delivery system may be secured and this results in its retention for a longer duration in 
the study. The pig cervix is continuous with the vaginal canal hence the delivery system can 
only be place in the canal where it can be easily pushed out through peristaltic-like vaginal 
wall movements.  
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Figure 6.5: Digital images of the delivery system and X-rays images of the delivery system observed in situ in the 
vaginal cavity during the pilot study when; (a) the delivery system was inserted using a metal speculum and a 
radio opaque string lined sponge was used to ensure the caplet stays in place in the vaginal cavity, (b) the 
engraved delivery system was tied right round and attached to the mucosa in the vaginal cavity using a silk 
suture material and (c) the delivery system was enclosed in a silk material pouch and the pouch was attached to 
the mucosa in the vaginal cavity. 
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6.3.2. In vivo X-ray imaging of the intravaginal polymeric delivery system 
The composite polymeric delivery system was observed in situ in the vaginal cavity by X-ray 
of the pelvic region of the Large White pigs as depicted in figure 6.6. Figures 6.6a.i-v 
(delivery system with no drug) show that the polymeric delivery system increasingly swells 
with the increase in its residence time in the vaginal cavity. The swelling was likely caused 
by the absorption of vaginal fluids by the poly(acrylic acid) and  polyvinyl 
acetate/polyvinylpyrolidone (KSR) which constitute the polymeric delivery system. Figures 
6.6b.i-v depicts the AZT loaded composite polymeric delivery system on days; 3, 7, 14, 21 
and 28 after it was inserted in the vaginal cavity. The delivery system in group B pigs was 
observed to increasingly fade in contrast, from the outside inwards, with time which may 
have been due to drug and polymer solubilization and possibly the formation of pores within 
the polymeric delivery system as a result of the solubilization of the polyvinyl pyrolidone part 
of polyvinyl acetate/polyvinylpyrolidone (KSR) as vaginal fluids penetrated the interior of the 
delivery system. The drug-loaded delivery system was observed to swell more than the 
delivery system with no drug. This was likely a result of the drug, zidovudine, which is 
partially hydrophilic, which dissolved as vaginal fluid permeated into the polymeric delivery 
system matrix and percolation out (Figure 6.6). X-ray images of the delivery system in pigs 
from group C and D (Figure 6.6c.i-v and 6.6d.1-v) show that the swelling was more 
pronounced and this was most likely caused by the absorption and solubilisation of BP36 
which is more hydrophilic than AZT. Some of the caplets were pushed out before 28 days 
(Figure 6.6c.iii-v and 6.6d.v). 
 
 131 
 
 
Figure 6.6: X-ray images of the pig pelvic region depicting the composite polymeric delivery system: with no drug 
loaded observed on days 3 a.i), 7 (a.ii), 14 (a.iii), 21 (a.iv) and 28 (a.v);  loaded with AZT (300mg)  observed on 
days 3 (b.i), 7 (b.ii), 14 (b.iii), 21 (b.iv) and 28 (b.v); loaded with BP36 (600mg) observed on days 3 (c.i), 7 (c.ii), 
14 (c.iii), 21 (c.iv) and 28 (c.v) and; loaded with BP36 (150mg)  and AZT (150mg) observed on days 3 (d.i), 7 
(d.ii), 14 (d.iii), 21 (d.iv) and 28 (d.v). 
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6.3.3. Quantitative chromatographic determination of plasma drug released from the 
delivery system 
6.3.3.1. Chromatographic conditions and separation of AZT from 3TC 
High resolution chromatographic peaks of the internal standard (lamivudine) and the analyte 
(AZT) were obtained by UPLC-PDA (Figure 6.7a). The IS and analyte spiked in diluent were 
both eluted within two minutes and effectively separated by approximately one minute with 
an observed IS retention time (Rt) of 0.894min and that of the analyte being 1.854min 
(Figure 6.7a). Figure 6.7b shows the chromatogram of blank plasma depicting several 
peaks.
 
There was no change in IS or analyte peak shape when they were spiked in blank 
plasma. In addition, there was a minor shift in the IS and analyte Rt when both were spiked 
with the IS Rt shifting to 0.893min whist analyte’s Rt became 1.852min (Figure 6.7c).  
 
 
Figure 6.7:  Chromatograms obtained for; (a) IS and AZT spiked in diluent, (b) typical blank plasma sample and 
(c) IS and AZT spiked in plasma sample 
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6.3.3.2. AZT Chromatographic assay validation 
6.3.3.2.1. Selectivity 
Chromatograms of five plasma samples obtained from five different Large White pigs 
showed peaks at Rt= 0.786, 1.418, 1.550, 1.679, 1.859 minutes as exemplified by figure 
6.7b. Although plasma chromatogram peaks at Rt= 0.786min and 1.859min are closer to the 
peaks due to the IS (Rt= 0.893min) and the analyte (Rt= 1.852min), due to their relative 
intensity they did not interfere with the IS and analyte peaks as depicted in figure 6.7c, 
indicating satisfactory selectivity. 
Acetonitrile was shown to be more efficient than methanol and ethanol at eluting the analyte, 
with an analyte recovery of 87.1705% (Table 6.2). Therefore, all other chromatographic 
assays were performed using acetonitrile as the eluent.  
 
Table 6.2: Solvent elution efficiency of methanol, ethanol and acetonitrile as given by drug 
recovery after SPE 
 Elution solvent 
 Methanol Acetonitrile Ethanol 
AUC (AZT/IS) before SPE 1.5608 1.5608 1.5608 
AUC (AZT/IS) after SPE 0.7297 1.1743 0.9371 
Recovery (%) 46.7497 87.1705 60.0059 
 
6.3.3.2.2. Recovery 
Mean recoveries (n=3) calculated for analytes of concentrations; 1, 5 and 10µg/mL are 
presented in table 3 (approximately 78-94%). Analyte recovery increased as the 
concentration of the spiked analyte was increased (Table 6.3).  
 
Table 6.3:  Mean recoveries of AZT after SPE from spiked blank plasma (n=3) 
 AZT concentration (µg/mL) 
1 5 10 
Recovery (%) 78.2750 94.1276 94.493 
RSD (%) 4.4037 12.1093 9.4753 
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6.3.3.2.3. Linearity, limit of detection and limit of quantification  
Calibration curves plotted, using SigmaPlot 12.0 (Systat Software Inc, San Jose, California, 
USA), of area under the curve of analyte/IS area ratio against the analyte concentration over 
a standard analyte concentration range of 1-10µg/mL (n=10) were analysed by linear 
regression to produce slopes, intercept and correlation coefficients given in table 6.4. The 
computed limit of detection (LOD) and limit of quantification (LOQ) were 1.1045µg/mL and 
3.3470µg/mL respectively.  
 
Table 6.4: Calibration curve parameters obtained through linear regression on three different 
days (n=3) 
Curve (day) Slope (estimate ± 
SD) 
Intercept 
(estimate ± SD) 
Correlation 
coefficient (R2) 
Linear range 
(µg/mL) 
Curve (day 1) 0.6694±0.0348 0.2873±0.2160 0.9707 1-10 
Curve (day 2) 0.5778±0.0411 0.2188±0.2550 0.9611 1-10 
Curve (day 3) 0.6077±0.0328 0.2294±0.2034 0.9773 1-10 
 
6.3.3.2.4. Precision and accuracy 
Chromatographic assay precision and accuracy were determined by analyzing three 
different analyte concentrations (1, 5 and 10µg/mL). Precision was given by the RSD values 
and the accuracy by the RE values (Table 6.5). Intra-day and inter-day precision (RSD) 
ranged from 1.2461% to 4.8946% and 0.4653% to 2.84975% respectively whilst Intra-day 
and inter-day accuracy (RE) ranged from 1.8174% to 18.7545% and 3.4762% to 14.8580% 
respectively (Table 6.5). Both precision and accuracy were acceptable since they were less 
than 20% (Iriarte et al., 2009).  
 
Table 6.5: Intra-day and inter-day precision and accuracy calculated as RSD and RE for 
three AZT concentration levels; 1, 5 and 10µg/mL (n=3) 
 Concentration level  
 Low (1µg/mL) Medium (5µg/mL) High (10/mL) 
 intra-day inter-day intra-day inter-day intra-day inter-day 
RSD (%) 4.8946 0.4653 1.8688 1.1044 1.2461 2.8497 
RE (%) 18.7545 14.8580 1.8174 4.9049 2.1037 3.4762 
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6.3.3.2.5. Stability of analyte and internal standard 
Chromatographic conditions employed [column and sample temperature of 40ºC, light 
exposure, diluent of acetonitrile:water (50:50) and eluent, 0.2% formic acid water and 
acetonitrile] to detect and quantify AZT did not affect the stability of the analyte and the 
internal standard as their peak shapes remained similar and their retention times did not 
significantly shift when tested after 0, 12, 24, 48 and 72 hours (Figure 6.8). 
 
 
Figure 6.8: Chromatograms of the analyte (AZT, 5µg/mL) and IS (3TC, 3µg/mL) spiked plasma samples obtained 
at times; (a) 0hrs, (b) 12hrs, (c) 24hrs, (d) 48hrs and (e) 72hrs revealing analyte and IS stability during the 
chromatographic assay.  
 
6.3.3.3. Concentration of AZT in porcine plasma, vaginal fluid and vaginal tissue 
samples 
Figure 6.9 depicts a typical chromatogram obtained for plasma, vaginal fluid and tissue 
samples showing suitable IS and analyte separation with the IS peak observed at 
Rt≈0.95min, AZT peak Rt≈1.85min. Other peaks that may be attributed to plasma, vaginal 
fluid and tissue constituents were also observed at Rt≈ 0.8min and Rt≈1.5min. 
 
 
Figure 6.9: Typical UPLC chromatogram obtained for plasma, vaginal fluid and tissue samples 
 
AZT concentration in plasma and vaginal fluids computed from the area under the curve of 
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for days 3, 7, 14, 21 and 28 were plotted against time and presented in figure 6.10. 
Generally, both plasma and vaginal fluid AZT concentrations were observed to decrease 
with time (Figure 6.10) with low AZT plasma concentrations ranging from 
1.1838±0.0124µg/mL to 1.1304±0.0153µg/mL. The highest plasma concentration (Cmax) was 
obtained on day 7 (Figure 6.10a). AZT concentrations in vaginal fluid (range: 
4.9966±0.9839µg/mL to 2.8679±0.8123µg/mL) were higher than those in plasma (Figure 
6.10) which may be explained in that, AZT needed to permeate through the vaginal mucosa 
for it to get to the blood (plasma), therefore the majority of the drug was entrapped within the 
vaginal tissue.  
 
The decreasing trend observed in vaginal fluid AZT concentrations may have been due to 
the fact that vaginal fluid has to penetrate the polymeric matrix of the delivery system, 
dissolve AZT out of the submicrospheres and percolate out of the caplet matrix for it to be 
measured in the vaginal fluid. Therefore, with the time, vaginal fluid will have to permeate 
through a longer distance into the matrix interior and percolate out with increasing resistance 
from the hydrophobic part of the polymeric matrix [poly(D,L-lactide) and the polyvinyl acetate 
part of the polyvinyl acetate/polyvinylpyrolidone (KSR)]. Vaginal tissue AZT concentrations 
(range: 4.2176±0.3396µg/mL to 2.9604±0.1901µg/mL) taken after 28 days were higher than 
plasma AZT concentrations and were in the same range as vaginal fluid (Figure 6.11).  
 
 
Figure 6.10: AZT concentration measured in, (a) plasma and (b) vaginal fluid samples collected on days; 3, 7, 14, 
21 and 28 from group B pigs. 
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Figure 6.11: AZT concentration measured in vaginal tissue samples excised from group B pigs after the 28 day 
study  
 
6.3.3.4. Detection and quantification of BP36 in porcine plasma, vaginal fluid and 
vaginal tissue 
Figure 6.12 depicts a chromatogram of BP36 showing several peaks at different retention 
times. The presence of several peaks indicates the low level of purity of BP36. BP36 is a 
herbal extract that is still undergoing standardization and its chromatogram presented in 
figure 6.12  suggests that BP36 may be composed of several different molecules which may 
include impurities (possibly 8 molecules). BP36 was detected in the pig vaginal fluid (vaginal 
swab) and vaginal tissue but not in the pig plasma. Therefore, BP36 concentration in 
samples from pigs in group C and D were qualitatively analysed. 
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Figure 6.12:  UPLC-PDA chromatogram of BP36  
 
6.3.4. Histopathology analysis of porcine vaginal epithelia 
Histological analysis of cut and formalin fixed sections (Figure 6.13) of the excised porcine 
vaginal mucosa after extended vaginal delivery of AZT and BP36 by means of a composite 
polymeric intravaginal drug delivery system resulted in the scored abnormality observations 
that include; epithelial erosion/ulceration, epithelial proliferation, epithelial exocytosis, 
subepithelial leukocyte influx, stromal fibrosis, perivascular cell cuffing and tissue necrosis 
as shown in table 6.6 and figure 6.14. Vaginal epithelia and lamina propria that were normal 
or had minimum abnormality were mostly observed in pigs from group C (Table 6.6, Figure 
6.14a). On microscopy examination, superficial loss of epithelial cells (epithelial erosion) was 
observed in 3 pigs from group A, 2 pigs from group B, 2 pigs form group C and none from 
group D (Table 6.6, Figure 6.14b). Most of the erosion was minimal to moderate except in 
pigs A4 and C3 were there was enhanced loss of the epithelium (Table 6.6, Figure 6.14b). 
The observed erosion of the porcine vaginal epithelia might have been caused by irritation, 
inflammatory process, leukocyte influx and exocytosis into the epithelia as a result of the 
presence of the drug delivery system. The epithelial erosion observed in pigs in group A may 
have been slightly enhanced as compared to that of pigs in other groups because the 
delivery system in group A pigs was not drug loaded hence did not swell as much and did 
not allow vaginal fluid to infiltrate its interior as it did in the delivery system in other groups, 
which had a hydrophilic drug encapsulated within. This resulted in the delivery systems in 
group A pigs remaining more solid and rigid as compared to the ones in other groups as 
depicted in figure 6.6, which might have led to the slight increase in the delivery system’s 
abrasiveness hence increased group A pig epithelial erosion. Epithelial erosion is bad 
because it diminishes the barrier properties of the vaginal epithelia and may lead to an 
increase in HIV-1 transcytosis and transmission.   
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Epithelial proliferation (due to epithelial hyperplasia) normally associated with low-grade 
subacute to chronic irritation was found to be mild to moderate in all group pigs (Table 6.6, 
Figure 6.14c). An increased level of influx (epithelial exocytosis) may be a result of 
inflammation as was observed in the vaginal mucosa of most pigs (Table 6.6, Figure 6.14d). 
In the lamina propria directly underneath the vaginal epithelium, inflammatory infiltrates 
(subepithelial leukocyte influx), mainly neutrophils, some eosinophils and macrophages were 
detected in almost all vaginal mucosa examined with scoring varying from minimum to 
severe abnormality signifying minimum to severe inflammation (Table 6.6, Figure 6.14e).  
There was more severe inflammation in group A pig vaginal epithelia as compared to other 
group epithelia (Table 6.6). Inflammation of the vaginal mucosa weakens the epithelial 
barrier properties leading to possible HIV-1 transmission. 
 
Stromal fibrosis, observed as fibroplasia in the deeper layers of the lamina propria 
underneath the vaginal epithelium, was scored minimum to mild in the epithelial sections 
examined (Table 6.6, Figure 6.14f). Perivascular cell cuffing identified as lymphocytic 
infiltrates and small nodules of lymphocytic perivascular inflammation was detected and 
scored as minimum to moderate in the epithelial sections examined except for one (B5) 
which was scored as severe (Table 6.6, Figure 6.14g). Only in one vaginal epithelial section 
examined (B4) where a focal area of muscle and tissue necrosis where glaucomatous 
inflammation was observed (Table 6.6, Figure 6.14h). Within the area of tissue necrosis, 
numerous mononuclear cells as well as polymorphonuclear exudation were found and 
macrophages as well as few multinucleated giant cells could be identified. There seemed to 
be an infectious granuloma in the wall of the porcine vagina in pig B4. Pig B4’s tissue 
necrosis might have been an isolated case.  
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Figure 6.13: Digital photographs of the excised vaginal tissue; (a) soon after being excised from the pig on day 28 
of the experiment with the composite delivery system still attached and (b) placed in 10% normal buffered 
formalin for storage before histopathology analysis 
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Table 6.6: Histopathological observations of the vaginal sections excised from the pigs from groups; A, B, C and D 
Group  A B C D 
Pig identity A1 A2 A3 A4 A5 B1 B2 B3 B4 B5 C1 C2 C3 C4 C5 D1 D2 D3 D4 D5 
Epithelial erosion/ulceration - 1+ 3+ 4+ - - - - 1+ 2+ - - +4 - +1 - - - - - 
Epithelial proliferation 2+ 1+ - - - - - 1+ 2+ 2+ - - - - +2 +2 +2 - - - 
Epithelial exocytosis 3+ 4+ 4+ 4+ 1+ 3+ 3+ 1+ 3+ 4+ +1 +1 +3 +1 +4 +3 +3 +2 +3 +2 
Subepithelial leukocyte 
influx 
3+ 4+ 4+ 4+ 1+ 2+ 2+ 1+ 3+ 4+ - - +3 +1 +3 +3 +2 +1 +3 +2 
Stromal fibrosis - - 1+ 1+ - - - - 2+ 2+ - +1 +3 - +1 +2 +2 +1 +3 +2 
Perivascular cell cuffing 1+ 2+ 3+ 3+ 1+ 1+ 1+ - 3+ 4+ - +1 +3 - +1 +2 +2 +1 +3 +2 
Tissue necrosis - - - - - - - - 3+ - - - - - - - - - - - 
- no abnormality 
1+ minimal abnormality 
2+ mild abnormality 
3+ moderate abnormality 
4+ severe abnormality 
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Figure 6.14: Histopathology images of excised pig vaginal tissue depicting; (a) normal epithelia and lamina 
propria, pig C1, (b) epithelial erosion/ulceration, pig B4, (c) epithelial proliferation, pig A1, (d) epithelial 
exocytosis, pig A4, (e) subepithelial leukocyte influx, pig B4, (f) stromal fibrosis, pig B5, (g) perivascular cell 
cuffing, pig B4 and (h) tissue necrosis and polymorphonuclear exudation, pig B4. 
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6. 4. Concluding remarks 
The in vivo study reported in this chapter successfully tested an intravaginal composite 
polymeric delivery system in the pig as a model for extended microbicide delivery intended 
to prevent heterosexual vaginal HIV-1 transmission. The delivery system was observed in 
situ over 28 days and X-ray images showed that the drug loaded delivery system swelled 
and faded gradually with time once vaginal fluid permeated into its matrix core. An ultra 
performance liquid chromatography-photodiode array assay was developed and optimised 
for selectivity, recovery, linearity, precision, accuracy and analyte stability then used to 
determine AZT concentrations in plasma, vaginal fluid samples obtained at predetermined 
time points over 28 days and in vaginal tissue samples excised on day 28 after 
experimentation. Retention times shown as distinguishable peaks at approximately 0.9min 
for the internal standard at 1.9min for the analyte were observed.  
 
The assay was relatively precise (RSD<5%) and accurate (RE<20%). Vaginal fluid and 
plasma AZT concentrations were shown to decrease gradually over the 28 days and the 
plasma AZT concentrations were lower than those of the vaginal fluid. AZT concentration in 
excised vaginal tissue samples were relatively constant and were in the same range as 
those of the vaginal fluid. BP36 was also detected using UPLC-PDA but could not be 
quantified due to low purity and inconsistence in the BP36 herbal extract. It was difficult to 
pinpoint which peak belonged to the active anti-HIV-1 agent in BP36 thus there is need to 
standardize the BP36 extract. Drug kinetics (AZT) in this study was positive since much of 
the drug was detected in the vaginal fluid and vaginal tissue samples which normally receive 
the first exposure to HIV-1 during heterosexual intercourse and little drug was detected in 
the plasma suggesting less systemic drug side effects would be caused by the drug. 
However, this study does not address the issue of how much drug should be in the vaginal 
fluid, vaginal tissue and plasma for successful HIV-1 prevention. Further research is 
necessary in this regard. 
 
Histopathological analysis exposed different scores of abnormalities on the excised vaginal 
tissue. Although the majority of abnormalities were minimum to moderate including; epithelial 
proliferation and exocytosis, subepithelial leukocyte influx and perivascular cell cuffing, there 
were isolated cases of epithelial erosion, stromal fibrosis and tissue necrosis which raise 
concern regarding the breakdown of the barrier properties of the vaginal mucosa which may 
lead to HIV-1 transmission. More research is necessary to improve microbicide 
pharmacokinetics and reduce pathotoxicity if we are to use microbicides as an alternative 
female-controlled pharmaceutical tool to reduce HIV-1 transmission. 
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CHAPTER 7 
CONCLUSIONS AND RECOMMENDATIONS 
 
7.1. Conclusions 
HIV/AIDS is a debilitating disease that diminishes ones immune system, exposing the body 
to other opportunistic infections such as tuberculosis. HIV/AIDS also impacts negatively on a 
person’s social and economic activity. Although antiretrovirals are being used to manage 
people living with HIV/AIDS with relative success, prevention of HIV-1 transmission in the 
first place would reduce the disease burden and all the social and economic downturns that 
are brought about by HIV/AIDS. The use of microbicides as a prevention modality for male to 
female HIV-1 transmission is advantageous in that it has the ability to shift the control of HIV-
1 prevention from the male to female. In essence use of microbicides empowers women in 
the fight against HIV-1 transmission. 
 
This dissertation details the successful design and formulation of a composite polymeric 
microbicide delivery system to be inserted in the posterior fornix of the human vagina as an 
alternative to the gel, cream, tablet, sponges and ring delivery systems developed thus far. 
This delivery system is a caplet-shaped composite system comprising zidovudine (AZT) and 
BP36-loaded pectin-mucin-polyethylene glycol submicrospheres embedded within a 
poly(D.L-lactide), magnesium stearate, polyvinyl acetate/polyvinylpyrolidone (KSR) and 
poly(acrylic acid) based polymeric caplet matrix.  The delivery system was able to deliver 
anti-HIV-1 agents (zidovudine and BP36) over 28 days in both in vitro experiments and in 
vivo in the pig model. X-ray illustrated the delivery system swelling and its matrix contrast 
fading over time as vaginal fluid permeated the matrix’s core. Plasma, vaginal fluid and 
tissue drug was detected and quantified using ultra performance liquid chromatography-
tandem photodiode array detector. AZT plasma and vaginal fluid concentrations measured 
on days; 3, 7, 14, 21 and 28 decreased gradually with time. Vaginal tissue AZT 
concentrations (after 28 days) were higher than plasma AZT concentrations and in the same 
range as vaginal fluid AZT concentrations. BP36 was also detected in plasma, vaginal fluid 
and tissue and qualitatively analysed. 
 
This study saves as a significant contribution towards addressing the questions surrounding 
microbicide research whereby potent anti-HIV-1 agents are successfully tested in vitro but 
fail to pass all clinical trials. The aim and objectives of the study were mostly achieved since 
the formulated and optimised microbicide delivery system was able to deliver a combination 
of anti-HIV-1 agents over 28 days which means that there would be less dosing and more 
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patient compliance, the anti-HIV-1 agents would be bioavailable in the vaginal cavity long 
enough to outlast HIV-1 and the delivery system may be used discretely by women. In 
addition there is scope for the delivery system to be adopted to delivery other therapeutic 
agents such as antibacterials, antifungals and insulin. The benefits of a cheap, safe, easy to 
use and effective microbicide formulation are far reaching in the fight against HIV/AIDS and 
this work is a contribution to the extensive microbicide research taking place worldwide. 
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7.2. Recommendations 
Given the failure of microbicides to pass all clinical trials, pharmaceutical scientists and 
developers have come to the conclusion that it is just not enough for microbicides agents to 
be potent against HIV-1. There are other variables at play such as the maintenance and 
enhancement of the vaginal barrier properties against HIV-1, the need to use different 
approaches that include employing two or more anti-HIV-1 agents that have different 
mechanisms of action and the determination and use of the appropriate quantities of the 
anti-HIV-1 agents. As research on microbicide agents is ongoing, there is need to focus 
more on these and many other variables as opposed to just looking at how potent an anti-
HIV-1 agent may be. Much of the work performed in this study in designing and formulating 
a composite delivery system was largely successful. However, there is need for further work 
on some aspects that include; partaking on further tests such as immunohistopathology to 
determine the safety of the delivery system and determining the quantity of the microbicide 
that has to be delivered for sufficient anti-HIV-1 prevention.  
 
Although this study involved the delivery of two anti-HIV-1 agents with different mechanisms 
of action, one of the agents (BP36) is a raw herbal extract that is still undergoing 
standardization. As much as BP36 showed potency against HIV-1 in vitro, drug delivery is a 
more precise science and there is need to further isolate and purify the anti-HIV-1 active 
pharmaceutical ingredient. This should generally be standard for any herbal based 
microbicide candidate to ensure easy formulation, delivery, detection and quantification. 
 
Another issue that arose in the in vivo studies using the pig as a model which particularly 
affected the caplet delivery system was that although the human and the pig reproductive 
systems are similar, there are some differences that include the absence of vaginal fornices 
in the pig where the cervix is continuous with the vagina as opposed to in human females 
where the cervix protrudes into the vaginal cavity to form the anterior and posterior fornices 
where the caplet could be inserted securely for extended residence and microbicide delivery. 
This difference resulted in the pigs pushing out the caplet once inserted in the vaginal cavity. 
In this regard, use of other animal models, such as primates, that have vaginal fornices 
similar to humans would be advantageous. With continuous research and review of the 
pitfalls of microbicides, a female controlled HIV-1 transmission prevention modality with huge 
health and economic benefits may be developed. 
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Purpose: 
All membranes covering human body cavities are lined by mucus. This is a viscoelastic gel-like secretion that has 
diverse properties and purposes which include; protecting the body against infection, lubricating the membranes 
they cover to prevent abrasion and preventing self digestion as in the case of gastric mucus. Equal to these 
benefits, mucus poses various challenges especially in pharmaceutical drug delivery. Our study is to determine 
the interactions of mucin, the major structural component of mucus, with a biodegradable and biocompatible 
polymer, pectin, commonly used in pharmaceutical formulations and to further harness this unique relationship to 
fabricate a unique drug delivery carrier in the form of pectin-mucin microspheres.  
 
Methods: 
Turbidity measurement by absorbance: Different ratios of aqueous pectin and mucin were examined for UV 
absorbance at 600nm using a nanophotometer. A comparison was done between the turbidity of aqueous 
solutions of pectin and mucin in combination and those of native pectin and mucin respectively. The difference in 
turbidity of the blended pectin-mucin solution and the sum of that of the individual native polymer solutions was 
regarded a measure of pectin-mucin interactions.  
 Rheological analysis: A modular advanced rheometer was used to determine the viscosity, loss and storage 
moduli of different aqueous ratios of pectin-mucin. Subsequent computation of the difference in the viscosity, loss 
and storage moduli of the pectin-mucin blend and the sum of the individual pectin and mucin was regarded a 
measure of the interactions of pectin and mucin. 
Fourier transform infrared (FTIR) analysis of pectin-mucin: Dry lyophilized polymer blends of pectin and mucin 
were analyzed by FTIR to determine pectin-mucin interactions. 
Fabrication and characterization of pectin-mucin microspheres: Pectin-mucin microspheres were fabricated using 
a crosslink-emulsion technique. 0.5g of a pectin-mucin blend with pectin: mucin ratio of 4:1 was solubilized in 
deionized water at 25°C by stirring for an hour then a crosslinking agent, calcium chloride (CaCl2) and plasticizer, 
polyethylene glycol 400 (PEG 400) were added to further increase the pectin mucin interpenetration. This 
aqueous mixture was used as the aqueous phase, cyclohexane was used as the oil phase and span 85 was the 
surfactant in the sonication of pectin-mucin microspheres. 
 
Results: 
Results revealed turbidometric and rheological synergism between pectin and mucin and FTIR disclosed 
hydrogen bonding as a major contributor to the pectin-mucin interactions. The successful fabrication of 
microspheres of pectin and mucin with a size range of 0.2-0.5µm is also testimony of the intricate interpenetration 
of pectin and mucin to form one compatible polymer blend that can be utilized in pharmaceutical applications as a 
drug carrier.  
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